Restoration of corticosteroid sensitivity in severe asthma by Mercado, Nicolas & Mercado, Nicolas
 1
 
Restoration of corticosteroid 
sensitivity in severe asthma 
 
 
A thesis submitted to the Imperial College of London for the degree of 
Doctor of Philosophy 
 
                                                     by 
 
Nicolas Mercado 
 
             May 2008 
 
 
Airway Disease 
National Heart & Lung Institute 
Imperial College 
Dovehouse Street 
London SW3 6LY 
 2
I, Nicolas Mercado declare that this thesis to be submitted, has been 
entirely written by myself 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3
Abstract 
 
Severe asthma accounts for a small number of asthmatics but represents a 
disproportionate cost to health care systems. The underlying mechanism in severe 
asthma remains unknown and most of the cost is the result of inadequate 
treatment. Although the disease presents a very heterogeneous profile it displays a 
certain degree of resistance to corticosteroid therapy. It is hypothesized that 
corticosteroid insensitivity can be reversed pharmacologically.   
We investigated the effects of drugs which are currently used for treatment of 
asthma on glucocorticoid sensitivity in peripheral blood mononuclear cells 
(PBMCs) from patients with mild, moderate and severe asthma and healthy 
volunteers. Long acting β2 receptor agonists (LABAs) were found to be able to 
reverse corticosteroid insensitivity in some severe asthmatic patients. These 
patients showed a defect of glucocorticoid receptor (GR) nuclear translocation 
with hyperphosphorylation of GR. Furthermore, LABAs were found to inhibit GR 
phosphorylation through inhibition of p38MAPKγ phosphorylation. Other severe 
asthmatics patients were also found to be “responders” to theophylline, another 
current add-on treatment, and showed a defect in histone deacetylase activity. 
Further studies were conducted in order to find additional molecular abnormalities 
which may define novel add-on treatments to reverse corticosteroid resistance. 
Using simple laboratory methods in peripheral blood mononuclear cells (PBMCs) 
by one blood sampling, analysis of GR nuclear translocation potential, GR 
dependent transrepression (IL-8, IL-2 inhibition) and GR-dependent 
transactivation (Histone-4 lysine-5 acetylation, GILZ expression) revealed a 
heterogeneous population in severe asthma. Low levels of corticosteroid response 
were associated with a decrease in lung function in severe asthma. The use of 
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possible add-on treatments such as an IKK2 inhibitor, a PI3K inhibitor, 
macrolides and a p38MAPKα/β inhibitor as well as existing treatments 
(theophylline and formoterol) confirmed that different molecular mechanisms 
were involved in severe asthma and the best add-on treatment is possible to be 
chosen individually for each patient. Particularly, a p38MAPKα/β inhibitor was 
broadly effective in severe asthma. This screening might be useful in determining 
the underlying phenotype of each individual patient.  
In the last chapter, I evaluated the effects of nortriptyline hydrochloride (NH), 
which is a well-known compound but recently identified as a novel add-on 
treatment to corticosteroids. Studies using PBMCs showed that there were 
“responders” and “non-responders” to NH in severe asthma. Analysis by 
correlation with other compounds suggested that NH can modify PI3K signalling. 
In fact NH inhibited phosphorylation of Akt, a surrogate marker of PI3K under 
oxidative stress, and restored HDAC activity defective under oxidative stress. 
This new combination will be one of choice for the treatment of severe asthma. 
This thesis gives new insights on phenotyping of severe asthma patients and novel 
add-on treatments to corticosteroids, possibly leading to future tailor-made 
treatment. 
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1. Introduction  
 
1.1 Asthma   
1.1.1 Prevalence, Morbidity and Mortality 
Asthma is a worldwide problem with an estimated 300 million affected 
individuals (Masoli et al., 2004; Beasley, 2004). It is the third leading cause of 
hospitalization among people under 18 years of age in the United States (Health, 
2005). An increase in the prevalence of asthma has been reported in the UK 
(Soriano et al., 2003) and in Australia (Robertson et al., 1991). Furthermore, an 
increase from 15 to 46% of children has been reported to have had asthma or 
wheezing at some time during their first seven years of life (Robertson et al., 
1991). Although conflicting results exist, the prevalence of the disease is still 
rising (Carvajal-Uruena et al., 2005; Yan et al., 2005), whereas it is stable in some 
countries (Teeratakulpisarn et al., 2004). The World Health Organisation (WHO) 
estimated that 15 million disability-adjusted life years (DALY) are lost annually 
due to asthma, which represents a one percent of the total disease burden (Masoli 
et al., 2004). Globally, asthma accounts for an estimated 180000 deaths per year 
(WHO, 2005). 
 
1.1.2 Social and economic burden 
The incidence of asthma is higher in low-income populations which in the 
Western world are disproportionately from ethnic minorities generally living 
close to industrial areas (AAAAI, 2008). The cost of asthma in the UK and the 
United States is of great significance both to the health care system as well as to 
the work force. Asthma is the major cause of absenteeism in many countries 
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including UK, Australia, Sweden and United States (Action Asthma, 1990; Karr 
et al., 1978; Thompson, 1984; Weiss et al., 1992; Weiss and Sullivan, 1993). 
From the perspective of both the patients and society, the cost of asthma seems 
high, but the cost of not treating asthma is even higher (GINA, 2007).  
 
1.1.3 Causes of asthma  
1.1.3.1 Genetic 
Genetic linkage has been identified in loci containing major genes that can 
influence atopy and asthma (Cookson and Moffatt, 2000). Several asthma and 
allergy susceptibily genes have been identified through genome-wide linkage 
analysis such as ADAM33, PHF, DPP10, HLA-G and GPRA as well as through 
candidate gene studies for TIMP-1 and prostanoid DP receptor genes (Holloway 
and Koppelman, 2007) 
 
1.1.3.2 Gender 
The ratio of asthma prevalence is twice the amount of male to female up to 13 to 
14 years of age. The ratio then progressively reverses to a 2 to 1 ratio for woman 
to man (Schatz and Camargo, Jr., 2003). The reason might be that the lung size is 
smaller in males than females at a younger age but is larger in adulthood 
(Martinez et al., 1995). Differences in hormone regulation are also known to play 
an important role (Postma, 2007). 
 
1.1.3.3 Environment 
The role of the exposure to environmental allergens in asthma development is not 
fully understood. The levels of exposure to house-dust mite, cat and dog dander 
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were not related to childhood asthma, although sensitization to mite and cat 
allergens was associated with indoor allergen exposure (Lau et al., 2000). Other 
studies suggest the contrary in that they may be a causal factor in the development 
of asthma (Sears et al., 2003). In any case, intervention studies have failed to find 
convincing evidence of a reduction in the risk of asthma among children 1 to 8 
years of age after an implementation of allergen and food avoidance strategy 
(Simpson and Custovic, 2004). Other epidemiologic studies have found that early 
exposure to dogs and cats may protect a child against allergic sensitization or the 
development of asthma (Gern et al., 2004; Platts-Mills et al., 2001), although this 
is not consistent with all studies (Remes et al., 2001). 
The “hygiene hypothesis” has received much attention lately. This suggests that 
exposure to infections early in life influences the development of a child’s 
immune systems along a non-allergic pathway resulting in a risk reduction of 
asthma and other allergic diseases (Cullinan, 2006). There is also evidence that 
the number of older siblings affects the risk of hay fever and eczema. This risk 
decreases as the number of older sibling increases (Karmaus and Botezan, 2002). 
The same is found with regards to asthma in which the day care attendance can 
play an important role (Ball et al., 2000) 
 
1.1.3.4 Air pollution 
Evidence suggests that outdoor air pollution (ozone, particulate matter) decreases 
lung function and triggers asthma exacerbations (Tatum and Shapiro, 2005). 
Although the exact causes remains controversial (ATS, 2000b) studies have found 
that children living within a distance of 50 to 90 meters of a major road are at an 
increased risk of wheezing but not airway hyperresponsiveness. In fact, ozone and 
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diesel exhaust particles have been shown to enhance airway inflammation in 
human (Hirsch et al., 1999; Nicolai et al., 2003; Venn et al., 2001). 
 
1.1.3.5 Tobacco smoke 
Studies of lung function after birth have shown that maternal smoking during 
pregnancy has a negative influence on lung development (Martinez et al., 1995). 
Passive and active smoking is associated with a reduced therapeutic response to 
corticosteroids reducing the likelihood of asthma being controlled (Strachan et al., 
1996; Withers et al., 1998). Active smokers have more severe asthma symptoms, 
accelerated decline in lung function and impaired short-term therapeutic 
responses to corticosteroids (Chalmers et al., 2002; Strachan et al., 1996). 
Smoking also accelerates the clearance of drugs such as theophylline by induction 
of metabolizing enzymes. The highest proportion of asthma related admissions to 
hospital are from smoking individuals (Thomson et al., 2004). 
 
1.1.3.6 Infections 
The interaction between atopy and viral infections is complex. Reduced lung 
function and increased markers of inflammation observed before virus inoculation 
in the asthmatic patients with high levels of total IgE may be a risk factor for an 
adverse response to infection with rhinovirus (Zambrano et al., 2003). Viruses 
have been shown to be potent triggers of asthma exacerbations, and the inability 
to restrict the symptoms of rhinovirus infections in the upper respiratory tract may 
be considered a hallmark of asthma at all ages (Corne et al., 2002). Contrary to 
this, population-based studies assessing infections exposure in children for viruses 
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have found that exposure to infectious agents protects against asthma 
(Yazdanbakhsh and Wahyuni, 2005). 
Parasite infection has long been hypothesized to reduce asthma prevalence 
although a recent review concluded that parasite infections do not in general 
protect, but infection with hookworm may reduce the risk of the disease 
(Leonardi-Bee et al., 2006). 
 
1.1.3.7 Occupational sensitizer 
Over 300 natural and synthetic chemicals have been listed to be causes of 
occupational asthma. These agents include isocyanates, irritants, platinum salts, 
wood dusts, allergen from laboratory animals and insects (Mapp, 2001; Mapp et 
al., 2005; van, V et al., 2000). Occupational asthma has been found to be more 
predominant in adults, and occupational sensitizers are estimated to cause about 
10% of asthma among adults at working age (Nicholson et al., 2005). Asthma is 
the most common occupational respiratory disorder in industrialized countries 
(Blanc and Toren, 1999). 
 
1.1.4 Diagnosis of asthma 
The clinical diagnosis of asthma is based on symptoms such as episodic 
breathlessness, wheezing, cough and chest tightness (Levy et al., 2006). Seasonal 
variability of symptoms, family history and atopic disease are important 
indicators. In older patients, distinguishing severe chronic asthma from COPD can 
be difficult and the two disorders co-exist in those who have smoked cigarettes 
(Tattersfield et al., 2002). Gastroesophageal reflux, postnatal drip, chronic 
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sinusitis and vocal-cord dysfunction need to be considered as alternative 
diagnoses (Irwin et al., 1998). 
 
1.1.4.1 Diagnosis tests and monitoring 
Measurement of lung function provides an assessment of the severity of airway 
limitation, its reversibility and variability and provides confirmation of the 
diagnosis of asthma (BTS, 2007). 
Obtaining a history of the variability is an important component of the diagnosis 
in asthma. The use of spirometry measures airflow limitation and reversibility in 
asthma. The Forced Expiratory Volume in 1 second (FEV1) and the Forced Vital 
Capacity (FVC) are routinely used for this measure. The degree of reversibility in 
FEV1 which indicates a diagnosis of asthma is generally accepted as ≥ 12% and ≥ 
200 ml from the pre-bronchodilator value (Pellegrino et al., 2005). FEV1 is shown 
to be decreased with age. Because many of lung diseases can result in a reduction 
of FEV1, a useful assessment of airflow limitation is the ratio of FEV1 to FVC. 
This ratio is usually greater than 0.75 to 0.80, but less suggests airflow limitation 
(Pellegrino et al., 2005). 
The measure of Peak Expiratory Flow (PEF), using a peak flow meter, is very 
important in both the diagnosis and the monitoring of asthma. A 20% or more of 
pre-bronchodilator PEF improvement after inhalation of a bronchodilator, or 
diurnal variation of more than 20%, suggest a diagnosis of asthma (Dekker et al., 
1992). Self monitoring of symptoms or PEF for treatment of exacerbations has 
shown to improve asthma outcomes and could also be used to measure 
occupational asthma (Gibson and Powell, 2004). 
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Measurement of airway responsiveness is used for patients with symptoms 
consistent with asthma but that have a normal lung function. This requires the 
measurement of FEV1 response to an allergic or “trigger” challenge 
(methacholine) (Cockcroft, 2003). The limits of the method lie in the fact that 
airway hyperresponsiveness can be found in allergic rhinitis sufferers and also in 
patients that suffer from airway obstruction due to fibrosis or COPD (Ramsdale et 
al., 1985; van Haren et al., 1995). 
Levels of exhaled nitric oxide and carbon monoxide can also be used as “non-
invasive” markers of airway inflammation (Kharitonov et al., 1997; Pizzichini et 
al., 1996). The levels of nitric oxide have been shown to be increased in asthma 
severity (Brindicci et al., 2007). 
The measure of allergic status is of importance in order to establish the risk 
factors that can cause asthma symptoms in individual patients. The presence of 
allergens is measured by skin testing or measure of IgE in serum (GINA, 2007). 
 
1.1.5 Classification of asthma 
The Global Initiative for Asthma (GINA) has been classifying asthma since 1998 
through the combined efforts of the National Health, Lung and Blood Institute 
(NHLBI) and the World Health Organization (WHO) (GINA, 1998). Until 2006, 
the GINA guidelines divided asthma by severity based on the levels of symptoms, 
airflow limitation and lung function variability into four categories: intermittent, 
mild persistent, moderate persistent and severe persistent. This classification by 
severity is now thought to be useful when decisions are being made about 
management at the initial assessment of a patient. Nevertheless, asthma severity 
involves both the severity of the underlying disease and its responsiveness to 
 29
treatment (Tarlo and Liss, 2003). In this case, asthma can present with severe 
symptoms and airflow limitation classifying it as severe persistent initially, but by 
responding fully to treatment becomes classified as moderate persistent. The old 
classification of asthma severity is based on clinical parameters before treatment. 
It will retain its value as a cross-sectional means of characterizing a group of 
patients with asthma who are not on inhaled corticosteroids. Its limitation resides 
in the poor value for predicting the adequate treatment required and what a 
patient’s response to treatment will be. For this purpose, a periodic assessment of 
asthma control is more relevant and useful. The new 2007 guideline is based on 
asthma control, which in general, may indicate disease prevention or even cure. It 
refers to control of the manifestations of disease. Ideally, the classification should 
not only apply to clinical manifestations, but also to laboratory markers of 
inflammation and pathophysiological features of the disease (GINA, 2007). 
National asthma guidelines play an important role in the management of asthma 
locally. In the UK, the British Thoracic Society updates each year the new 
understandings of asthma management based on literature (BTS, 2007). Their 
approach to asthma management is based on a pharmacological approach aiming 
at controlling or minimizing symptoms during the day and night; reducing the 
need of reliever medication; reducing exacerbations to a minimum; achieving no 
limitation of physical activity and achieving a normal lung function. Importantly, 
they aim to use a stepwise approach, starting treatment at the most appropriate 
stage of severity and trying to achieve early control by stepping up or down 
therapy as necessary (BTS, 2007). 
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1.1.6 Pathogenesis of asthma 
Asthma is an inflammatory disorder of the airways which involves several 
inflammatory cells and multiple mediators that result in characteristic 
pathophysiological changes (BTS, 2007; Barnes, 1996). 
 
1.1.6.1 Inflammatory cells and mediators 
The characteristic pattern of inflammation consists of a dense inflammatory 
infiltrate in which eosinophils, mast cells, CD4+ helper T lymphocytes 
predominates (Hogg, 1993). Neutrophil infiltration also arises during asthma 
exacerbations in more severe cases (Fahy et al., 1995). Dendritic cells play an 
important role in antigen presentation to T cells. In response to T cells, B cells 
produce antigen specific IgE leading to mast cell activation and degranulation 
(Brightling et al., 2002). Immune cell interaction with airway smooth muscle 
might be related to its degree of contraction as airway hyperresponsiveness is 
linked to mast cells (Leckie et al., 2000) (Figure 1.1). CD4+ Th2 cells are believed 
to initiate and perpetuate the disease expression by activating markers of 
inflammation such as CD25, Class II Major Histocompatibility Complex (MHC), 
IL-4, IL-5 and IL-13 (Robinson et al., 1992). CD4+ Th1 cells have also been found 
in bronchial alveolar lavage (BAL) during acute asthma exacerbations in some 
asthmatics and produce IFN-γ (Corrigan et al., 1988). Although Th1 cells alone 
do not produce any characteristic features of asthma in mice, Th1 cells activated 
in the respiratory tract with inhaled antigen cause a neutrophil-predominant 
inflammatory response (Cohn et al., 1997). This might suggest that asthma is not 
Th2 exclusive. 
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Airway eosinophilia is however the most characteristic finding in asthma and is 
central in the pathogenesis of the disease. Th2 cytokines control eosinophil 
recruitment and maturation by IL-5, IL-4 and IL-13 (Mathew et al., 2001; 
Nakajima et al., 1992). Eosinophils recruited to the respiratory tract secrete major 
basic protein, eosinophil cationic protein and eosinophil peroxidase cytokines 
such as TNFα, GM-CSF, IL-4, IL-13 and IL-5, and chemokines eotaxin and 
RANTES (Rothenberg, 1998). These factors damage airway epithelial cells, 
stimulate mucus secretion and fibrosis and induce bronchospasms and AHR 
(Bousquet et al., 1990). 
Macrophages are also increased in numbers in the airway and may be activated by 
allergens through low-affinity IgE receptors to release inflammatory mediators 
and cytokines that amplify the inflammatory response (Peters-Golden, 2004). 
Neutrophils were shown to be increased in the airway sputum in response to Th1 
chemokines such as IL-8 in severe asthma and in smoking asthmatics (Wenzel, 
2003). 
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Figure 1.1 Mechanism of asthma. Dendritic cells and macrophages bind to allergens 
and consequently activate mast cells. Mast cell degranulation results in airway 
hyperresponsiveness via cell interaction with airway smooth muscle. Th2 and Th1 cells 
can initiate and perpetuate disease by recruiting eosinophils and neutrophils. This results 
in the damage of the airway epithelium, fibrosis and mucus hypersecretion. Smooth-
muscle-mass increases due to hyperplasia and vascular dilatation. Angiogenesis can 
cause airway oedema. All these processes can result in airway remodelling. 
 
1.1.6.2 Cell signaling 
Intracellular mechanisms play an important role in the pathogenesis of asthma, 
regulating inflammatory mediators’ production or cell survival and apoptosis. 
Signalling via kinase cascades regulate these intracellular mechanisms. 
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1.1.6.2.1 Kinase pathways of inflammation 
c-Jun N-terminal kinases (JNK) 
The c-Jun NH2-terminal kinases (JNKs) phosphorylate and activate members of 
the activator protein-1 (AP-1) transcription family as well as other substrates 
involved in numerous intracellular functions, such as apoptosis, cytoskeletal 
rearrangements, transcriptional activation and protein ubiquitination (Chen et al., 
2001). Ten isoforms are created by alternative splicing of mRNA transcripts 
derived from three genes: JNK1, JNK2 and JNK3. JNK is activated by dual 
phosphorylation of the motif Thr-Pro-Tyr located in the activation loop (Manning 
and Davis, 2003). The inactivation can occur through dual specificity MAP kinase 
phosphatases such as MKP-1, MKP-3, MKP-5 and MKP-7 (Karin and Gallagher, 
2005). MAP2K4 (MKK4) and MAP2K7 (MKK7) are two upstream kinases that 
can activate JNK. MKK4 phosphorylates JNK on tyrosine and MKK7 on 
threonine. Both sites are needed for full activation and MKK7 is essential for 
TNFα activation (Manning and Davis, 2003). Upstream of MKK4 and MKK7 are 
transforming growth factor-β-activated kinase and the MAPK/ERK group which 
share the signalling cascades. The specificity of signal transduction by JNK is due 
to the docking motif of the substrate (D domain) that is distant from the active site 
(Karin and Gallagher, 2005).. 
SP600125 is a JNK1 inhibitor that has been widely used in various disease 
models. It has proven to inhibit TNFα and IL-2 production in human monocytic 
and Jurkat cells respectively (Bennett et al., 2001). It was also shown to inhibit 
TNFα- and IL-1β-induced GM-CSF, RANTES and IL-8 production in primary 
human airway smooth muscle cells (Oltmanns et al., 2003).  
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P38MAPK 
JNK and p38 activities are mainly induced by environmental stress (osmotic 
shock, hypoxia, heat-shock and ultraviolet radiation (UV)) and of particular 
interest, by pro-inflammatory stimulus and cytokines, such as lipolysaccharide 
(LPS), IL-1, transforming growth factor-β (TGF- β) and tumour-necrosis factor 
(TNF) (Ashwell, 2006) (Figure 1.2). 
Four different isoforms have been identified: p38α (SAPK2a), p38β (SAPK2b), 
p38γ (SAPK3) and p38δ (SAPK4). P38α and p38β are 74 % identical at the 
amino acid (aa) level and are widely expressed in the body. P38α is the only 
isoform that has crucial non-redundant functions in vivo (Kuida and Boucher, 
2004). P38γ has 63% aa identity with p38α while p38δ has 61% aa identity. P38γ 
expression has been largely identified in skeletal muscle (Kuida and Boucher, 
2004) although recent studies in rheumatoid arthritis have identified the 
expression in macrophages and T lymphocytes (Korb et al., 2006). P38β, p38γ 
and p38δ knock-out mice are viable and fertile with no obvious health problems 
(Ashwell, 2006; Sabio et al., 2005; Kumar et al., 2003). P38MAPK is known to 
be activated by dual phosphorylation on Thr180 and Tyr182 by upstream kinases 
(MKK6 and MKK3) which in turn are activated by upstream kinases 
(MAPKKKs) which are activated by a widely variety of stimuli (Kumar et al., 
2003).  
The activity of p38MAPK can be down-regulated by dephosphorylation by 
various protein phophatases, such as PP2A. Dual-specificity phosphatases such as 
MKP-7 and MKP-5 also dephosphorylate p38 (Kumar et al., 2003). 
Dexamethasone has been shown to inhibit p38 by inducing the transactivation of 
MKP-1 (Lasa et al., 2002). 
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Substrates for p38 are various and include other kinases such as ribosomal S6 
kinase (RSK), the MAP kinase-interacting kinase 1 and 2 (MNK1/2), the mitogen 
and stress-activated kinase 1 (MSK1); transcription factors such as activation 
transcription factors 2 and 6 (ATF2/6), myocyte enhancer factor 2C (MEF2C), 
C/EBP homologous protein (CHOP), Elk1 and SAP-1A. The substrate-docking-
site may contain short peptide sequences that confer specificity and enhance 
phosphorylation efficiency (Lee et al., 2000). 
P38 has an important role in cytokine regulation and expression. Adenosine and 
uridine-rich elements (AREs) in the 3’ untranslated region of cytokines’ mRNA 
are responsible for their high turnover rate. The AREs control mRNA degradation 
via interactions with specific binding proteins. P38 is though to act through the 
phosphorylation of its substrate MAPKAPK-2 to release mRNA from a state of 
translational arrest imposed by the ARE. This results in an increase of protein 
translation and plays an important role in the stabilization of various pro-
inflammatory cytokines such as IL-8, IL-6, TNFα, IL-1 and COX-2 (Clark et al., 
2003) (Figure 1.2) 
The p38 pathway can also act by enhancing the accessibility of NF-κB-dependent 
promoters. This is thought to be via the induction of Histone-3 (H3) 
phosphorylation through a phosphorylation cascade (via MSK1 possibly). H3 
phosphorylation at serine increases the binding of several Histone Acetylases 
(HATs) and promotes the translation machinery. The specific promoters found to 
be controlled this way were IL-6, IL-8, IL-12p4α and MCP-1, but not MIP-1α or 
TNFα (Saccani et al., 2001; Saccani et al., 2002). P38 activity was previously 
found to be responsible for glucocorticoid receptor (GR) phosphorylation and 
inactivation of transcriptional activity in IL-2/4 treated PBMCs (Irusen et al., 
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2002). GR might not be a direct substrate to p38 as it has been proposed before 
(Rogatsky et al., 1998a). However, using a mouse mammary tumor virus 
(MMTV) promoter-driven luciferase construct in Hela cells, MKK6 activation 
resulted in GR phosphorylation (Szatmary et al., 2004). 
Several p38MAPK inhibitors can block IL-1, TNFα and other cytokines through a 
combined effect at the level of transcription and translation (Kumar et al., 2003). 
The possible modulation of GRα nuclear function by p38 also raises interest in the 
restoration of corticosteroid responsiveness in steroid resistant asthmatics (Irusen 
et al., 2002). SB203580 and related analogues act as pyridinyl imidazoles binding 
to both the active and inactive p38α/β in an ATP-competitive manner (Wilson et 
al., 1997). P38α/β inhibitors have shown to inhibit IL-1, TNFα and IL-6 in in vitro 
and in vivo models, in addition to COX-2 and iNOS inhibition (Badger et al., 
2000; Guan et al., 1998). Ex vivo studies showed that SB242235, inhibited 
endotoxin induced IL-1β, TNFα and IL-6 and IL-8 production (Fullerton, 2000). 
An ovalbumin challenged rat model of asthma also concluded a role for p38 
inhibition of BAL’s TNFα production and reduction in neutrophilia (Escott et al., 
2000; Underwood et al., 2000). Similarly, a respirable p38α antisense 
oligonucleotide (ISIS 101757) has recently been reported to inhibit ovalbumin-
induced pulmonary eosinophilia, mucus hypersecretion, and airway 
hyperresponsiveness in a murine model of asthma (Duan et al., 2005a; Escott et 
al., 2000; Underwood et al., 2000). 
Several p38 inhibitors have been used in clinical studies with significant success. 
BIRB796 was shown to decrease TNFα and IL-6 (Regan et al., 2002). RWJ67657 
prevented neutrophil and endothelial activation against disease biomarkers (Fijen 
et al., 2002). Despite initial hopes, a major setback has been the increase in liver 
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toxicity of many first generation p38 inhibitors. New, second generation, drugs 
have focused in reducing the effects on cytochrome P450 and clinical trials of 
VX-702, HEP689 and CIN-1493 are testing efficacy in chronic inflammatory 
disorders such as psoriasis, rheumatoid arthritis and Crohn’s disease (Adcock et 
al., 2006). The broad spectrum of the drug with the subsequent toxicity could be 
overcome by using inhaled therapeutics or by looking at downstream substrates 
such as MAPKAPK2 (Barnes, 2006c). 
 
 
 
 
 
 
 
 
 38
 
Figure 1.2 p38MAPK pathway of action. Stress (eg: reactive oxygen species) and 
cytokines (TNFα, IL-1) activate p38MAPKα/β/δ/γ via a cascade through small GTPases, 
MAPKKK and MKK3 and MKK6. p38MAPK regulate the action of various proteins 
such as ribosomal S6 kinase (RSK), the MAP kinase-interacting kinase 1 and 2 
(MNK1/2), the mitogen and stress-activated kinase 1 (MSK1); transcription factors such 
as activation transcription factors 2 and 6 (ATF2/6), myocyte enhancer factor 2C 
(MEF2C), C/EBP homologous protein (CHOP), Elk1 and MAPKAP2/3/5. These last 
ones are known to phosphorylate adenosine and uridine-rich elements (AREs). 
Phosphorylation and degradation of AREs will increase cytokine translation of de-
repressed mRNAs. 
 
 
Phosphoinositide 3-kinase (PI3K)/Akt 
Phosphoinositide 3-kinase (PI3K) generates lipids that play a prominent role in 
various inflammatory cells by controlling cell growth, differentiation, survival, 
proliferation and cytokine production through its downstream components 
(Koyasu, 2003). PI3Ks have been divided into 3 classes. Class I PI3Ks are further 
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divided into Class IA enzymes, consisting of p110 catalytic subunit (α,β,γ) 
complexed to a regulator subunit (p85, p50 and p55) (Figure 1.3). They signal 
downstream of tyrosine (tyr) kinases and Ras. Class I consist of the p110 catalytic 
subunit complexed to the p101 regulatory subunit and signals downstream of the 
G-protein-coupled receptors (GPCRs) and Ras (Ito et al., 2007a; Vanhaesebroeck 
et al., 2005). Class II PI3Ks are monomeric; they lack adapter subunits and 
preferentially use phosphatidylinositols (PIs) and phosphatidylinositol-phosphates 
(PIPs) as substrates. Three isoforms have been identified in mammalians, PI3Ks-
C2α and PI3K-C2β and the liver-specific PI3K-C2γ. Class III PI3Ks are 
heterodimeric enzymes consisting of adaptor (p150) and catalytic (Vps 34, 100 
kDa) subunits. They are important in vesicle trafficking and implicated in 
regulation of autophagy (Hennessy et al., 2005). 
Class I PI3Ks produce phosphatidylinositol (3,4,5)-triphosphate (PI(3,4,5)P3) 
which is a key lipid second messenger that controls a wide range of cellular 
responses via downstream effectors such as adaptor proteins and protein kinases 
(phosphoinositide-dependent kinase 1 (PDK1) or Akt/PKB). PKC and MAPK 
signalling pathways are also activated downstream PI3K (Ito et al., 2007a).  
Three known isoforms exist, Akt1, Akt2 and Akt3. Two crucial amino acids are 
phosphorylated and necessary for activation; one in the kinase domain (threonine 
308 in Akt1) is phosphorylated by constitutively active PDK1, stabilizing the 
activation loop, and serine 473 in Akt, in the hydrophobic C-terminal domain, 
which is phosphorylated by PDK2 and is necessary for full activation (Alessi et 
al., 1996; Blume-Jensen et al., 1998) (Figure 1.3). 
PI(3,4,5)P3 signalling can be impaired by the lipid phosphatases PTEN 
(phosphatase and tensin homologue deleted on chromosome ten) and Src-
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homology 2 (SH2) domain containing inositol 5’-phosphatase (SHIP) which 
converts PI(3,4,5)P3 into PI(3,4)P2 and PI(4,5)P2 respectively (Vanhaesebroeck et 
al., 2005) (Figure 1.3). PTEN is reported to play a pivotal role in Th2-mediated 
airway inflammation and airway responsiveness (Kwak et al., 2003). 
Overexpression of PTEN was shown to reduce airway hyperresponsiveness and 
vascular endothelial growth factor expression in a murine model of asthma (Lee et 
al., 2006a) while SHIP knock-out mice had increased mast cell degranulation, B-
cell activation, increased chemotaxis and a lethal accumulation of macrophages 
and neutrophils in the lungs (Helgason et al., 1998; Rauh et al., 2003).  
Recent observation by Fukao et al. (Fukao and Koyasu, 2003) have also 
concluded that Class IA PI3Ks are important regulators of the Th1 versus Th2 
response in vivo and that they control IL-12 production. Another study in mouse 
T-cells found that PI3K is required for IL-2 production as the activity was found 
to be essential for the transcriptional activity of both NF-AT and AP-1 (Eder et al., 
1998). The PI3Kγ isoform was shown to be essential for PIP3 production, Akt 
activation and superoxide production in neutrophils exposed to chemoattractants 
such as IL-8. The chemotaxis of other leukocytes (macrophages, T lymphocytes) 
was also shown to be impaired in the absence of PI3Kγ in vitro and in vivo (Ito et 
al., 2007a).   
Two commercially available PI3K inhibitors, wortmannin and LY294002 have 
contributed greatly in the understanding of the biological role of PI3K in 
inflammation (Ito et al., 2007a). Wortmannin is a fungal metabolite that 
irreversibly inhibits p110, and the flavenoid derivate, LY294002, is a reversible 
inhibitor that inhibits Class I PI3Ks but has some off-target activity (Hennessy et 
al., 2005). Inhibition of PI3K by LY294002 attenuates OVA-induced pulmonary 
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inflammation, release of Th2 cytokines, airway mucus production, eosinophil 
count and eotaxin in AHR sensitized mice. This was shown to be associated with 
a significant suppression of OVA-induced serine phosphorylation of Akt, a direct 
downstream substrate of PI3K (Duan et al., 2005b). Another study found that 
LY294002 and wortmannin attenuated eosinophilic inflammation in a murine 
model of asthma (Ezeamuzie et al., 2001; Kwak et al., 2003).  
Recently, a selective p110δ inhibitor, IC87114, was shown to reduce IgE in the 
serum, eosinophilia, airway mucus production, Th2 cytokines, VCAM and 
RANTES in a mouse model of asthma. The reduction in OVA-induced 
hyperresponsiveness to inhaled methacholine also corresponded to a reduction in 
OVA-induced Akt serine phosphorylation (Lee et al., 2006b). 
In vitro experiments have also shown that oxidative stress by hydrogen peroxide 
reduces HDAC2 expression, and that LY294002 and an Akt inhibitor were able to 
restore HDAC2 expression and activity in those cells. HDAC2 reduction plays an 
important role in corticosteroid insensitivity in COPD and evidence points to 
PI3K playing an important role in steroid sensitivity through the reduction of 
HDAC activity (Ito et al., 2006b; Ito et al., 2007a; Kozikowski et al., 2003). 
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Figure 1.3 PI3K pathway of action. Oxidative stress, growth factor signals and 
activation of the Ras pathway via β2-adrenoreceptor stimulate the phosphoinositide 3-
kinase (PI3K) pathway. PI3Ks stimulate the activation of  phosphatidylinositol (3,4,5)-
triphosphate (PI(3,4,5)P3) which is a key lipid second messenger that controls a wide 
range of cellular responses via downstream effectors such as adaptor proteins and protein 
kinases (phosphoinositide-dependent kinase 1 (PDK1) or Akt/PKB). PKC and MAPK 
signalling pathways are also activated downstream PI3K. Two crucial amino acids are 
phosphorylated and necessary for activation; one in the kinase domain (threonine 308 in 
Akt1) is phosphorylated by constitutively active PDK1, stabilizing the activation loop, 
and serine 473, in the hydrophobic C-terminal domain, which is phosphorylated by PDK2 
and is necessary for full activation. PI(3,4,5)P3 signalling can be impaired by the lipid 
phosphatases PTEN (phosphatase and tensin homologue deleted on chromosome ten) and 
Src-homology 2 (SH2) domain containing inositol 5’-phosphatase (SHIP) which converts 
PI(3,4,5)P3 into PI(3,4)P2 and PI(4,5)P2 respectively.  
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1.1.6.2.2 Pro-inflammatory transcription factors 
Activator Protein 1 (AP-1) 
AP-1 is a major family of transcription factors activated in asthma and COPD. 
AP-1 is encoded by protooncogenes and regulates various aspects of cell 
proliferation and differentiation. AP-1 can either be composed of homodimers or 
heterodimers between members of the Jun (c-Jun, u-Jun, Jun-B and Jun-D), Fos 
(c-Fos, Fos-B, Fra-1 or Fra-2), activating factor (ATF-2, ATF-3, B-ATF, JDP-1, 
JDD-2) or Maf (v-Maf, Maf A.B/F/G/K, Nr1) families. They all form part of the 
basic zipper (bZIP) family of sequence-specific dimeric DNA-binding proteins 
(De Bosscher et al., 2003). The leucine zipper of the Jun family proteins can form 
homodimeric complexes, as well as Jun-Fos heterodimers, while Fos proteins are 
capable only of heterodimer formation (Wisdom, 1999). Various stimuli are 
known to induce AP-1 activity, these include physiological agents (growth factors, 
mitogens, hormones, cell-matrix interactions and inflammatory cytokines), 
bacterial/viral infections, pharmacological compounds and cellular stress (De 
Bosscher et al., 2003). Recently, cigarette smoke was also shown to activate AP-1 
in monocytes through an oxidant pathway (Walters et al., 2005). The AP-1 
complex has been shown to confer negative regulation to nuclear factors such as 
glucocorticoid receptor by direct interaction or through the competition of 
cofactors (Barnes, 2006d). The interaction of NF-AT proteins with AP-1 is a good 
example of a cell-specific transcription factor, as it is largely confined to T-
lymphocytes. NF-AT is very important for IL-2, IL-4 and IL-5 cytokine 
expression (Barnes, 2006d). 
 
 
 44
Nuclear factor κB (NF- κB) 
Transcription regulation of the NF-κB promotes the expression of more than 100 
target genes, the majority participating in the host immune response (De Bosscher 
et al., 2003). NF-κB proteins are a group of transcription factors which in 
mammals consist of five members; p65 (RelA), RelB, c-Rel, NF-κB1 (p50/p105) 
and NF-κB2 (p52/p100). All five have a Rel homology domain (RHD) for 
dimerization, a DNA binding domain and a regulatory domain. A nuclear 
localization domain (NLS) inside the RHD is inactivated by specific inhibitors, 
known as Iκ-B proteins (Karin et al., 2004). Iκ-Bα can be phosphorylated and this 
results in the ubiquitination and proteosome degradation of Iκ-Bα, which then 
releases NF-κB to promote gene transcription (Karin and Ben-Neriah, 2000). The 
phosphorylation and degradation of Iκ-B takes place through the IKK complex, 
which is composed of the catalytic subunits IKKα(1), IKKβ(2) and IKKγ(3). 
IKK1 and IKK2 share 52% overall sequence identity in their catalytic domain 
whereas IKK3 acts more as a scaffolding protein for the complex (Ghosh and 
Karin, 2002). Phosphorylation of Iκ-B mediates their degradation and subsequent 
NF-κB nuclear translocation. NF-κB then binds specific DNA sequences and 
recruits coactivators to stimulate target gene expression. One of the targets is the 
Iκ-Bα gene, resulting in a feed back loop control (Brown et al., 1993). A wide 
variety of genes are regulated by NF-κB, including cytokines (IL-1, IL-2, IL-6, 
IL12, TNFα, GM-CSF), chemokines (IL-8, MIP-1α, MCP-1, RANTES and 
eotaxin), adhesion molecules (ICAM, VCAM, and E-selectin) and inducible 
effector enzymes (Ghosh and Karin, 2002). The NF-κB mechanism of action is 
summarized in Figure 1.4. 
 45
At the same time, NF-κB is activated by a range of stimuli which includes pro-
inflammatory cytokines, growth factors, DNA-damaging agents and viral proteins 
(Barnes, 2006d). Post-translational modification of NF-κB involves site-specific 
phosphorylation and regulates its transcriptional response. The RelA subunit has 
phosphoacceptor sites that are specifically targeted by kinases. Protein kinase A 
(PKA) can phosphorylate at serine 276 within the RHD domain regulating DNA-
binding and oligomerization of NF-κB (Ganchi et al., 1993). TNFα can also 
stimulate serine 276 via a PKA-independent pathway involving MSK-1. The only 
difference lies in that TNFα phosphorylation occurs in the nucleus and PKA in the 
cytoplasm. TNFα also targets serine 311 within the RHD through the action of 
protein kinase C (PKC) (Chen and Greene, 2004). RelA is also the subject of 
phosphorylation by IKKs at serine 536, inducing transcriptional activity (Sakurai 
et al., 1999). Serine 536 is also phosphorylated by RSK (Bohuslav et al., 2004). 
GSK-3β and Akt/phosphoinositide 3-kinase (PI3K) have also shown modulation 
of transcription through phosphorylation (Chen and Greene, 2004). RelA can also 
be acetylated and deacetylated at various residues. Acetylation of lysine 221 
enhances DNA binding by RelA and impairs assembly with Iκ-B whereas 
acetylation of lysine 310 is required for full transcriptional activity of RelA 
without Iκ-Bα binding assembly (Chen et al., 2002). Negative effects on 
transcription, by lysine 122 and 123 acetylation, have also been reported (Kiernan 
et al., 2003). Similarly, histones in areas surrounding the promoter of various NF-
κB targets are subject to modifications by acetylation. IKK phosphorylation of 
Histone-3 (H3) may be responsible for NF-κB promoter regulation (Israel, 2003). 
LPS stimulation has been shown to induce hyperacetylation of H3 and H4 within 
the regulatory regions of the IL-8, MIP-1α and IL-12/p40 genes as well as H4 
 46
acetylation in the IL-6 promoter (Saccani and Natoli, 2002). Interestingly, H3 
phosphorylation by a p38 dependent pathway, leading to H3 acetylation at the 
same cytokines just mentioned was also discovered (Saccani et al., 2001; Saccani 
et al., 2002). Notable exceptions of this control were promoters for TNFα and 
MIP-α genes.  
The IKK/ NF-κB system is of great interest for drug development as NF-κB is 
enhanced in various inflammatory diseases, including asthma and COPD (Adcock 
et al., 2006). Many different strategies exist in order to inhibit NF-κB (Karin et al., 
2004). Interfering with NF-κB-binding to DNA can be accomplished by using a 
decoy κB sites or their analogues. Interference with NF-κB activation by 
inhibiting Iκ-B degradation and NF-κB nuclear translocation is also possible 
(Alkalay et al., 1995). The inhibition of E3 ubiquitin ligases and E2 ubiquitin-
conjugating enzymes, responsible for the phosphorylation-dependent 
ubiquitination of Iκ-B and p100 is a more specific way of preventing NF-κB 
activation (Li et al., 1999). 
The most effective and selective approach remains the inhibition of IKK 
activation of NF-κB. The development of specific IKK-2 inhibitors are already in 
pre-clinical stages in the form of small-molecules inhibitors such as SPC-839 
which has shown to be effective against IL-6 and IL-8 production in Jurkat (T-
lymphocytes) cells and TNFα in LPS challenged rats (Karin et al., 2004; Palanki 
et al., 2002). Recently, a novel IKK2 inhibitor, IMD-0354, has been shown to 
decrease neutrophils and lymphocytes in mice administered with bleomycin, with 
a reduction in TNFα and IL-1β (Inayama et al., 2006). A concern for long-term 
inhibition of NF-κB is that it could result in immune suppression and impair 
normal immune defences (Barnes, 2006c). 
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Figure 1.4 NF-κB pathway of action. NF-κB (RelA and p50) exists inactivated in the 
cytoplasm in a complex with its inhibitor Iκ-B. Stimuli such as TNFα, IL-2 and IL-8 can 
result in the inactivation and degradation of Iκ-B via inhibitors of Iκ-B (IKKs). This 
results in the release of NF-κB, which after specific phosphorylation via PKA or IKK is 
able to translocate to the nucleus and initiate the transcription of pro-inflammatory 
precursors. A different cascade pathway is able to control transcriptional activity of NF-
κB in the nucleus via additional phosphorylation to the RelA subunit and to histones in a 
promoter specific manner. This results in acetylation of histones by p300/CBP/pCAF and 
increased transcriptional activity of NF-κB. A feed-back loop is completed in the 
regulation of NF-κB activity by stimulating transcription of Iκ-B and recycling to the 
cytoplasm of RelA and p50. 
 
1.1.6.3 Structural changes in the airway 
In chronic asthma, the normal repair process becomes disturbed and ineffective 
repair leads to remodelling involving several structures (Elias et al., 1999). 
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Structural cells in the airway and the matrix respond to inflammation resulting in 
airway thickening and reduction in the airway laminal diameter (Homer and Elias, 
2000). Deposition of collagen and proteoglycans in the subepithelial layer reflects 
the hyperplasia and hypertrophy of myofibroblast and mucus glands (Bento and 
Hershenson, 1998). The increased deposition of extracellular matrix is due to 
fibroblast activation, resulting from the upregulation of a number of cytokines and 
growth factors such as tumour growth factor beta (TGF-β) and IL-11. 
Subepithelial fibrosis is an important feature of airway remodelling (Sumi and 
Hamid, 2007). Smooth muscle mass increases due to hyperplasia and vascular 
dilatation, and angiogenesis results in increased vascular permeability and airway 
oedema (Homer and Elias, 2000).  
 
1.1.6.4 Airway hyperresponsiveness 
Airway remodelling and inflammation result in airway hyperresponsiveness 
(AHR) and airway obstruction, which causes breathlessness and wheezing.  AHR 
is defined as an increased bronchoconstrictor response to a non-specific stimulus. 
AHR can be measured in the laboratory using non selective stimulus that 
provokes bronchoconstriction and is generally performed using dose response 
curves by inhalation of these agents, such as methacholine. Variability in the 
results is observed and this may be due in part to the different challenges, low 
sensitivity of the tests, the difficulty of standardization and the variable nature of 
asthma and airway responsiveness (Eder et al., 2006). The magnitude of AHR 
correlates with the level of airway inflammation (Jeffery et al., 1989). 
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1.1.7 Current therapies for asthma 
1.1.7.1 Corticosteroids (Glucocorticoids) 
Glucocorticoids influence the activity of almost every cell in the body, 
modulating the expression of approximately 10% of our genes (Buckingham, 
2006). From an endogenous point of view, cortisol is the principal glucocorticoid 
in humans and is synthesized from cholesterol in the adrenal cortex according to 
circadian patterns (Buckingham, 2006). Free cortisol is the biologically active 
form of the hormone and is converted to cortisone by the type II 11-β-
hydroxysteroid dehydrogenase. Conversely, type I 11-β-hydroxysteroid 
dehydrogenase converts cortisone into cortisol (Rhen and Cidlowski, 2005).  
Inhaled corticosteroids are by far the most successful therapy available for the 
control of asthma. Introduced initially for the control of severe asthma, they are 
now used in mild and moderate forms of the disease. Decreased mortality (Barnes 
et al., 1998) and the effectiveness in controlling symptoms by reducing 
exacerbations and improving health status of asthmatics patients has made inhaled 
corticosteroids a first line therapy in any patients needing to use β2-adrenoreceptor 
agonist inhaler more than once a day (Barnes, 2006b). The majority of the 
benefits from inhaled corticosteroids are achieved in adults at relatively low doses 
(equivalent to 400 μg of budesonide a day) and increasing to higher doses 
provides little further benefits in terms of asthma control and increases the risk of 
side-effects (Kankaanranta et al., 2004; Powell and Gibson, 2003). Poor 
adherence and cigarette smoking will result in the gradual increase in symptoms 
and airway responsiveness (Barnes, 2006b). 
Corticosteroid therapy can result in various side effects. There is a consensus that 
the desired anti-inflammatory effects of corticosteroids are mainly mediated via 
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repression of gene expression and that side effects are mediated via 
transactivation of gene expression such as for diabetes and glaucoma. Other side 
effects are known to be caused via negative glucocorticoid response element 
(GRE) binding resulting in suppression of the hypothalamic-pituitary-adrenal axis 
and osteocalcin repression which results in osteoporosis. Many other side effects 
are known although their exact mechanism remains poorly understood (delayed 
wound healing, muscle atrophy, cataracts, Cushing’s syndrome, diabetes, growth 
retardation, pancreatitis, hypertension, obesity, etc.) (Schacke et al., 2002). 
Inhaled steroid therapy are believed to decrease the risk of side effects, however, 
an increase above the 5mg of cortisol per day may be enough for increased risk in 
osteoporosis (Ledford et al., 1998). Severe asthmatics that use oral corticosteroid 
predispose themselves for corticosteroid-induced side effects. The search for new 
corticosteroids with altered transactivation and repression effects have provided 
four different definitions. The development of “selective GR modulators” 
describes compounds with an improved therapeutic index in vivo by whatever 
mechanism. “Gene selective” compounds refer to those that act on the receptor to 
alter gene expression in a gene- or promoter-specific fashion. The “dissociated 
steroid” dissociates activation from repression. Finally, “soft steroids” act at or 
near the site of administration but are inactivated promptly by enzymes (Rosen 
and Miner, 2005). A new generation of steroids with different effects was made 
possible through the changes in the structure that bind to the helix-12 domain of 
GR, responsible for selective coactivator recruitment and recruitment for ligand-
dependent transcription (Rhen and Cidlowski, 2005). 
All corticosteroids, including dexamethasone can be considered as partially 
dissociated steroids since lower doses induce only transrepression while higher 
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ones are required for transactivation. It is important that the effects of 
transactivation and transrepression are directly compared (McMaster and Ray, 
2007). 
Single inhaler in asthma control are now widely prescribed in asthma as the use of 
long acting beta agonists (LABAs), such as salmeterol and formoterol in 
combination with fluticasone propionate or budesonide respectively, achieve 
better control of asthma than the corticosteroids alone (Barnes, 2007). In fact, a 
large review of the different studies comparing the effect of increasing inhaled 
corticosteroid or the addition of LABAs, leukotriene receptor antagonist (LTRA) 
or theophylline found that the addition of these drugs improves asthma control 
more effectively than the steroid alone (Kankaanranta et al., 2004). 
 
1.1.7.1.1  Glucocorticoid Receptor 
Glucocorticoid hormones are essential for hormonal survival and their effects are 
mediated by the ubiquitously expressed GR receptor (McMaster and Ray, 2007). 
They are the most effective anti-inflammatory treatment for asthma and have 
become the first line therapy in all patients with persistent asthma and with other 
inflammatory and immune diseases (Barnes, 2006a). 
 
1.1.7.1.2 Structure of GR 
Glucocorticoids exert their effect by binding to a single 777 amino acid (aa) 
glucocorticoid receptor (GR) that is localized in the cytoplasm of almost all cell 
types (Adcock and Ito, 2000; Rhen and Cidlowski, 2005) (Figure 1.5). Similar to 
other members of the nuclear receptor superfamily, GR is a modular protein with 
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each domain carrying distinct functions (Giguere et al., 1986). The N-terminal 
encodes primarily the constitutive transcriptional activation function (AF1) 
composed of 421 aa. In the middle region, 65 aa residues compose a highly 
conserved zinc finger DNA-binding domain (DBD) and play a critical part in the 
receptor homodimerization and interaction with cofactors. The C-terminus region 
encodes the ligand-binding domain (LBD) and contains the motif for ligand-
dependent transcriptional activation function (AF2). Functionally, the C-terminal 
region is involved in protein-protein interactions with cytosolic chaperones or co-
regulators, depending on the binding of a ligand. Nuclear localization signals are 
also found embedded in both the DBD and LBD regions (Tang et al., 1998).  
 
1.1.7.1.3 Alternative splicing 
The glucocorticoid receptor is located on chromosome 5q31-32 and consists of 
nine exons, which are highly conserved across species (Stolte et al., 2006) (Figure 
1.5). GR exists in a number of splice variants. The most common one encodes 
GRα. A C-terminal variation results in GRβ. GRδ is principally expressed in 
cancer, and a constitutive splice variant, GRγ, has an additional arginine in the 
DNA binding domain. Both GRδ and GRγ have unknown functions (Lu and 
Cidlowski, 2004; Yudt et al., 2003). A special mention to GRβ is that from the 9 
exons that it shares with GRα, they are identical up to exon 9α of 2475 nucleotide 
in size, of which the first 150 base pairs (bp) encode for 50 aa. The exon 9β is 
separated by a 158 bp short intron sequence, and continues for another 1478 
nucleotides with the first 45 coding for 15 distinct residues of the GRβ C-terminus 
(Zhou and Cidlowski, 2005). GRβ does not bind ligand and most have a dominant 
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negative action on GRα and may affect corticosteroid response in a cohort of 
inflammatory diseases (Chikanza, 2002; Hamid et al., 1999; Honda et al., 2000). 
 
Figure 1.5 Structure of GR and alternative splicing. Glucocorticoid receptor mRNA 
consists of 9 exons that can translate from alternative splicing into GRα (1 to 9α) or GRβ 
(1 to 9β). GRα is a 777 amino acid (aa) with a transcriptional activation function (AF1) 
composed of 421aa in the modulatory region. The DNA-binding domain (DBD) 
comprises 65 aa. The C-terminus domain is responsible for ligand binding, dimerization, 
co-factor binding and nuclear localization. GRβ is a 742 aa protein unable to bind 
steroids due to its truncated C-terminus in the ligand binding domain (LBD). 
 
 
1.1.7.1.4 Cytoplasmic inactive GR 
In absence of hormone, the corticosteroid receptor exists as a multiprotein 
heterocomplex containing a dimer of Heat Shock Protein 90 (hsp90), 
substoichiometric amounts of hsp70, an acidic 23 kDa protein, p23, and an 
immunophilin or protein phosphatase 5 (PP5) (Kanelakis et al., 2002). The hsp90 
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acts as a molecular chaperone preventing the nuclear localization of the 
unoccupied GR. Once the ligand binds to the GR, hsp90 dissociates, allowing 
nuclear translocation of the activated GR-steroid complex via association with 
import proteins, such as importin-α (Adcock, 2003). 
 
1.1.7.1.5 Mechanism of action of GR 
Transactivation of GR dependent genes 
Nuclear translocation of GR upon ligand binding, results in the association of GR 
to DNA at specific sequences in the promoter region of corticosteroid-responsive 
genes known as glucocorticoid response elements (GREs). Two GR molecules 
come together as homodimer to bind GRE (Barnes, 2006a). The number of genes 
per cell directly regulated by corticosteroids is estimated to be between 10 and 
100, but many genes are indirectly regulated through interaction with other 
transcription factors and coactivators. GR recruits CBP/p300 through AF-1 or 
indirectly through coactivators with AF-2 (Kurihara et al., 2002). pCAF 
(p300/CBP-associated factor) and the p160 coactivator family also mediate AF-1 
transcriptional regulation under certain conditions (Ito et al., 2006a) (Figure 1.6). 
The SRC family (1, 2 and 3) are responsible for ligand dependent interaction with 
GR in AF2 with SRC-1, which subsequently recruits pCAF and leads to specific 
modifications of histone H3 (Li et al., 2003). In contrast, other studies have 
shown that activated GR also induces acetylation of lysine-5 on Histone-4 (Ito et 
al., 2000; Matthews et al., 2004), suggesting that GR might recruit SRC-1 to its 
complex. SRC-1 recruitment of GR complex was confirmed by Grenier et al 
(Grenier et al., 2006). Interestingly, the GR coactivator, SRC-1 and SRC-2 can 
also act as corepressor of GR which underlines that the selection of corepressors 
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and coactivator associated with GR is crucial for the specificity of GR action, and 
ligands seem to achieve this (Ito et al., 2006a). Several genes switched on by GR 
have anti-inflammatory effects, such as Lipocortin-1, secretory leukocyte 
peptidase inhibitor (SLPI), IL-10, the inhibitor of NF-κB (IκB-α), MAP kinase 
phosphatase (MKP-1), β2-adrenergic receptor and glucocorticoid induced leucine 
zipper (GILZ) (Ito et al., 2006a). 
 
GR cis-repression 
Negative GRE sites have also been described in which GR results in gene 
repression (cis-repression) (Dostert and Heinzel, 2004). Examples are associated 
with corticosteroid side effects as described in the pro-opiomelanocortin (Drouin 
et al., 1993) and prolactin promoters (Sakai et al., 1988) (Figure 1.6). In the 
osteocalcin promoter, glucocorticoid-mediated repression occurs via a 
competitive mechanism between TFIID and GR and physiologically results in 
long-term osteoporosis (Meyer et al., 1997). 
 
GR transrepression 
A very telling study was performed in transgenic mice expressing GR mutants 
that cannot dimerize and therefore cannot bind to GREs. It found that despite this 
mutation, corticosteroids were perfectly capable of anti-inflammatory effects and 
able to suppress NF-κB activated genes in the normal way (Reichardt et al., 2001). 
This experiment underlines the importance of the transrepressive actions of GR 
on anti-inflammatory effects of glucocorticoids. 
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Transrepression by interaction with transcription factors 
Direct physical interaction between GR and NF-κB subunit p65 (RelA) has been 
shown with mutual inhibition of both factors (Barnes and Karin, 1997; Nelson et 
al., 2003) (Figure 1.6). AP-1 cross-talk with GR also results in mutual inhibition 
of activity via the interaction of heterodimeric complexes of AP-1 and GR 
(Reichardt and Schutz, 1998; Tuckermann et al., 1999). GR interaction with 
STAT5 results in the inhibition of the IL-2 receptor (Goleva et al., 2002b). Finally, 
interactions with STAT6 and IL-4 have also been detected (Nelson et al., 2003). 
 
Transrepression by GR recruitment of HDAC 
The repressive action by glucocorticoids may be due to the competition between 
GR and the binding sites on CBP for other transcription factors including AP-1, 
NF-κB and STAT (Adcock and Caramori, 2001). More importantly, at low steroid 
concentrations, activated GR recruits Histone Deacetylases (HDACs), such as 
HDAC2, reversing the unwinding of DNA around histones and repressing 
inflammatory gene transcription (Ito et al., 2000) (Figure 1.6). Selective knock-
down of HDAC2 in epithelial cell line using RNA interference technique, resulted 
in an increase in the expression of pro-inflammatory GM-CSF and reduced 
sensitivity to corticosteroids (Ito et al., 2006b). This mechanism can account for 
the anti-inflammatory effects of glucocorticoids in asthma and other inflammatory 
diseases. It was also observed in bronchial biopsies of asthmatics that Histone 
Acetyl Transferase (HAT) activity was reduced in patients with asthma controlled 
by inhaled corticosteroids (Ito et al., 2002a). 
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Figure 1.6 Glucocorticoid mechanism of action in the cell. Inactive GR is associated in 
the cytoplasm with heat-shock proteins (hsp). Upon corticosteroid binding, GR 
dissociates from hsp and translocates into the nucleus. It can dimerize and act as a 
transcription factor binding to glucocorticoid response elements (GRE), engaging co-
factors such as SRC and enabling the recruitment of p160 and CBP/p300 with HAT 
activity. This allows the unwinding of DNA from histones (active chromatin), the binding 
to RNA Pol II and subsequent transcriptional activation. Several genes switched on by 
GR have anti-inflammatory effects, such as secretory leukocyte peptidase inhibitor 
(SLPI), IL-10, MAP kinase phosphatase (MKP-1) and glucocorticoid induced leucine 
zipper (GILZ). GR dimers can also bind negative GRE (nGRE) repressing the 
transcription of various genes (osteocalcin, prolactin) in a process called “cis-repression”. 
Various stimuli (LPS, cytokines, and oxidative stress) can excite inflammatory mediators 
such as IKK, JNKs, p38MAPK and PI3Ks responsible for the activation of pro-
inflammatory transcription factors. AP-1, NF-κB and STAT are able to enlist co-factors 
with HAT activity enhancing the transcriptional activation of pro-inflammatory genes via 
RNA Pol II recruitment. GR can act as a monomer, bind AP-1 and effectively 
transrepress its function via sequestration. It can also transrepress via the recruitment of 
HDAC2 to the transcription machinery and deacetylate histones, inactivating chromatin. 
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1.1.7.1.6 Post-translational modifications of GR 
The complexity of multiple receptor isoforms of GR generated by alternative 
splicing is enhanced by the post-translational modifications in the forms of 
phosphorylation, acetylation, nitration and sumoylation. 
 
Phosphorylation 
GR is a phosphoprotein containing multiple potential sites for phosphorylation. 
such as serines 113, 141, 203, 211 and 226 in humans (Zhou and Cidlowski, 
2005). The receptor is constitutively phosphorylated under physiological 
conditions, but also undergoes an agonist-induced and cell-cycle-dependent 
hyperphosphorylation (Zhou and Cidlowski, 2005). Wang et al. found that 
alternative phosphorylation at S203 and S226 could result in the recruitment of a 
phosphatase (PP5) that prevents hyperphosphorylation at the other site (Wang et 
al., 2007). PP5 might then be involved in nuclear-cytoplasmic shuttling via 
dephosphorylation of GR (Dean et al., 2001). S211 has been found to be 
phosphorylated in the nucleus after ligand binding with a potential role as a 
biomarker of activated GR (Wang et al., 2002) although another evidence 
suggests that GR phosphorylation decreases GR ligand binding in the nucleus 
(Irusen et al., 2002). Altered GR phosphorylation might also affect hsp90 
interactions (Hu et al., 1994), subcellular localization (Somers and DeFranco, 
1992) and transactivation potential (Wang et al., 2007).  
Cell cycle variations might determine GR phosphorylation, as it was observed that 
cells in G2/M are less sensitive to corticosteroids where the receptor is highly 
phosphorylated (Bodwell et al., 1998). This evidence supports a molecular 
mechanism of resistance to corticosteroids based on a hyperphosphorylated GR. 
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Recent evidence also points at the possibility that phosphorylated GR is involved 
in receptor turnover by ubiquitination and proteosomal degradation (Wallace and 
Cidlowski, 2001). GR serines are targets for major kinases such as p38MAPK 
(Irusen et al., 2002), cyclin-dependent kinases (CDK) (Krstic et al., 1997), 
glycogen synthase kinase-3 (GSK-3) (Rogatsky et al., 1998b) and c-Jun N-
terminal kinases (JNK) (Itoh et al., 2002). 
 
Acetylation 
Studies have shown that both androgen receptor and oestrogen receptor-α are 
acetylated within their hinge/ligand binding domains and that this can modulate 
hormone-induced gene transcription (Fu et al., 2003; Wang et al., 2001). The 
acetylation site is conserved among nuclear receptors and is located at amino 
acids 492-495 (KTKK) within the DBD region of GR. GR is acetylated following 
ligand binding and becomes a substrate of HDAC2. Deacetylation of GR by 
HDAC2 may be a prerequisite for GR association with p65-NF-κB activated 
complex with subsequent suppression of inflammatory gene expression. This 
mechanism provides a molecular explanation for the ability of GR to distinguish 
between recruitment of coactivator and corepressor proteins and the subsequent 
ability to transactivate or repress gene transcription (Ito et al., 2006b). Although 
not directly involved in GR post-translational modifications, it is important to 
point out that HDAC6 regulates hsp90 acetylation and chaperone-dependent 
activation of glucocorticoid receptor (Kovacs et al., 2005). 
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Nitration, ubiquitination, sumoylation 
Post-translational modifications of GR via nitration resulting from 
oxidative/nitrative stress (Rahman and Adcock, 2006), ubiquitination leading to 
GR degradation (Wallace and Cidlowski, 2001) and sumoylation, involved in  
protein-protein and protein-DNA interactions (Ito et al., 2006a), are thought to 
play an important role in GR activity. 
 
1.1.7.2 β2-adrenoreceptors  
Short acting β2-adrenoreceptors (SABAs) are drugs prescribed to asthmatics that 
produce bronchodilation that last for about 6 hours. The inhaler salbutamol and 
terbulatine are usually used as controller medication in mild, moderate and severe 
asthmatics. LABAs, which produce bronchodilation that last up to 12 hours, are 
prescribed in the form of formoterol (full agonist) or salmeterol (partial agonist) 
and have bronchoprotective action against a wide range of stimuli that induce 
airway obstruction in asthma (Bond et al., 2007). LABAs should not be given as 
monotherapy and are most effective when combined with inhaler steroids 
(Lemanske, Jr. et al., 2001). β2-adrenoreceptor agonists are believed to cause 
airway smooth muscle relaxation primarily by increasing intracellular levels of 
cyclic adenosine monophosphate (cAMP) and opening potassium channels (Rabe 
and Schmidt, 2001). All β2-agonists exert their effects through cell-surface β2-
adrenoreceptors, which are 7-transmembrane, G-protein-coupled receptor family. 
After ligand binding, the α-component of the associated Gs-protein dissociates 
and activates adenylate cyclase. This results in the intracellular accumulation of 
cAMP and subsequent PKA activation, which regulates a number of intracellular 
regulatory proteins through phosphorylation (Johnson, 2004). β2-agonists 
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influence gene transcription through cAMP by PKA-mediated phosphorylation of 
CREB (Montminy et al., 1990).  
Other mechanisms besides acting as a bronchodilator have been described. In 
mast cells, β2-agonists have shown to inhibit the release of histamine and 
cyteinyl-leukotrienes in vitro (Chong et al., 1998). In endothelial cells, both 
salmeterol and formoterol inhibit plasma exudation by preventing separation of 
endothelial cells in post capillary venules (Baluk and McDonald, 1994; Bolton et 
al., 1997; Chong et al., 1998). LABAs were also shown to reduce adhesion of 
neutrophils and eosinophils to venular endothelial cells, inhibiting granulocyte 
trafficking into the airway wall (Bowden et al., 1994). In animal models of 
neutrophilic inflammation, LPS induced inflammation in mice and β2-agonists 
were shown to have inhibitory effects on neutrophil recruitment to the lung. This 
was confirmed in mild asthmatic patients by using formoterol (Maneechotesuwan 
et al., 2005; Miyamoto et al., 2004).  
Mounting evidence also exists which proves that there are positive interactions 
between β2-agonists and corticosteroids contributing to the efficacy of the 
combination therapy as a rescue therapy as well as a maintenance treatment 
(Barnes, 2007). Combination of fluticasone propionate and salmeterol has been 
found to work better for the inhibition of NF-κB by induction of Iκ-Bα in 
peripheral blood T cells. The interactions between corticosteroid and LABA have 
resulted in complementary inhibition on cytokine and chemokine release, such as 
GM-CSF, RANTES and IL-8 (Pace et al., 2004). 
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1.1.7.2.1 Effect of LABA on GR 
Molecular evidence has shown that LABAs enhance the action of corticosteroids 
through the increase of GR nuclear translocation in airway smooth muscle cells 
(Roth et al., 2002), airway epithelial cells (Korn et al., 2001), and in macrophage 
cell lines (Usmani et al., 2005) (Figure 1.7). The mechanism of LABA priming of 
GR remains controversial. Some studies point at the activation of MAPK by 
cAMP/PKA that results in the phosphorylation of GR (Daaka et al., 1997). This 
phosphorylation of GR has been confirmed by Zhou et al., (Zhou and Cidlowski, 
2005) although phosphorylation of GR results in a decreased corticosteroid 
sensitivity as observed in G2/M cell cycles (Hsu and DeFranco, 1995; Hu et al., 
1997) or by Irusen at al. (Irusen et al., 2002) in PBMCs from severe asthmatics. It 
is possible that cAMP increases protein phosphatases such as PP2A (Feschenko et 
al., 2002) and this could result in dephosphorylation of GR and subsequent 
nuclear localization (Galigniana et al., 1999; Somers and DeFranco, 1992).  
 
1.1.7.2.2 Effect of GR on LABAs 
Corticosteroids increase transcription of the β2-adrenoreceptor gene, resulting in 
increased expression of β2-agonists at the cell surface (Mak et al., 1995) (Figure 
1.7). The prevention of downregulation of β2-adrenoreceptor by corticosteroids in 
animal models has been observed, which may prevent the development of 
tolerance to LABAs (Mak et al., 2002). 
Recently much effort is being directed in the development of a new generation of 
β2-agonists called “ultra long-acting β2-agonists” in order to reduce drug intake to 
once per day (Cazzola et al., 2005; Mak et al., 2002).  
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Figure 1.7 Formoterol pathway of action. Long acting beta-agonists (formoterol and 
salmeterol) act through β2-adrenoreceptors. After ligand binding, the α-component of the 
associated Gs-protein dissociates and activates adenylate cyclase. This results in the 
intracellular accumulation of cAMP and subsequent PKA activation, which is responsible 
for bronchodilation. PKA activation is thought to be responsible for an increase in 
efficacy of steroid, such as improved nuclear translocation, GRE binding and anti-
inflammatory effects. GR increases LABAs’ potential via increased β2-receptor 
expression and coupling, decreased down-regulation and prevention of β-agonist 
tolerance.  
 
1.1.7.3 Theophylline 
Theophylline has been relegated to the third-line therapy in asthma in the GINA 
guidelines (GINA, 2007; Mak et al., 2002). Theophylline is considerably less 
expensive than LABAs and may be the only affordable add-on treatment when the 
cost of medication is limited (Barnes, 2003). Studies have confirmed that addition 
of theophylline may be equal to doubling the dose of inhaled corticosteroids in the 
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treatment of asthma (Evans et al., 1997; Ukena et al., 1997). Theophylline is 
useful in the management of patients with severe asthma as demonstrated by 
improvement of clinical parameters in patients on high doses of inhaled 
corticosteroids (Rivington et al., 1995).  
Initially theophylline was used as a bronchodilator with a therapeutic range 
established at 10 to 20 mg/l (Barnes, 2003). Its molecular mechanism involves the 
inhibition of PDE3/4 resulting in an increase of cAMP via PDE5 inhibition 
resulting in cGMP accumulation (Rabe et al., 1995). At high doses (above 20 
mg/l) theophylline acts as an adenosine receptor antagonist (A1, A2, and A3) 
which accounts for some of the side effects (Barnes, 2003). High doses have been 
also found to be responsible for IL-10 increase and preservation of Iκ-B 
expression (inhibition of NF-κB) (Umeda et al., 2002). Interestingly, high 
concentrations (75 μM) were shown to inhibit the PI3Kδ subunit (p110) that has 
been implicated in oxidative stress. High doses were also shown (800 μM) to be 
inhibitory doses of PI3Kγ, involved in chemotactic response to neutrophils and 
monocytes (Barnes, 2003). At lower doses, theophylline (1 to 10 μM) has been 
shown to activate HDAC activity thus suppressing inflammatory genes (Ito et al., 
2002b). This effect was blocked by the HDAC2 inhibitor trichostatin A (TSA). 
The effect of corticosteroids did not activate HDAC as the effect of theophylline 
was observed in nuclear extracts from immunoprecipitated NF-κB gene 
complexes (Cosio et al., 2004b). Corticosteroids effect is only confined to the 
recruitment of HDAC2 (Ito et al., 2000). Although the HDAC activation is 
relatively small, Barnes reminds that small differences in the number of acetylated 
histones results in relatively large biophysical changes (Barnes, 2003). 
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Interestingly, the effect of theophylline seems to be stronger under oxidative 
stress (Cosio et al., 2004b) where HDAC activity is reduced (Ito et al., 2002b). 
 
1.1.7.4 Others 
Leukotrienes (LTs), including cysteinyl LTs (CysLTs; LTC4, LTD4, LTE4) and 
LTB4, are pivotal molecules in the complex network of inflammatory disease. 
LTs are potent lipid mediators derived from arachidonic acid (AA) through the 5-
lipoxygenase (5-LO) pathway (Montuschi et al., 2007). Biosynthesis of LTs 
requires cellular activation, such as IgE receptor cross-binding on cell surface for 
arachidonic acid metabolism (Dahlen, 2006). 5-LO and the existing LTs are 
differentially expressed in cell types conferring potential selectivity for drugs. 
Two G protein-coupled receptor subtypes for CycLTs (CysLT1 and CysLT2) have 
been identified and most of the pathophysiology of asthma is mediated by CysLT1 
receptor (Dahlen, 2006). Most of the evidence for the role of CysLTs in asthma 
comes from the clinical effectiveness of CysLT1 receptor antagonist such as 
montelukast, zafirlukast and pranlukats, as well as from 5-LO inhibitors (zileuton) 
in patients with asthma (Busse and Kraft, 2005). CysLT1 receptor antagonists 
improve pulmonary function, symptoms, quality of life, reduce β-agonist use, 
eosinophilia, asthma exacerbations and the required dose of inhaled 
corticosteroids in asthmatic patients (Kankaanranta et al., 2004; Montuschi et al., 
2007).  
LTB4 inhibition may prevent neutrophil recruitment in severe asthma and asthma 
exacerbations (Wenzel et al., 1997). BLT1, a LTB4 receptor subtype is required 
for CD8+ T cell-mediated, mast cell-dependent AHR in mice. The number of this 
subset of CD8+ T cells are increased in steroid-resistant asthma compared to 
 66
steroid-sensitive asthmatics (Gelfand and Dakhama, 2006; Lofdahl et al., 1999). 
Add-on therapy with CysLT1 receptor antagonist enables a reduction in the dose 
of inhaled corticosteroid required to control asthma with an equivalent therapeutic 
response (Lofdahl et al., 1999). 
TNFα’s importance in severe asthma was underlined in a study which shows a 30-
fold increase in gene expression in the airway of enhanced circulating 
mononuclear cell expression of membrane precursor of TNF, the TNFα-cleaving 
enzyme (TACE) and its receptors p75 and p55 (Erzurum, 2006), as well as 
increased secretion of soluble TNFα even in the presence of high dose inhaled or 
oral corticosteroids (Waserman et al., 2000). Etanercet responded well in some 
severe asthmatics in a recent study (Berry et al., 2006) although another trial with 
the anti-TNFα antibody in asthma remained inconclusive (Erin et al., 2006). An 
extensive study focusing only in severe asthma is needed to confirm the 
importance of TNFα in this disease. 
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1.2 Severe Asthma 
1.2.1 Definition, diagnosis and natural history 
Asthma is a chronic inflammatory disorder of the airway, characterized by 
episodic dyspnoea, coughs and wheezing, associated with hyperresponsiveness of 
the airways to a variety of environmental stimuli (GINA, 2007). Most patients 
with asthma have mild to moderate forms of the disease, which is well controlled 
by corticosteroids or a combination of corticosteroids and β2-adrenoreceptors 
agonists. However, for between 5-10% of patients, asthma remains symptomatic 
despite treatment with corticosteroids (Sorkness et al., 2008). This group of 
patients account for about 50% of total health care cost in asthma (Barnes and 
Woolcock, 1998; Chung et al., 1999). This disproportionate use of health care 
resources results from hospital admissions, unscheduled doctor visits and use of 
emergency services (Dolan et al., 2004; Godard et al., 2002). The search for new 
therapies in asthma is particularly diverted towards severe asthmatics as these 
patients are poorly controlled and suffer from adverse side effects of treatments. 
A European Respiratory Task Force adopted the term “difficult asthma” in 1999 
and defined it as “asthma poorly controlled in terms of chronic symptoms, with 
episodic exacerbations, persistent and variable airway obstruction and continued 
requirement for short-acting β-agonists and high doses of inhaled corticosteroids” 
(Chung et al., 1999; Dolan et al., 2004). Later, in 2000, the American Thoracic 
Society (ATS) defined “refractory asthma” by one or two major and two or more 
minor criteria, based on medication required, asthma symptoms, frequency of 
exacerbations and degree of airway limitation (ATS, 2000a; Dolan et al., 2004) 
(Table 1.1). The diagnosis of severe asthma should be reserved for those who 
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have refractory asthma after an extensive re-evaluation and an appropriate 
observation by an asthma specialist for at least six months (GINA, 2007). 
 
Table 1.1 American Thoracic Society (ATS) criteria for refractory asthma 
Major criteria: 
1.   Treatment with continuous inhaled corticosteroid 
2.   Requirement for treatment with high doses of oral corticosteroids 
Minor criteria: 
1. Requirement for daily treatment with a controller medication in addition to 
inhaled corticosteroids. 
2. Daily use of short-acting β-agonist, theophylline or leukotriene antagonist. 
3. Persistent airway obstruction (FEV1<80% predicted; diurnal PEF 
variability>20%) 
4. One or more urgent care visits for asthma per year 
5. Three or more steroid “burst” per year 
6. Prompt deterioration with ≤25% reduction in oral or inhaled corticosteroid 
dose 
7. Near fatal asthma event in the past 
FEV1: Forced expiratory volume in one second 
PEF: Peak expiratory flow 
 
1.2.2 Contributing factors to asthma severity 
1.2.2.1 Environmental exposures 
According to the European Network for Understanding Mechanisms of Severe 
Asthma (ENFUMOSA) survey in Europe (ENFUMOSA, 2003), atopy was 
present in about 60% of patients in which perennial allergens, including those 
derived from house-dust mite, cockroaches and fungi (especially Aspergillus 
Alternia species) contribute to ongoing disease. Another study of patients with 
severe asthma found that all 28 patients had skin tests positive to at least one of 
the following antigens: dust mite, dog or cat. In addition, 20 out of 28 were 
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positive to all 3 compared with a much lower rate of allergen positivity in patients 
with mild asthma (Tunnicliffe et al., 1999). 
Bronchopulmonary allergic apergillosis is a rare but important asthma subtype 
because if left untreated it can lead to bronchiectasis (Gibson, 2006). Nevertheless, 
even in the presence of atopy, severe asthma becomes less dependent on 
aeroallergen exposure (Nieves et al., 2005). Occupational exposure should be 
assessed (Holgate and Polosa, 2006). Avoiding allergens in some patients should 
be monitored: for example, 7 out of 22 patients sensitized to cats continue to keep 
cats, and 4 out of 17 of those sensitized to dogs still had a dog at home (Adcock 
and Ito, 2004). 
Smoking has been shown to increase symptoms of severe asthma, increasing 
exacerbations, and resulting in a more rapid decrease in lung function. In fact, 
smoking is regarded as the biggest cause of corticosteroid resistance. The 
mechanism of corticosteroid insensitivity in smokers with asthma is currently 
unexplained but could be due to alterations in airway inflammatory cell 
phenotypes, changes in GR alpha/beta ratio, and/or reduced histone deacetylase 
activity (Thomson et al., 2006). Cigarette smoke also increases the clearance of 
theophylline and other drugs as it induces P450-1A2, responsible for the 
metabolism of theophylline, increasing the clearance by 60 to 100% (Zevin and 
Benowitz, 1999). 
 
1.2.2.2 Adherence 
Adherence is often found to be suboptimal in asthma (Lacasse et al., 2005). A 
systemic assessment of 100 patients has found that severe asthmatics that referred 
to a tertiary centre were diagnosed alternatively in 32% of the cases and nearly 
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50% did not adhere to therapy (Robinson et al., 2003). Children and adolescent 
with poor asthma control have been associated with insufficient corticosteroid 
treatment adherence. Poor adherence was also suggested to increase with the 
severity of the disease (Moser et al., 2006). 
 
1.2.2.3 Psychological factors 
Depression, anxiety disorders and panic attacks may be mistaken for asthma. 
About 11% of patients in a Brompton Hospital study were thought to have a 
major psychiatric component to their disease (Robinson et al., 2003). It is difficult 
to distinguish whether the psychiatric aspects are the result, rather than the cause 
of the disease. Another study found that among patients with asthma, increased 
panic and anxiety are associated with the use of more intensive corticosteroid 
regimes, overuse of bronchodilators, and more frequent hospitalizations 
regardless of the objective lung function (Smoller et al., 1996). 
 
1.2.2.4 Co-morbidities 
Several co-morbidities and aggravating factors may contribute to the severity of 
asthma. Many factors have been associated with frequent exacerbations, including 
severe nasal and sinus disease, gastroesophageal reflux, recurrent respiratory 
infection and psychological dysfunction (ten Brinke et al., 2005). 
Gastroesophageal reflux’s high association with asthma in adults and children 
(Gibson et al., 2003) could be caused by the proximity of the organs and neural 
connections. However, some treatments suggest that its contribution to asthma 
severity is variable (Coughlan et al., 2001; Kiljander et al., 2006; Littner et al., 
2005). Allergic and non-allergic rhinosinusitis has also been associated with 
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severe asthma and is considered to influence asthma outcome, especially when it 
is associated with aspirin-induced asthma (Mascia et al., 2005; Wark et al., 2005).  
Obesity has been shown to be associated with asthma, particularly in women 
(Weiss and Shore, 2004). A study has shown that weigh reduction is associated 
with better asthma control and a reduction in asthma severity (Ford, 2005). 
Gender differences in asthma have already been recognized, with exacerbation of 
symptoms in women a few days prior to the onset of menstruation, called 
“premenstruation” asthma affecting up to 40% of women with asthma (Chhabra, 
2005; Tan, 2001). The severe cases, more rare, are characterized by an impaired 
response to systemic corticosteroids. 
 
1.2.3 Phenotypes of asthma 
Emerging evidence suggest that asthma is characterized by its heterogeneous 
condition, which includes several different phenotypes (Wenzel, 2005). 
Phenotyping of severe asthma will improve our understanding of the underlying 
mechanisms, natural history and prognosis as well as help with the discovery of 
new therapeutic interventions. 
Severe asthma is a multifaceted condition that can be divided into different 
phenotypes. They can be classified using several features of the disease including 
symptoms, health status, asthma control, airway obstruction (variable or partially 
fixed), bronchial hyperresponsiveness (BHR), atopy, inflammation, exacerbation 
and response to treatment.   
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1.2.3.1 Brittle asthma 
The identification of brittle asthma or explosive asthma (Ayres et al., 1998) was 
found to be associated with strong atopic characteristics (Miles et al., 1995), 
psychosocial morbidity (Miles et al., 1997) and an increase frequency of adverse 
reaction to foods (Baker et al., 2000). In addition, female patients with this 
phenotype are at a significant excessive risk of premenstrual asthma, which is 
often severe. Such exacerbations are characterized by an impaired response to 
systemic corticosteroids, probably due to a decreased receptor density during the 
luteal phase (Miles et al., 1997). Two types of brittle asthma were defined. Type I 
brittle asthma is characterised by a maintained large PEF variability (> 40% 
diurnal variation for > 50% of the time over a period of at least 150 days) despite 
considerable medical therapy including a dose of inhaled steroids of at least 
1500 µg of beclomethasone (or equivalent). Type II brittle asthma is characterised 
by sudden acute attacks occurring in less than three hours without an obvious 
trigger on a background of apparent normal airway function or well controlled 
asthma (Ayres et al., 1998). 
 
1.2.3.2 Fixed airway obstruction 
All studies of chronic severe asthma have identified a degree of fixed airflow 
obstruction as a distinctive feature (ENFUMOSA, 2003; Bel, 2004). This is 
characterized by a reduced baseline function, which is only partially reversible 
with combination of β2-agonist and corticosteroids. The pathology of remodelling 
and persistent airflow obstruction in asthma differs from that observed in COPD, 
and is characterized by a higher number of eosinophils in peripheral blood and 
airway wall, lower number of neutrophils, higher CD4+/CD8+ ratio of T cells and a 
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thicker reticular layer of the epithelium basement membrane (Fabbri et al., 2003). 
Subjects with refractory asthma with eosinophils had a thickened subbasement 
membrane (SBM) and increase number of submucosal cells positive for TGF-β, a 
cytokine with known fibrogenic properties (Wenzel et al., 1999). 
Genetic studies have identified single nucleotide polymorphisms in ADAM33, IL-
4, IL-4R and TGF-β that are associated with lower than normal lung function, and 
IL-4 single nucleotide polymorphism has also been associated with near-fatal 
exacerbations of asthma (Jongepier et al., 2004; Pulleyn et al., 2001; Sandford et 
al., 2000). Recently Wenzel et al. have found that single nucleotide 
polymorphisms (SNPs) in IL-4Rα are associated with severe asthma 
exacerbations, lower lung function and increased mast cell-related tissue 
inflammation (Wenzel et al., 2007) 
A subpopulation of severe asthmatics exhibited elevated number of eosinophils as 
well as neutrophils in bronchial biopsies (Wenzel et al., 1997). Sputum 
eosinophilia appeared to be the only independent factor associated with persistent 
airflow limitation. This refractory eosinophilic inflammation might be the 
reflection of a clinical asthma phenotype exhibiting more severe and active 
disease or ongoing inflammation in regions of the airway that are not or hardly 
accessible to inhaled drugs, such as the small airways (Wenzel et al., 1997). 
Another clinical study in chronic asthmatics found that there was an inverse 
correlation between induced sputum neutrophil counts and maximal FEV1, 
indicating that chronic asthma results in irreversible airflow obstruction and 
suggest a possible role for neutrophils in this process. IL-8, a known neutrophil 
chemoattractant, was also abundant in induced sputum from those patients (Little 
et al., 2002). The increase in neutrophils may be explained by a change in the 
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inflammatory pattern away from Th2 towards a Th1-like pattern with increased 
expression of TNFα and IFNγ (Balzar et al., 2005; Truyen et al., 2006).  
 
1.2.3.3 Corticosteroid resistance in asthma 
Although corticosteroids remain highly effective in the control of asthma and 
other chronic inflammatory diseases, a small proportion of patients with asthma 
fail to respond even to high doses of corticosteroids (Barnes and Adcock, 1995; 
Szefler and Leung, 1997). It is likely that there is a spectrum of glucocorticoid 
responsiveness, with the rare resistance at one end, but a relative resistance is seen 
in patients who require high doses of inhaled and oral glucocorticoids 
(glucocorticoid-dependent asthma) (Adcock and Lane, 2003). It remains unclear 
as to why these patients might respond less well to inhaled and oral 
glucocorticoids. A distinct pathophysiology present in a subgroup of patients with 
severe asthma might account in part for these differences in responsiveness, such 
as neutrophilic inflammation (Wenzel et al., 1999) or cases of a T-cell and 
eosinophilic inflammation (Chakir et al., 2002; Silkoff et al., 2005). Other causes 
might be excessively remodelled airways that are fixed and non-responsive to 
corticosteroids (Lazaar and Panettieri, Jr., 2003). It is important to look at both 
clinical and molecular features of corticosteroid resistance in asthma to better 
understand the complexity of the disease. 
 
1.2.4 Clinical features of CR asthma 
Some patients with severe asthma have been termed “steroid resistant” or “steroid 
insensitive”. They are characterized by pre-bronchodilator FEV1 of less than 70% 
predicted with a maintained bronchodilation response. Corticosteroid-resistant 
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(CR) asthma is defined by administration course of oral prednisilone (40 mg/day) 
for two weeks and the observation of the effects of morning pre-bronchodilator 
FEV1 (Lee et al., 1996). If the FEV1 fails to increase by 15%, the patient is 
considered to be steroid resistant. This, however, is very rare with a prevalence of 
less than 1:1000 patients with asthma. More common is a reduced responsiveness 
to corticosteroids, described as corticosteroid-dependent (CD) asthma, when large 
inhaled or oral doses are needed to maintain some degree of control although this 
is often sub-optimal. As mentioned before, it is likely that there is a range of 
responsiveness to corticosteroids and that CR is at one end of a spectrum of 
corticosteroid responsiveness (Barnes, 2004). Evaluation of corticosteroid 
pharmacokinetics is important to identify patients with incomplete corticosteroid 
absorption, failure to convert an inactive form (prednisilone) to an active form 
(prednisone) or rapid elimination (Hill et al., 1990; Spahn et al., 1997). Increased 
clearance of prednisilone and methylprednisilone has been observed in 25% of 
severe asthmatics and enhanced elimination of the steroids might be due to 
interaction with other drugs. Ritampin, and the anticonvulsants phenytoin and 
carbamazepine are known to enhance corticosteroid metabolism (ATS, 2000a). 
 
1.2.5 Molecular mechanisms of CR asthma 
1.2.5.1 Abnormalities in GR receptor 
Mutations to the Glucocorticoid Receptor (GR) gene are extremely rare but have 
been identified and result in reduced ligand affinity (Bray and Cotton, 2003). Sher 
et al. have described 2 patterns of ligand binding abnormalities in patients with 
CR asthma. The most common, type 1 defect, is associated with a reduced 
binding affinity (Kd) of the nuclear GR and normal receptor number (specific to T 
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cells). The less common, type 2, is associated with reduced nuclear GR receptor 
density and a normal Kd in the monocyte population (Sher et al., 1994). 
 
1.2.5.2 Inflammatory cytokines 
Sher and colleagues also reported that peripheral blood mononuclear cells 
(PBMCs) with a type 1 GR defect had their ligand binding affinity restored to 
normal levels after incubating in media for 48 hours (Sher et al., 1994). But if 
incubated with high concentrations of IL-2 and IL-4 or IL-13 alone, it mimicked 
corticosteroid resistance (Irusen et al., 2002; Sher et al., 1994; Spahn et al., 1996). 
This was not the case for type 2 patients (Sher et al., 1994). The combination of 
IL-2 and IL-4 has also been shown to induce CR in vitro through the activation of 
p38MAPK, which results in GR serine phosphorylation. (Irusen et al., 2002) 
(Figure 1.8). IL-2 and IL-4 cytokines have also been observed to be elevated in 
bronchoalveolar lavage (BAL) cells of steroid naïve severe asthmatics (Leung et 
al., 1995). Similarly, in a murine cell line, incubation with IL-2 induced steroid 
resistance via activation of Janus-associated kinase 3 (JAK3), phosphorylation of 
STAT5 and sequestration of GR in the cytoplasm (Goleva et al., 2002a). In 
contrast, in CD4+ T cells, enhancement of TCR signalling by IL-2-mediated 
costimulation abrogated the suppressive effect of dexamethasone on c-Fos 
expression and AP-1 function. A role in ERK upregulation was essential in T cell 
resistance to dexamethasone (Tsitoura and Rothman, 2004).  
 
1.2.5.3 Defect of GR nuclear translocation and GR-GRE binding 
Matthews et al. have found that one subgroup of patients with CR and CD asthma 
exhibited impaired nuclear translocation of GR after dexamethasone treatment, 
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whereas the second group showed a decrease in transactivation potential as 
measured by Histone-4 acetylation (Matthews et al., 2004) (Figure 1.8). 
Electrophoretic mobility shift assay (EMSA) data from Adcock et al. has shown 
that CR asthmatics also presented a decrease of GR binding to the glucocorticoid 
response elements in DNA (GRE) compared to non asthmatics after 
dexamethasone stimulation of PBMCs. This was concluded to be caused by a 
reduction in the number of GR available to bind to the GRE rather than a change 
in affinity to the GRE in CR asthmatics (Adcock et al., 1995). 
 
1.2.5.4 Glucocorticoid receptor beta 
The increased expression of an alternative splice variant of the GR receptor, GRβ, 
which binds DNA but not corticosteroids, has been extensively reported (Goleva 
et al., 2006; Leung and Bloom, 2003; Sousa et al., 2000) (Figure 1.8). RNA 
silencing of GRβ in CR asthma BAL cells resulted in the enhancement of 
dexamethasone-induced GRα transactivation (Goleva et al., 2006). Acting as a 
dominant negative inhibitor or a decoy receptor, competing for GRE binding sites 
with GRα (Hamid et al., 1999), GRβ is reported to be increased in steroid 
insensitive diseases, such as inflammatory bowel disease and severe asthma, but 
there is some controversy as to its role since not all studies confirm enhancement 
in CR asthma (Gagliardo et al., 2000; Irusen et al., 2002; Torrego et al., 2004). 
Interestingly, the highest expression of GRβ has been found in neutrophils, which 
are known to be relatively corticosteroid insensitive (Strickland et al., 2001). 
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1.2.5.5 Defect of transrepression: Interaction with transcription factors 
Corticosteroids are able to suppress inflammatory genes regulated by binding to 
pro-inflammatory transcription factors such as AP-1 and NF-κB. However, high 
numbers of transcription factors binding to GR, result in reduction of functional 
GR needed to inhibit inflammation (Adcock and Lane, 2003; Sousa et al., 1999) 
(Figure 1.8). In fact, there is extensive evidence that AP-1 activity is increased in 
PBMCs from CR asthma as well the expression of the AP-1 subunit, c-Fos, in 
both biopsies and PBMCs (Adcock et al., 1995; Lane et al., 1998). Also, Loke and 
colleagues found that basal levels of c-jun and JNK phosphorylation were 
increased in leukocytes from CR and CS asthmatics. A two-week course of 
prednisilone reduced phosphorylation of CS but not of CR asthmatics (Loke et al., 
2006).  
 
1.2.5.6 Defect of GR transactivation 
Matthews et al. have shown that CR asthmatics presented one phenotype with low 
GR nuclear translocation and another phenotype with defective acetylation of 
Histone-4 Lysine 5, which is a marker of corticosteroid transactivation of steroid-
responsive genes (Matthews et al., 2004) (Figure 1.8). Matthews et al. also 
speculated that the defect of GR transactivation was due to either a loss of a 
specific HAT or to increased activity of a specific HDAC in those patients 
(Matthews et al., 2004). 
 
1.2.5.7 IL-10 
The anti-inflammatory cytokine IL-10 is produced in response to dexamethasone 
in Th2 (CD4+) cells in patients sensitive to corticosteroids but the mechanism is 
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defective in patients with CR asthma (Hawrylowicz et al., 2002). IL-10 secretion 
is also defective from alveolar macrophages and circulating monocytes of patients 
with asthma, particularly severe ones (John et al., 1998; Tomita et al., 2002). 
Xystrakis et al. showed that CD4+ T cells from CR asthmatics were shown to be 
defective for IL-10 secretion after dexamethasone treatment, and this was 
reversed by pre-incubating with vitamin D3 (Xystrakis et al., 2006).  
 
1.2.5.8 Cigarette smoking 
Patients with asthma who smoke may be less responsive to the anti-inflammatory 
actions of corticosteroids than non-smokers (Thomson et al., 2006). Bronchial 
biopsies from smoking asthmatics showed reduction of HDAC2 expression and 
activity which may account for the loss of GR function (Ito et al., 2002b). As well 
as smoking, an increase in oxidative stress in severe asthma has been reported 
(Katsoulis et al., 2003; Kharitonov and Barnes, 2003). Reactive oxygen species 
(ROS) were shown to reduce HDAC2 activity (Ito et al., 2004) and impair GR 
nuclear translocation (Okamoto et al., 1999). 
 
1.2.5.9 Viral infection 
Corticosteroid resistance may evolve as a result of viral infection resulting in the 
activation of transcription factors interfering with corticosteroid action or 
reduction of HDAC. In children with severe asthma, there is evidence for 
persistent adenovirus infection in the airways (Macek et al., 1994) and adenovirus 
infection decreased corticosteroid action in guinea pigs (Hayashi and Hogg, 2007; 
Bellettato C., 2003). Recent evidence has suggested that rhinoviral infection can 
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reduce GR nuclear translocation and reduce corticosteroid action (Bellettato C., 
2003). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Mechanism of corticosteroid resistance. The combination of IL-2 and IL-4 
or IL-13 alone is known to reduce corticosteroid sensitivity in glucocorticoid receptor 
(GR) possibly through the activation of some kinases. GRβ isoform is unable to bind 
steroids and can act as a dominant negative inhibitor competing for GR in binding to 
specific sites in DNA. A defective pattern of Histone-4 lysine 5 acetylation is also known 
to affect transcriptional potential of GR in the nucleus. Oxidative stress can result in the 
activation of some kinase pathways (such as PI3K) leading to the reduction of HDAC2 
activity necessary for GR transrepression activity. LPS, chemokines and cytokines can 
activate kinase pathways (JNK, p38MAPK) or IKKs resulting in overexpression of pro-
inflammatory transcription factors (AP-1, NF-κB) and decreased GR availability in the 
nucleus. 
 
1.2.6 Abnormal Th1/Th2 balance 
The “Th2 hypothesis for asthma” was initially suggested by Mosnman et al. in 
1989 (Mosmann and Coffman, 1989) and it divides two distinct subtypes of 
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helper T cells in mice, Th1 and Th2. Th2 cells, which produce IL-4 (enhancing 
IgE synthesis), IL-5 (increasing eosinophil growth and differentiation), IL-9 
(enhancing mast cell differentiation) and IL-13 (increasing mucus production and 
inducing hyperactivity) control and amplify the allergic response (Umetsu et al., 
2002; Wills-Karp, 1999). Th1 lymphocytes produce IFNγ and IL-2, which 
activate mechanisms important in defence against viruses and bacteria (Mosmann 
and Coffman, 1989). The Th2 hypothesis for asthma describes that asthma is 
caused by a relative increase in Th2 cellular response in combination with a 
decrease in Th1 response. Knock-out mice models support the Th2 hypothesis in 
that adoptive transfer of differentiated Th2 cells can induce airway eosinophilia 
and AHR on inhaled challenge (whereas Th1 cells do not), and both IL-4 and IL-5 
were implicated in airway eosinophilia and AHR in different knock-out and 
antibody studies (Foster et al., 1996; Lloyd et al., 2001). Recently, T-bet was 
described as a controller of Th1 development and is shown to direct IFNγ 
production and IL-12R β2 expression (Afkarian et al., 2002; Szabo et al., 2000). 
The transcription factor GATA3, which is implicated in Th2 development in 
mouse and human T cells, also plays an important role in the binding of the IL-5 
gene locus (Zheng and Flavell, 1997).  
Other studies have found contradictory results, in which IFNγ in asthmatic blood 
and airway is increased in acute severe asthma during exacerbations (Corrigan 
and Kay, 1991). More recently, some studies have found that IFNγ production in 
CD8+ T cells in asthmatic airway was increased and correlated with asthma 
severity, bronchial hyperresponsiveness and blood eosinophilia (Magnan et al., 
2000). Examining the capacity of Th1 to counter balance of the pro-asthmatic 
effects of Th2, a mouse model of asthma showed that Th1 cells did not attenuate 
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Th2 cell-induced airway hyperactivity and inflammation (Hansen et al., 1999). 
Moreover, introduction of the Th1 cells worsened the underlying airway 
inflammation. Similarly, another study found that Th1 potentiates the asthmatic 
inflammatory response (Randolph et al., 1999). Very recently, a study also found 
an increase in sputum IFNγ mRNA levels predominantly in patients with 
moderate to severe asthma. However, most individuals with increased IFNγ 
mRNA levels also had increased IL-4 mRNA levels with a significant correlation. 
Thus both Th1 and Th2 cytokines can be increased in parallel in the airway and 
both could contribute to disease development (Truyen et al., 2006).  
 
1.2.7 Neutrophilic inflammation 
The role of the eosinophil in mediating airway inflammation in mild and moderate 
atopic asthma has been reported and widely accepted (Gauvreau et al., 1999). 
There is now increasing evidence that patients with bronchial asthma are 
heterogeneous with respect to the type of inflammation in the airways (Douwes et 
al., 2002; Peters, 2003). The pathological abnormalities observed in the airways 
of subjects who suffered a fatal asthma attack included both eosinophils and 
neutrophil infiltration (Wark and Gibson, 2006). In particular, neutrophils 
predominated in those patients who died suddenly after the attacks, while 
eosinophils were more frequent in fatal events with a slow onset (Carroll et al., 
1996; Sur et al., 1993). A strong association exist between neutrophilic 
inflammation of the airways with severe asthma (Little et al., 2002; Wenzel et al., 
1997) and corticosteroid resistant asthma (Pavord et al., 1999; Wenzel et al., 
1999). A strong relationship is also present with smoking asthmatics (Chalmers et 
al., 2001). Some studies found out that FEV1 was inversely proportional to 
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neutrophil number. Neutrophils were also found to be present in the small airways 
and correlated with markers of neutrophil degranulation (Gibson et al., 2001; 
Little et al., 2002; Wenzel et al., 1997). Influx of neutrophils in response to IL-8 is 
already known to occur (Ribeiro et al., 1991). In severe disease, eosinophils and 
neutrophils are usually found together (Wenzel et al., 1999) although neutrophils 
may gradually replace eosinophils in proportion to the severity or duration of the 
disease (Wenzel et al., 1997). Reduction in eosinophils and eosinophilic markers 
such as IL-5 and eotaxin mRNA with an increase in neutrophils both in the central 
and peripheral airways may represent the different responses of each cell to 
corticosteroid therapy. Neutrophils have apoptosis inhibited whereas eosinophils 
have their apoptosis activated by corticosteroids (Cox, 1995; Meagher et al., 
1996). 
  
1.2.8 Current treatment of CR asthma 
Standard treatment for corticosteroid resistant severe asthma includes high doses 
of inhaled corticosteroid (beclamethasone diproprionate > 1000 μg daily) 
combined with long-acting inhaled β2-agonist (LABA) (GINA, 2007). Systemic 
corticosteroids are needed in patients with severe unremitting disease although the 
risk of side effects is significantly increased (Polosa, 2008). Other therapies have 
been investigated with mixed results. 
 
1.2.8.1 Immunosuppressant 
To reduce the chronic need for systemic corticosteroids and reduce their side 
effects, anti-inflammatory and immunomodulatory therapies, such as 
methotrexate, oral gold and cyclosporine have been investigated (Frew and 
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Plummeridge, 2001). Although a recent study has found a substantial reduction in 
the steroid dose in a steroid-dependent asthmatic group taking methotrexate 
(Comet et al., 2006), other studies have shown a small overall benefit in 
comparison to the frequency of adverse effects (Aaron et al., 1998; Marin, 1997). 
Some improvements in two studies were observed with the inhibitor of CD4+ T-
cell activator, cyclosporine, although the toxicity of the compound jeopardized the 
findings (Alexander et al., 1992; Lock et al., 1996). 
 
1.2.8.2 IgE antibody  
Anti-IgE is presented in the form of Omalizumab, an IgG1 mAb administered one 
or twice monthly as a subcutaneous injection (Holgate et al., 2006). Clinical trials 
have confirmed its efficacy in severe asthma by controlling disease and reducing 
exacerbations (Humbert et al., 2005). However, 30% of patients show little or no 
response to the therapy (Holgate et al., 2005). Separating “responder” from “non-
responder” has proven difficult as high plasma IgE predictable. Advantages of the 
therapy are its relatively safe side effect profile and the ability to improve allergic 
inflammation outside other than the lung (Holgate et al., 2005), yet the high cost 
of the therapy makes it only likely to be used in patients with severe-steroid 
dependent disease (Walker et al., 2003). No effect on bronchial 
hyperresponsiveness (BHR) has been observed with more than half of patients not 
showing any clinical improvement (Walker et al., 2003). This might support the 
theory that severe asthma is a very heterogeneous disease involving alternative 
pathways. 
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1.3 Hypothesis 
Severe asthma is a heterogeneous disease, both in its mechanisms and the cell 
types involved. Guidelines have attempted to define the many pathways involved 
but ultimately the disease is presented with a profile of total or partial loss of 
steroid sensitivity associated with a pharmacologically poor response. Genetics, 
physiological factors associated with reduced corticosteroid absorption, or poor 
adherence are mentioned as likely factors responsible for the uncontrolled 
response to therapy. However, various molecular mechanisms can affect steroid 
response, such as reduction of nuclear translocation of the glucocorticoid receptor, 
crosstalk with transcriptional factors, signalling abnormalities including histone 
acetylation and deacetylation. The high cost to the health care also calls for new 
therapies for the treatment of CR asthma. 
Reversing corticosteroid insensitivity in severe asthma can be performed by using 
add-on treatments based on patients’ abnormalities, and the best add-on 
treatments can be selected based on the abnormality by using simple laboratory 
based-methods. This will contribute to tailor-made treatment for severe asthma. 
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1.4 Aims 
- To measure and detect corticosteroid insensitivity systemically in asthma. 
- To characterize the molecular mechanisms involved in the loss of corticosteroid 
sensitivity. 
- To study the best add-on treatment necessary for restoration of corticosteroid 
sensitivity based on the abnormality. 
- To further study the mechanisms of restoration of corticosteroid sensitivity by 
formoterol and a novel compound: nortrityline hydrochloride. 
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2. Materials and methods 
2.1 Materials 
PBMCs separation system Accuspin system-Histopaque, HDAC2 antibody, 
bovine serum albumin (BSA), glycerol, NP-40, RPMI-1640 Medium, Dulbecco’s 
Modified Eagle’s Medium (DMEM), dimethyl sulfoxide (DMSO), hydrogen 
peroxide (H2O2), Phosphate Buffered Saline (PBS), recombinant glucocorticoid 
receptor (GRα), Hank’s buffered saline solution (HBSS), nortriptyline 
hydrochloride, theophylline, budesonide and dexamethasone from Sigma Ltd 
(Poole, UK); formoterol from AstraZeneca (Lund, Sweden); SB203580 and 
LY294002 from Calbiochem (Darmstadt, Germany); IMD0354 from IMMD 
(Tokyo, Japan); erythromycin and EM703 from  Kitazato Institute (Tokyo, 
Japan); recombinant IL-2 and IL-4, Duo Set ELISA for IL-2, IL-4 and IL-8, 
Substrate Reagent pack, Phospho-MAPK-Array Kit from R&D Systems Ltd 
(Abingdon, UK); anti-human anti-CD3 and anti-CD28 from Becton Dickinson 
Ltd (Oxford, UK); Nuclear Extraction Kit from Active Motif Europe Ltd 
(Rixensard, BE); complete protease inhibitor cocktail from Roche Diagnostics 
(Lewes, UK); mRNA Cell-to-Signal from Ambion Europe Ltd (Huntington, UK); 
One-Step RT-PCR Mater Mix Reagents, Taqman primers for Dual Specificity 
Phosphatase 1 (DUSP1), p38MAPKγ, p38MAPKδ, β2−adrenergic receptor, 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Glucocorticoid-Induced 
Leucine Zipper (GILZ) and Guanine Nucleotide Binding Protein (G protein) beta 
polypeptide 2 like 1 (GNB2L1), and Taqman universal master mix from Applied 
Biosystems (Warrington, UK); Omniscript RT kit, RNase-free water, RNeasy 
Mini Kit from Qiagen (Crawley, U.K.); GR(E-20), GR(P-20), A/G agarose beads 
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and Lamin A/C antibodies from Santa Cruz Biotech Ltd (California, USA); anti-
Histone-4 lysine-5 acetylation antibody from Serotec Ltd (Kidlington, Oxford, 
UK); p38α active, p38δ active, p38γ active, ATP, anti-pan-phospho-serine 
antibody from Upstate, now part of Millipore (Watford, UK); anti-pan-phospho-
serine antibody from Zymed, now part of Millipore (Watford, UK); Western blot 
stripping solution from Chemicon, now part of Millipore (Watford, UK); β-actin 
and anti-pan-phospho-serine antibody from Abcam (Cambridge, UK); anti-GRα 
antibody from Affinity Bioreagents (Golden, USA); HDAC activity fluorescent 
assay kit from Biomol International (Exeter, UK); Bradford Assay kit from Bio-
Rad laboratories (Hemel Hempstead, UK); anti-mouse, anti-rabbit secondary 
antibodies from DakoCytomation (Cambridgeshire, UK); IntraPrep 1 and 2 from 
Beckman Coulter (High Wycombe, UK); ELISA 96-well plates and 8-well slide 
chambers from Fisher Scientific (Loughborough, UK); TOPRO-3, i-Blot Dry 
Blotting System, anti-FITC-Dex, Immunoblot apparatus from Xcell SuperLock 
Mini-Cell and Blot module from Invitrogen (Carlsbad, CA, USA); Tris-Glycine 
SDS-PAGE from Invitrogen Ltd (Paisley, UK); ECL and ECL plus developing 
solution and Hybond ECL from Amersham Biosciences (Buckinghamshire, UK); 
Nuclease-free water, random hexamer primers, EDTA from Promega 
(Southampton, UK); Spectramax Plus from Molecular Devices (Wokingham, 
UK); Synergy HT from BioTek (Winooski, USA); siRNA of p38MAPKγ 
(MAPKK12), p38MAPKδ (MAPKK 13) from Dharmacon (Colorado Springs, 
USA); Nucleofector Device, Human Monocyte and T cell Nucleofactor kit from 
Amaxa (Cologne, Germany); donkey anti-rabbit IgG, F(ab,)2-cy3 conjugated 
secondary antibody from Jackson Laboratories (West Grove, USA); VectaShield 
mounting medium from Axxora (Nottingham, UK); confocal microscopy and 
 89
imaging analysis software from Leica (Heidelberg, Germany); Fluorescent 
microscope from Olympus Optical Co. (London, U.K.); Soft Imaging System 
(Munster, Germany). 
 
2.2 Methods 
2.2.1 Isolation of PBMCs  
Venous blood (60 ml) was collected in acid citrate dextrose (ACD) syringes and 
PBMCs were separated using a porous high density polyethylene barrier (Sigma-
Aldrich ACCUSPIN™ System-HISTOPAQUE®-1077). After centrifugation of 20 
ml anticoagulated blood in each tube (10 minutes at 1000 x g at RT), PBMCs 
were collected and washed twice with Hank’s buffered saline solution (HBSS) 
between two centrifugation steps each for 10 minutes at 250 x g at 21°C. PBMCs 
were resuspended in RPMI-1640 medium containing 10% FCS and 15 mM 
glutamine and cells were counted and plated.  
 
2.2.2 Culture of cells 
2.2.2.1 HUT78 
HUT78 (human lymphoblastoid T cell lines) cells were maintained in continuous 
cell culture at 37°C, 5% CO2 in RPMI-1640 medium containing 10% foetal calf 
serum (FCS) and 15 mM glutamine. Cells (2x107) were incubated with or without 
human interleukin 2 (IL-2, 20 ng/ml) and interleukin 4 (IL-4, 10 ng/ml) (R&D) 
for 48 hours in RPMI-1640 medium containing 1% FCS and 15 mM glutamine. 
HUT78 cells were counted and washed twice with HBSS and 5x106 cells were 
stimulated with or without dexamethasone (10-6M) for one hour in starvation 
RPMI-1640 medium. Cells were finally collected for nuclear extraction. 
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2.2.2.2 U937 
U937 (human monocytic cell lines) cells were maintained in continuous cell 
culture at 37°C, 5% CO2 in RPMI-1640 medium containing 10% FCS and 15mM 
glutamine. Cells (2x107) were incubated with or without human IL-2 (20 ng/ml) 
and IL-4 (10 ng/ml) for 48 hours in RPMI-1640 medium containing 1% FCS and 
15 mM glutamine. Cells were counted and washed twice with HBSS and 5x106 
cells were stimulated with or without dexamethasone (10-6M) for one hour in 
starvation RPMI-1640 medium. Cells were finally collected for nuclear extraction. 
For hydrogen peroxide (H2O2) stimulation, U937 were seeded (106 cells/ml) in 6 
well plates using RPMI-1640 (phenol red free), with 1% FCS and 15 mM L-
glutamine and left for an hour at 37°C, 5% CO2. 
 
2.2.2.3 PBMC 
PBMCs (2x107) were incubated with or without IL-2 (20 ng/ml) and IL-4 (10 
ng/ml) (R&D) for 48 hours in RPMI-1640 medium containing 10% FCS and 15 
mM glutamine. PBMCs were counted and plated again at 107 cells/ml before 
stimulating with or without formoterol (10-8M and 10-9M) for 20 minutes. Cells 
were finally collected for whole cell extraction to look at GR phosphorylation. 
IL-2 and IL-4 stimulated PBMCs were also plated at a concentration of 106 
cells/ml in 96-well plates ready for stimulation of cytokine release and detection 
by ELISA. 
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2.2.3 Protein sample preparation 
2.2.3.1 Nuclear protein extraction  
PBMCs, U937 and HUT78 pellets were lysed with ice-cold lysis buffer (10 mM 
TrisHCl pH 7.4, 150 mM NaCl, 0.5% (v/v) NP40 for PBMCs or 0.75% (v/v) 
NP40 for U937 and HUT78, one complete protease inhibitor cocktail tablet per 5 
ml) (Roche), for 10 minutes on ice and centrifuged at 15,000 x g at 4°C for 5 
minutes. Pellets were washed in wash buffer (10 mM TrisHCl pH 7.4, 13 mM 
EDTA/half a complete protease inhibitor cocktail tablet per 5 ml), then 
resuspended in nuclear extraction buffer (20 mM HEPES, 1.5 mM MgCl2, 0.42 M 
NaCl, 0.2 mM EDTA, 25% glycerol/one complete protease inhibitor cocktail 
tablet per 5 ml) for 20 minutes on ice and finally centrifuged at 15,000 x g at 4°C 
for 5 minutes. The supernatant was collected and added to neutralizing buffer (20 
mM HEPES, 50 mM KCl, 0.2 mM EDTA/half a tablet of complete protease 
inhibitor cocktail). The protein concentration was calculated by Bradford Bio-Rad 
Protein Assay® kit (Bio-Rad) using bovine serum albumin (BSA) as a standard. 
 
2.2.3.2 Whole cell extraction  
PBMCs pellet was lysed with RIPA buffer (50 mM TrisHCl pH 7.4, 150 mM 
NaCl, 1% (v/v) NP40, 0.25% (w/v) sodium deoxycholate, deionised water/one 
complete protease inhibitor cocktail tablet per 10 ml), incubated on ice for 20 
minutes and sonicated for 2 seconds. Samples were finally centrifuged at 15,000 x 
g for 5 minutes at 4°C and supernatant transferred into ice-cold eppendorf for 
subsequent protein concentration analysis by Bradford Bio-Rad Protein Assay® 
kit using bovine serum albumin (BSA) as a standard. 
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2.2.3.3 Bradford assay 
Protein concentration from nuclear and whole cell extracts were determined using 
Bradford Bio-Rad protein Assay® kit (Bio-Rad). Serial dilutions of bovine serum 
albumin (BSA) (0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 10.0 μg/ml) were used as standards 
and applied in duplicates to 96-well plates. The unknown samples were added 
into the 96-well plates, Bradford Bio-Rad solution was diluted 1:5 with distilled 
water and 200 μl of the dilution was added to each well. The plate was read at 600 
nm wavelength using a spectrophotometer plate reader. Using the optical densities 
of the standards, a graph of optical density against concentration was plotted and 
extrapolated to calculate the concentrations of the unknown values. 
 
2.2.4 HDAC activity assay 
The activity of all HDACs was measured in PBMCs nuclear extracts with a non-
isotopic assay using a fluorescent derivative of epsilon-acetyl lysine (Fluor de 
Lys™) from the HDAC fluorescent Activity Assay kit (Biomol). HDAC activity 
assay was performed on a 96-well plate (Fisher Scientific). HDAC assay buffer 
(50 mM TrisHCl pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) with or 
without trichostatin A (TSA) was used as a blank. Nuclear extracts were 
incubated in the presence or absence of TSA. Standards (Fluor de Lys 
deacetylated standard; 3 μM and 30 μM) were diluted in HDAC assay buffer. The 
substrate, containing acetylated lysine residues, was added to the samples, blanks 
and standards in the 96-well plates and incubated at 37°C for 30 minutes. Samples 
where deacetylation activity is present deacetylate the acetylated lysine in the 
substrate. The reaction was stopped by the addition of a developer (Fluor de Lys 
developer, 1:20 dilution in HDAC assay buffer). The 96-well plate was incubated 
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for 15 minutes in the dark and the formation of a fluorophore is measured using a 
fluorometric plate reader with excitation at 360 nm and emission at 460 nm. 
 
2.2.5 Quantitative real time RT-PCR 
2.2.5.1 RNA extraction 
PBMCs were harvested for total RNA isolation. Commercially available kits were 
used to extract total RNA (RNeasy Mini Kit, Qiagen). Briefly, cells were washed 
with ice-cold PBS and lysed with lysis buffer containing guanidine thiocyanate 
and 0.14 M β-mercaptoethanol. The cell lysate was then passed five times through 
20-gauge needle fitted to a ribonuclease (RNAse)-free needle (ribonuclease 
cleaves RNA) and mixed with equal amount of 70% ethanol. The homogenised 
sample was then transferred into an RNeasy mini column in a 15 ml collection 
tube and centrifuged for 15 seconds at 8,000 x g. The flow through was discarded 
and the RNA samples in the column were subsequently washed once with the 
supplied RW1 buffer and twice with the supplied REP buffer. The column was 
transferred to a new 2 ml tube and RNA sample was eluted with RNase-free water 
(from Qiagen kit). The concentration of RNA was measured with 
spectrophotometer at 260 nm and 280 nm wavelength.  
 
2.2.5.2 Reverse transcription 
To synthesize cDNA from total extracted RNA, reverse transcription was 
performed using Omniscript RT kit (Qiagen). Briefly, extracted RNA  (13 μl) was 
incubated with 1 μl reverse transcriptase (RT), 2 μl of 1x RT buffer, 2 μl of dNTP 
mix and 2 μl of random hexamer primers (500 μg/ml, Promega) at 37°C for 1 
hour using a Rotor-Gene 3000 (Corbett Research). The reaction was terminated at 
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93°C for 5 minutes; cDNA was synthesized and subsequently used for 
quantitative polymerase chain reaction (qPCR). 
 
2.2.5.3 Real time quantitative polymerase chain reaction (qPCR) 
Gene transcript level of GRα, GRβ, β2−adrenergic receptor, p38γ and the 
housekeeping gene GAPDH were quantified by real-time PCR using a Taq-man 
PCR system (Applied Biosystems) on a Rotor-Gene 3000 (Corbett Research). The 
primer pairs of GAPDH, β2−adrenergic receptor, and p38γ were purchased from 
Applied Biosystems and primers for GRα and GRβ were synthesized as 
previously reported (DeRijk et al., 2003) (Table 2.1). Previously prepared cDNA 
(0.5 μl) was mixed with 0.5 μl of Taqman-primer mixture (Applied Biosystems), 
4.5 μl of RNase free water and 5 μl of Taqman universal master mix (Applied 
Biosystems). PCR cycle was as followed: 50°C for 2 minutes, 95°C for 10 
minutes, then 40 to 50 cycles of denaturing at 95°C for 15 seconds and 60°C for 
60 seconds for annealing and extension. Each transcript was analyzed by delta 
(Δ)CT method and variations in cDNA concentrations between different samples 
were corrected using GAPDH. 
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Table 2.1 List of primers used 
Gene Oligo name Sequence Assay ID 
 
HDAC2 
TaqHD2 
TaqHD2R 
HD2P  
CCGTAATGTTGCTCGATGTT 
CTGGAATAGCTTGCATCTGG 
FAM-TGTGAGATTCCCAATGAGTTGCCA-
TAMRA  
 
 
GR alpha 
GRalphaTaq-F 
GRalphaTaq-R 
GRalphaTaq-
FAM  
GAGGAAGTTATCCTCTGCCTC 
TGTAAGCACCACCTTCCTGTCT 
FAM-
TTCCAACAGTGAGTCTGTCAGCGCA-
TAMRA  
 
 
GR beta 
GRbetaTaq-F 
GRbetaTaq-R 
GRbetaTaq-
FAM  
GGCAGCGGTTTTATCAACTGA 
GTGTGAGATGTGCTTTTCTGGTTTT 
FAM-
AAAACTCTTGGATTCTATGCATGAAA 
ATGTAATGTGG-TAMRA  
 
GAPDH   Hs99999905_m1 
ADRB2   Hs00240532_s1 
TCR2 (gilz)   Hs00608272_m1 
DUSP1 (mkp-1)   Hs00610256_g1 
GNB2L1   Hs00272002_m1 
P38 gamma   Hs00268060_m1 
 
2.2.6 Western Blot  
2.2.6.1 Polyacrylamide gel electrophoresis 
Protein samples were electrophoretically size-fractionated using sodium 
dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Precast Novex 
Tris-Glycine gel (8% and 4-20%) (Invitrogen) was rinsed with deionised water 
and set up in the Xcell SuperLock Mini-Cell tank (Invitrogen). Reservoirs in the 
tank were filled with SDS running buffer (Tris-base 30.3 g, glycine 144 g, 20% 
SDS 50 ml made up to 1 L deionised water). Protein samples were mixed with 
one third volume of 4x Laemmli buffer (0.25 M Tris-HCl pH 6.8, 20% (v/v) 
glycerol, 2% (v/v) SDS, 0.2% (w/v) bromo-phenol-blue, made up to 20 ml 
deionised water) and 4% mercaptoethanol. Samples were boiled at 100ºC for 5 
min. Protein (50 μl of whole cell extracts) was loaded onto the gels and run for 
125 Volts, 35 mA, 5 Watts for 100 mins.  
 96
2.2.6.2 Western blot protein transfer 
After gel electrophoresis, the precast gels were rinsed in distilled water and 
opened using a scalpel. The comb like section and bottom of the gel was trimmed 
off and the gel was placed in Western blot transfer buffer (Tris-base 30.3 g, 
glycine 144 g, up to 1 L deionised water). Two sponges were soaked in the 
transfer buffer; two filter papers (6 x 8 cm) were rinsed in the buffer and placed 
on the sponge. The gel was placed on the set up making sure to avoid trapped air 
bubbles. Nitrocellulose membrane (Amersham Biosciences) was rinsed in 
Western Blot transfer buffer and carefully placed on the gel. Two more filter 
papers were rinsed in the buffer and placed on the gel, followed by two sponges. 
The set up was inserted in a Western blot transfer module (Immunoblot apparatus 
Xcell SuperLock Mini-Cell) (Invitrogen) and proteins electrophoretically 
transferred to the nitrocellulose membrane.  
 
2.2.6.3 Protein detection 
The nitrocellulose membrane was equilibrated with blocking solution; 5% dry 
skimmed milk in TBST for 20 minutes at RT with shaking. Membranes were 
incubated with primary antibody and developed using the same method described 
previously. Phosphorylation level was determined by probing with anti-pan-
phospho-serine antibody (1:500) (Upstate) in the presence of a modified blocking 
buffer (1%BSA in TBST). Results were normalized with anti-GR (E-20) 
polyclonal (1:700) (Santa Cruz). For GR protein nuclear translocation detection, 
membranes were incubated with anti-GR (E-20) polyclonal antibody (Santa Cruz) 
after blocking with 5% milk and then with HRP conjugated anti-rabbit antibody. 
Bound antibodies were visualized by the ECL system (Amersham Biosciences). 
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The membranes were re-probed with anti-lamin A/C antibody (Santa Cruz) to 
confirm equal nuclear protein loading and with β-actin to confirm equal whole 
cell extract or nuclear protein loading. Primary antibody stripping was performed 
by diluting 10x Re-Blot Plus Mild (Chemicon) in distilled water and incubating at 
room temperature for 15 minutes with shaking. After two washes with TBST, 
nitrocellulose membranes were incubated again with blocking solution before 
new protein detection. 
 
2.2.7 Detection of phosphorylated GR by immunoprecipitation  
PBMCs extracted from healthy volunteers and severe asthmatics were counted 
and plated again at 5x106 cells/ml before stimulating with or without formoterol 
(10-8M and 10-9M) for 20 minutes and a whole cell extraction was performed. 
Glucocorticoid receptor (GR) was immuno-purified from PBMCs whole cell 
extracts by the addition of anti-GR (P-20) antibody conjugated with Agarose-G 
(Santa Cruz) and incubated for 4 hours at 4°C. The immune complex was then 
washed using RIPA buffer (50 mM TrisHCl pH 7.4, 150 mM NaCl, 1% (v/v) 
NP40, 0.25% (w/v) Sodium Deoxycholate, deionised water/one complete protease 
inhibitor cocktail tablet per 10 ml) three times and subsequently incubated with 40 
μl of 1x Laemmli buffer ((0.25 M Tris-HCl pH 6.8, 20% (v/v) glycerol, 2% (v/v) 
SDS, 0.2% (w/v) bromo-phenol-blue, made up to 20 ml deionised water) and 4% 
mercaptoethanol in PBS). Samples were boiled at 100ºC for 5 min and 
microcentrifuged at 15,000 x g for 10 seconds in order for denatured protein 
extract to be loaded onto the gels. Phosphorylation levels were determined by 
probing with anti-pan-phospho-serine antibody (Upstate). 
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2.2.8 Sandwich-ELISA (enzyme linked immunosorbent assay)  
Cells (106 cells/ml) were plated in 96-well plates and stimulated with or without 
dexamethasone (10-11M to 10-6M) for 1 hour before transferring the cells in a 96-
well plate F96 MaxiSorp nunc™ (Fischer) with or without anti-human anti-CD3 
(10 µg/ml) and anti-CD28 antibodies (8 µg/ml) (BD Pharmigen) but also with or 
without TNFα (1 ng/ml) overnight at 37°C, 5% CO2. 
The concentrations of IL-8 and IL-2 were measured using enzyme linked 
immunosorbent assay (R&D). A 96-well plate (F96 MaxiSorp nunc™) was 
coated with IL-2/IL-8 capture antibody overnight at 4°C (100 μl per well of 4 
μg/ml in PBS). The plate was washed twice with Wash buffer (0.05% Tween 20 
in PBS). Non-specific sites were blocked using 300 μl of Blocking buffer (1% 
BSA, 5 g sucrose, 0.05% NaN3 in PBS) for 1 hour at RT. Plates were washed 
again and serial dilutions of standards and PBMCs’ supernatants diluted  Reagent 
Diluent (1% BSA, 0.05% Tween 20 in Tris-buffered Saline pH 7.2-7.4 for IL-2 
and 0.1 % BSA for IL-8) were incubated for 2 hours at RT. Plates were washed 
and incubated with 100 μl of detection antibody (400 ng/ml and 20 ng/ml in 
Reagent Diluent respectively for IL-2 and IL-8) for 2 hours at RT. After washing, 
plates were incubated with Streptavidin-HRP (1:200 dilution in Reagent Diluent) 
for 20 minutes in the dark at room temperature and finally washed one last time 
before detection performed by the addition of 100 μl of Substrate solution (1:1 
dilution of reagent A, stabilized peroxide solution and colour reagent B, stabilized 
chromogen solution) was added to each well and incubated for 5 minutes at RT in 
the dark. The reaction was stopped by the addition of 50 μl of 2 N H2SO4.  
Optical density was measured at 450 nm and corrected with 550 nm. The 
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concentration of IL-8 and IL-2 were calculated using the standard curve and 
taking into account the supernatant dilution used. 
IL-4 baseline reading was also measured by enzyme linked immunosorbent assay 
(R&D). Detection limit for IL-2 is 15.6 pg/ml and 31.2 pg/ml for IL-4 and IL-8. 
 
2.2.9 Immunocytochemistry of GR 
GR localization was detected by immunocytochemistry as previously reported 
(Matthews et al., 2004). Briefly, PBMCs (0.5x106 cells) were cultured in 8-well 
slide chambers (Fischer) in the presence or absence of dexamethasone (10-6M). 
After washing twice with HBSS, cells were air-dried and incubated with blocking 
buffer (20% normal swine serum in PBS, 0.1% saponin; DakoCytomation) for 20 
minutes at RT before 1 hour incubation with primary antibody solution (1% BSA, 
0.1% saponin in PBS) in the presence of polyclonal anti-rabbit GR antibody 
(Santa Cruz) (1:50 dilution). Slides were washed twice and incubated with 
biotinylated swine anti-rabbit IgG (DakoCytomation) (1:200) for 45 minutes. 
Another wash took place before incubating with fluorescein isothiocyanate 
(FITC)-conjugated streptavidin (1:100) for 45 minutes. The slides were washed 
twice, counterstained with 20% hematoxylin and mounted. Immunoreactive cells 
were each resolved at the single cell level by fluorescent microscopy (Olympus 
and Soft Imaging System) to determine the subcellular localization of GR by 
counting positive nuclear staining of FITC. 
 
2.2.10 FITC-dexamethasone incorporation 
PBMCs were resuspended in RPMI-1640 medium containing 1% FCS and 15 
mM glutamine and incubated with FITC-conjugated dexamethasone (FITC-Dex, 
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10-6M) (Molecular Probe, Invitrogen) for 30 min at 37ºC. For negative control, to 
determine non-specific migration of FITC-Dex, non-conjugated dexamethasone 
(10-5M) was added. Cells were washed twice with same media by centrifugation 
and 0.25% NP-40-containing PBS was added to separate nuclei. Nuclei were 
collected by centrifugation (10,000 x g, 4°C, 30 seconds) and washed with 
nuclear wash buffer (10mM TrisHCl pH 7.4, 13 mM EDTA and complete 
protease inhibitor cocktail tablet (PI cocktail, Roche Diagnostics). Nuclei were 
incubated with PBS containing 0.5% NP-40 on ice. The FITC fluorescent levels 
were measured in the nuclear fraction, and the concentration of FITC-Dex 
determined using a standard curve raised by different concentrations of FITC-
Dex. Formoterol (10-9 and 10-8M) and salmeterol (10-8 and 10-7M) were added 20 
min before adding FITC-Dex.  
 
2.2.11 Kinase profiling 
Kinase-ProfilerTM (R&D) was used to detect phosphorylation of a wide-range of 
kinases using the manufactures instructions. Briefly, PBMCs (107 cell/ml) from 
healthy volunteers that were previously incubated for 48 hours with IL-2 and IL-4 
were stimulated with or without formoterol (10-9M) for 20 minutes. Whole cell 
extracts from each treatment were obtained by incubating cells with Lysis Buffer 
for 30 minutes with gentle rocking in ice. Protein concentrations were measured 
by Bradford Bio-Rad Protein Assay®. 250 μg of whole cell extracts were diluted 
with Array buffer 1. Nitrocellulose membranes, each containing 21 different anti-
kinase antibodies and 7 controls printed in duplicate were placed in a 4-Well 
Multi-dish and pre-incubated for an hour with diluted whole cell extracts with 
shaking. After removing cell extracts, membranes were washed with Wash Buffer 
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and incubated with Anti-Phospho-MAPK Detection Antibody Cocktail diluted in 
Array Buffer 2/3 (2 hours with shaking). Membranes were washed again three 
times with Wash Buffer and subsequently incubated with Streptavidin-HRP 
(1:2000 dilution in Array buffer 2/3) for 30 minutes. Membranes were finally 
exposed to chemiluminescent reagents (ECL™ Western Blotting Detection 
Reagents, Amersham). The dot-blot intensities were measured using 
densitometric analysis. 
 
2.2.12 RNA interference (RNAi) 
Short interfering (si) RNAs of the p38MAPKδ (MAPKK13) and p38MAPKγ 
(MAPKK 12) were purchased from Dharmacon and transfected by nucleofection 
using Human T Cell Nucleofector® Kit (for unstimulated T cells in PBMCs), 
(Amaxa) according to the manufacturer’s instructions. Briefly, PBMCs freshly 
isolated (107 cells) were centrifuged (250 x g for 5 minutes at RT), the pellet 
resupended in 300 μl of Nucleofector Solution and mixed either with 300 nM of 
siRNA for p38MAPKγ, p38MAPKδ, a non-specific control duplex (scrambled 
oligonucleotide: scr, 47% GC content, Dharmacon) or a blank. 100 μl were placed 
inside an Amaxa certified cuvette and the Nucleofector program for high 
efficiency was selected (V-24) on the Nucleofector™ Device. Nucleofected cells 
were immediately transferred in complete RPMI-1640 medium and cultured for 6 
hours before stimulation with or without IL-2 and IL-4 for 48 hours. Subsequent 
stimulation with anti-CD3 and anti-CD28 for IL-2 cytokine production in the 
presence of dexamethasone was performed for ELISA.  
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The Human Monocyte Nucleofector® Kit (Amaxa) was used to perform 
transfection by nucleofection on U937 monocytic cell line according to the 
manufacture’s instructions as described previously. 
 
2.2.13 Statistical analysis 
Data are expressed as mean ± SEM. Results from ex vivo studies were analyzed 
using Kruskal Wallis analysis of variance and if significant, comparisons were 
made using Mann-Whitney U-test by means of the PC analysis package Graph 
Pad Prism Software (Graph Pad Prism, San Diego, CA). The efficacies of add-on 
treatments were analysed by paired t-test. Friedman two-way analysis of variance 
was used to compare three or more matched groups and Dunn’s post test was 
performed to establish which groups differ from which other groups. All graphs 
indicate mean values of results. Correlation was analysed by non-parametric 
Spearman method. A p value < 0.05 was considered statistically significant.   
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3. Restoration of corticosteroid sensitivity by formoterol 
in severe asthma and its molecular mechanism 
3.1 Introduction 
Several clinical studies have shown that the combination of a long-acting β2-
agonist (LABA) with a low dose of inhaled corticosteroid achieves better asthma 
control than either drug alone or a higher dose of inhaled corticosteroid 
(Kankaanranta et al., 2004). LABA itself was reported to induce glucocorticoid 
action (Korn et al., 2001) and GR nuclear translocation (Roth et al., 2002; Usmani 
et al., 2005) in several cell culture systems. However, the exact mechanism of 
action remains unknown. 
It is widely acknowledged that heterogeneous mechanisms are involved in 
glucocorticoid insensitivity. Recent studies have also underlined distinct 
phenotypes likely to be involved in glucocorticoid insensitivity (Brasier et al., 
2008; Leung et al., 1997; Wenzel et al., 1999).  
The aim is to study the effect of LABA on restoration of corticosteroid sensitivity 
in severe asthma and clarify the molecular mechanism that may be responsible for 
corticosteroid resistance in severe asthma by comparing the effects with another 
existing add-on treatment, theophylline. 
 
3.2 Materials and methods 
3.2.1 Subjects  
Fourteen healthy non-smoking subjects, 6 mild asthmatics and 16 severe 
asthmatics were recruited from John Matthews’s clinic in Brompton Hospital 
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(Table 3.1). Mild and severe asthmatics were characterized according to the 
guidelines of the ATS Workshop on Refractory Asthma (ATS, 2000a). 
This study was approved by the Ethics Committee of the Royal Brompton & 
Harefield Hospitals National Health Service Trust, and all subjects gave written, 
informed consent. Some severe asthmatic patients were still taking inhaled 
corticosteroids on the day of blood sampling. Atopy was defined as a positive 
reaction to one or more allergens upon skin-prick testing. 
 
Table 3.1 Characteristics of the patients  
 
3.2.2 Effect of add-on treatment on steroid sensitivity  
PBMCs (106 cells/ml) were plated in 96-well plates and stimulated either with 
formoterol (10-9M or 10-8M), salmeterol (10-7M) or theophylline (10-6M) for 30 
minutes before being exposed with serial dilutions of dex (10-11M to 10-6M) for 1 
Healthy 
volunteer
Severe
asthma
N (M/F) 
Age (yrs) 
Atopy
Medication 
33.9 ± 1.4
14 (9/5) 16 (5/11) 
6/161/14
Oral prednisolone 
18.3 (10)±15.6 mg 
Inhaled steroid 
FEV1 
(%predicted) 
Intermittent
asthma
6 (3/3)
2/6
β - agonist
40.5 ± 2.7 37.1 ± 2.6 
2000 (2000)    ± 1000 μ g 
na 84.1 ± 6.7 56.4 ± 4.9 
na : non - applicable 
FEV1: Force expiratory volume 
Oral and inhaled steroid showed in mean (and median) 
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hour. Cells were subsequently transferred into a 96-well plate coated with TNFα 
(1 ng/ml) overnight at 37°C, 5% CO2. IL-8 levels were quantified using ELISA.  
 
3.2.3 IL-2 and IL-4 induced steroid resistant model 
PBMCs (106 cells/ml) stimulated with or without IL-2 and IL-4 were cultured in 
96-well plates and subsequently stimulated either with formoterol (10-9M or 10-
8M) or SB203580 (5x10-6M) for 30 minutes before being stimulated with serial 
dilutions of dex (10-11M to 10-6M) for 1 hour. Cells were then transferred into a 
96-well plate coated anti-human CD3 (10µg/ml) and CD28 antibodies (8µg/ml) 
overnight at 37°C, 5% CO2. IL-2 levels were quantified using ELISA.  
 
3.2.4 GR phosphorylation assay by p38MAPKγ 
3.2.4.1 In vitro assay 
Human recombinant GR (hrGR) (Sigma), at 5 or 10 μg/ml, was incubated in the 
presence of either; active recombinant p38α (4 ng/ml), active recombinant p38γ (4 
ng/ml) or active recombinant p38δ (4 ng/ml) (Upstate), in a kinase buffer (10 mM 
Tris-HCl pH 7.4, 150 mM NaCl, 10 mM MgCl2, 0.5 mM DTT in deionised water) 
containing 100 μM ATP (Upstate). 50 μl of assay volume per reaction was 
incubated at 30°C for one hour in the presence of controls (no hrGR or no active 
recombinant p38). 
Alternatively, U937 (107 cells/treatment) were homogenized using Disperser T10 
basic ULTRA-TURRAY (IKA) with sonicating in the presence of 50 μl of kinase 
buffer. The kinase buffer with cellular extract was incubated in the presence or 
absence of human recombinant GR (hrGR) (Sigma), at 5 μg/ml and active 
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recombinant p38γ (4 ng/ml). 50 μl of assay volume per reaction containing 100 
μM ATP was incubated at 30°C for one hour. 
 
3.2.4.3 Immunoprecipitation of GR  
50 μl of assay volume were incubated with 20 μl of anti-GR (P-20) antibody 
conjugated with Agarose-G (Santa Cruz) and incubated for 4 hours at 4°C with 
rocking. Agarose beads were washed with ice-cold kinase buffer with 
centrifugation at 600 x g for 10 seconds (x 3) and subsequently 50 μl of 1x sample 
buffer (3/4 kinase buffer and 1/4 4x sample buffer) was added. Samples were 
boiled for 5 minutes at 100°C and centrifuged at 15000 x g for 10 seconds ready 
for Western blot. 
Alternatively, 50 μl of cellular extracts with kinase buffer were pre-cleared with 
10 μl of Agarose-G (Santa Cruz) and incubated for 20 minutes on ice with 
rotation. After centrifuging at 600 x g for 20 seconds, supernatant was transferred 
into new eppendorf tubes and subsequently incubated with 25 μl of anti-GR (P-
20) antibody (Santa Cruz) for 4 hours at 4°C with rotation. 25 μl of Agarose-G 
were added for further 2 hours incubation. Agarose beads were collected by pulse 
centrifugation (600 x g for 20 seconds at 4°C) and washed twice with ice-cold 
kinase buffer. After final wash, supernatant was discarded and 50 μl of 1x sample 
buffer (3/4 kinase buffer and 1/4 4x sample buffer) was added. Samples were 
boiled for 5 minutes at 100°C and centrifuged at 15000 x g for 10 seconds ready 
for Western blot. 
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3.2.4.4 Western Blot 
Equal volume of immunoprecipitated samples were loaded into 10% Precast 
Novex Tris-Glycine gel (10%) (Invitrogen) and electrophoretically size–
fractionated using sodium dodecylsulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) as previously described. Phosphorylation level was determined by 
probing with anti-pan-phospho-serine antibody (Upstate, Ambion or Sigma) and 
normalized with anti-GR (E-20) (Santa Cruz). 
 
3.3 Results 
3.3.1 Glucocorticoid sensitivity is decreased in PBMCs of severe asthma 
PBMCs from normal, mild and severe asthmatics were separated and the ability 
of dexamethasone to repress TNFα induced IL-8 was measured by ELISA. The 
levels of IL-8 induced by TNFα in PBMCs were 446±123.1 pg/ml in healthy 
volunteers (n=14), 190.7±110 pg/ml in mild asthmatics (n=6) and 364.6±362 
pg/ml in severe asthmatics (n=14) with no difference between groups (Figure 
3.1A). 
Glucocorticoid sensitivity was determined by calculating 50% inhibitory 
concentration of dexamethasone (IC50dex) on TNFα-induced IL-8 production in 
PBMCs. Blood was initially collected from 2 healthy volunteers and 2 severe 
asthma patients at days 1, 14 and 27-35. PBMCs were separated and 
dexamethasone sensitivity on TNFα-induced IL-8 release was measured. IC50dex 
values were reproducible over one month (Figure 3.1) 
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Figure 3.1 Reproducibility of IC50dex 
measure over time. PBMCs from two 
healthy volunteers and two severe 
asthmatics were stimulated with TNFα 
(1ng/ml) in the presence of 
dexamethasone (10-11 – 10-6M). IC50dex 
values (50% inhibitory concentration) 
were calculated from concentration 
responsive curve and plotted. PBMCs were collected and analyzed over a period of 1, 14 
and 27-35 days. 
 
IC50dex value in severe asthma (180.7±111.1 nM; n=15) was significantly higher 
than those of healthy subjects (26.3±27.1 nM, p<0.001) and mild asthmatics 
(20.0±9.3 nM, p<0.001), suggesting severe asthma patients were over 7 times 
more glucocorticoid insensitive than others (Figure 3.2B). 
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Figure 3.2 TNFα-induced IL-8 production in PBMCs. (A) PBMCs were stimulated 
with TNFα (1 ng/ml) and incubated overnight. IL-8 production was determined by 
ELISA. NS: not significant. (B) Effect of dexamethasone on TNFα-induced IL-8 
production. PBMCs were stimulated with TNFα in the presence of dexamethasone (10-11 
– 10-6M). IC50dex values (50% inhibitory concentration) were calculated from 
concentration responsive curve and plotted. P<0.05 is significant. 
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3.3.2 Effect of add-on treatment of formoterol, salmeterol and theophylline. 
TNFα-induced IL-8 production and IC50dex were analysed in the presence of 
formoterol, salmeterol and theophylline. As shown in Figure 3.3, neither in vitro 
treatment of formoterol, salmeterol nor theophylline alone affected TNFα-induced 
IL-8 production (n=6). 
On the other hand, add-on treatment of formoterol (10-9M) and salmeterol (10-7M) 
decreased IC50dex value in severe asthmatics (For: 40.9±35.9 nM, n=6 vs. NT: 
186.5±34.0 nM, n=6; p<0.005) and (Sal: 67.2±45.2 nM, n=6 vs. NT: 186.5±34.0 
nM, n=6; P<0.05) although they did not change glucocorticoid sensitivity in 
healthy volunteers (Figures 3.4A and 3.4B). Mild asthmatics were only treated 
with salmeterol (10-7M) and no significant change in glucocorticoid sensitivity 
was detected (NT: 20.0±3.8 nM, n=6 vs. Sal: 14.7±3.5 nM, n=6) (data not shown), 
suggesting LABAs restored glucocorticoid sensitivity only in severe asthma. 
Add-on treatment of theophylline also restored glucocorticoid sensitivity in severe 
asthmatics (Theo: 41.3±35.0 nM, n=6 vs. NT: 186.5±34.0 nM, n=6; p<0.005), 
had no effect in healthy subjects (Figure 3.4C) and had a modest effect on mild 
asthmatics (Theo: 20.0±3.8 nM, n=6 vs. NT 10.3±2.9 nM, n=6; p<0.05, data not 
shown).  
As shown in Figure 3.4, there were responders and non-(less)-responders in each 
treatment. Correlation analysis also showed that formoterol responders were 
nearly identical to salmeterol responders (r=0.78, p<0.0005), but were different 
from theophylline responders (r=0.31) (data not shown). This suggests that 
formoterol and theophylline are effective in different patients.  
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Figure 3.3 Effects of 
formoterol, salmeterol and 
theophylline in TNFα-
induced IL-8 production in 
severe asthma. Formoterol 
(10-9M), salmeterol (10-7M) 
and theophylline (10-6M) were 
incubated for 30 mins in 
PBMCs and treated overnight 
with TNFα. IL-8 in supernatant was measured by ELISA. IL-8 in pg/ml values ± SEM 
are indicated at each point. NS: not significant, n=6 patients. 
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Figure 3.4 Corticosteroid sensitivity in the presence of add-on treatment. PBMCs 
from healthy volunteers and severe asthmatics were incubated with dexamethasone (10-11 
to 10-6 M) in the presence or absence of 30 minutes treatment of (A) formoterol (10-9M), 
(B) salmeterol (10-7M) or (C) theophylline (10-6M) and stimulated with TNFα overnight. 
IC50dex values were calculated and plotted. P<0.05 is significant. NS: non significant. 
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3.3.3 PBMCs with less GR nuclear translocation are more respondent to 
LABAs  
Glucocorticoid nuclear translocation after ligand binding is normally detected by 
immunocytochemistry or SDS-PAGE-Western blotting analysis. In this study, I 
developed a new system to evaluate GR nuclear translocation using FITC-
conjugated dexamethasone. The concentration of FITC-Dex in nuclei showed a 
significant correlation with the results of immunocytochemistry for detection of 
GR distribution in nuclei (r=0.79, p=0.01) (Figure 3.5A). Blood was collected 
from 4 healthy volunteers at days 1, 5 and 14. PBMCs were separated and treated 
with FITC-dexamethasone (10-5M). The FITC-Dex values were shown to be 
reproducible (Figure 3.5B) 
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Figure 3.5 Correlation between FITC-Dex and Immunocytochemistry and 
reproducibility of FITC-Dex assay. (A) The % of nuclei that resulted positive after 
immunocytochemisty of GR after dexamethasone (1 μM) treatment of PBMCs was 
plotted in the Y axis against the results of FITC-Dex assay (nM) in the X axis. Spearman 
correlation used. N=11, p<0.05 is significant. (B) PBMCs from four healthy volunteers 
were collected over 1, 5 and 14 days period and incubated with FITC-conjugated 
dexamethasone (FITC-Dex) (10-5M) for 30 min. Concentration of FITC-dex (nM) in 
nuclei was calculated from standard curve and plotted individually. 
 
A. B.
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The advantage of this method is its quantifiability and that it can be performed 
very quickly (1 hr).  
FITC-Dex levels in nuclei of PBMCs from healthy subjects were 11.0±4.3 nM 
(n=8), which was similar to the value in mild asthma patients (9.7±3.4 nM, n=6). 
Nuclear FITC-Dex levels in PBMCs from severe asthma showed a significant 
reduced nuclear GR (5.0±3.5 nM, n=17) when compared to mild (p<0.05) and 
healthy volunteers (p<0.005). I temporarily divided the severe asthmatics into two 
subgroups by the cut-off line of 4.6 nM, which is calculated by subtracting 1.5x 
standard deviation (SD) from average of FITC-Dex in healthy volunteers. This 
“cut-off” line defined by 1.5x SD englobes all values from healthy volunteers 
except for one (so 88%). The highest value outside 1.5x SD has been defined as 
an outlier by Prism. G1 subgroup showed FITC-Dex values less than 4.6nM 
(2.2±1.4 nM, n=9; p<0.0001, vs. 11.0±4.3 nM), which was significantly lower 
than that of healthy volunteers. G2 subgroup had FITC-Dex higher than 4.6nM 
(8.0±2.2 nM, n=8), which showed no significant difference from healthy 
volunteers (Figure 3.6).  
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Figure 3.6 Nuclear translocation in PBMCs by FITC-Dex. PBMCs from healthy 
volunteers, mild and severe asthmatics were incubated with FITC-conjugated 
dexamethasone (FITC-Dex) (10-6M) for 30 min. Concentration of FITC-dex (nM) in 
nuclei was calculated form standard curve and plotted individually. NS: non-significant, 
p<0.05 is significant. 
 
Addition of formoterol (10-9M and 10-8M) did not affect GR nuclear translocation 
in healthy subjects (For 10-9M: 6.7±1.4 nM and For 10-8M: 22.0±6.1 nM vs. NT: 
9.6±0.6 nM, n=7) and mild asthmatics (For 10-9M: 11.0±2.1 nM and For 10-8M: 
7.3±1.5 nM vs. NT: 9.7±1.4 nM, n=7) (Figures 3.7A and B), but significantly 
enhanced GR nuclear translocation in patients with severe asthma (For: 9.4±1.4 
nM, n=17 vs. NT: 5.0±0.8 nM; p<0.01) and also at 10-8M of formoterol  (For: 
11.0±2.6 nM, n=17 vs. NT: 5.0±0.8 nM; p<0.005) (Figure 3.7C). A similar effect 
was found after salmeterol treatment (10-7M) (Figure 3.8) were GR nuclear 
translocation was also significantly enhanced (Sal: 13.8±2.6 nM, vs. NT: 5.0±0.8 
nM; p=0.0005, n=17). In addition, formoterol showed higher efficacy in G1 
(8.8±2.5 nM, n=9; vs. basal: 2.2±0.4 nM, n=9; p<0.05) than in G2 (10.0±1.3 nM, 
n=8; vs. basal: 8.1±0.8 nM, n=8; ns). There was also a significant correlation 
between GR nuclear translocation and formoterol-dependent enhancement 
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(p<0.05, Figure 3.7D), suggesting PBMCs from patients with less GR nuclear 
translocation were more responsive to formoterol (10-9M) on restoration of 
glucocorticoid sensitivity. On the other hand, theophylline did not affect this 
FITC-Dex incorporation in nuclei (data not shown). 
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Figure 3.7 Effect of formoterol on FITC-Dex nuclear translocation. FITC-Dex (10-
6M) was added after 20 minutes pre-treatment of formoterol (10-9M or 10-8M). After 
separation of nuclei, FITC level was determined using a fluorometer in (A) healthy 
volunteers (n=7), (B) mild asthmatics (n=6) and (C) severe asthmatics (n=17). Wilcoxon-
matched pair test used. (D) Correlation between enhancement of GR nuclear 
translocation and enhancement of IL-8 inhibition by formoterol. Ratio of IC50dex 
values in the absence of formoterol versus in the presence of formoterol was calculated 
and plotted in the Y axis. Ratio of FITC-Dex in nuclei in the presence of formoterol vs. in 
the absence of formoterol (10-9M) was calculated and plotted in the X axis. P<0.05 is 
significant. NS: non-significant. 
A. B. 
C. D. 
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Figure 3.8 Effect of salmeterol on 
FITC-Dex nuclear translocation. 
FITC-Dex (10-6M) was added after 20 
minutes pre-treatment of salmeterol (10-
7M). After separation of nuclei, FITC 
level was determined using a 
fluorometer. 
 
 
 
 
3.3.4 PBMCs with less HDAC activity are less responsive to LABAs, but 
more responsive to theophylline  
As shown above, the patients with a defect in GR nuclear translocation are 
formoterol responder. To identify the molecular mechanism of formoterol non-
responsiveness, mRNA expression of HDAC2 and HDAC activity were evaluated 
in G1 and G2 subgroups that were previously defined based on the ability of GR 
to translocate into nuclei. Although the level of HDAC2 mRNA expression was 
not significantly lower in severe asthmatics (0.086±0.021 ratio, n=8) compared to 
normal subjects (0.077±0.029 ratio, n=3), G2 showed lower level of HDAC2 
expression than G1 (G2: 0.035±0.015 ratio, n=4 vs. G1: 0.137±0.009 ratio, n=4; 
p<0.05). The total HDAC activity was significantly lower in severe asthmatics 
(0.67±0.13 µM/µg, n=16) than that in normal subjects (1.25±0.13 µM/µg, n=8; 
p<0.05). G2 also showed lower levels of HDAC activity than G1 (G2: 0.24±0.05 
µM/µg, n=7 vs. G1:1.01±0.15 µM/µg, n=9; p<0.001) (Figures 3.9A and 3.9B). 
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Figure 3.9 HDAC2 mRNA expression and activity in severe asthma. (A) PBMCs 
from normal and severe asthmatics were lyzed and mRNA extracted for Taqman RT-
PCR. Trancripts of HDAC2 mRNA expression were measured and normalized with 
GAPDH. Normal (n=3), severe asthma (n=8), G2 (n=4) and G1 (n=4). (B) HDAC 
activity (μM/μg protein) was measured on the same individuals using nuclear extracts of 
PBMCs and subsequent use of Biomol HDAC assay kit. Normal (n=8), severe asthma 
(n=16), G2 (n=7) and G1 (n=9). P<0.05 is significant. NS: non-significant. 
 
As shown in Figures 3.3 and 3.4C, theophylline did not possess anti-inflammatory 
effects on its own but was able to restore glucocorticoid sensitivity in severe 
asthmatics at 10-6M. There was a good correlation between enhancement of 
glucocorticoid sensitivity by theophylline (calculated as ratio of IC50dex without 
theophylline / IC50dex with theophylline) and HDAC activity (Figure 3.10). This 
suggests that patients with less HDAC activity are more responsive to 
theophylline on restoration of glucocorticoid sensitivity. 
A. B. 
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Figure 3.10 Correlation between enhancement of glucocorticoid sensitivity by 
theophylline and HDAC activity in severe asthma. IC50dex without theophylline/ 
IC50dex with theophylline was calculated and plotted in the Y axis. HDAC activity was 
plotted in the X axis. P<0.05 is significant, n=13 subjects. 
 
3.3.5 GRα, GRβ and β2-adrenergic receptor expression in severe asthma 
As shown in Figure 3.11, there was no difference in mRNA expression of GRα, 
GRβ and β2-adrenergic receptor between healthy subjects, mild asthma and severe 
asthma, and also between G1 and G2 (data not shown). Furthermore, no 
difference was observed in protein expression of GRα and β2-adrenergic receptor 
between groups although GRβ was not detected in this amount of protein loaded 
(Figure 3.11).  
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Figure 3.11 GR and β2-adrenoceptor mRNA and protein expressions. Transcripts 
(mRNA levels) of GRα, GRβ, β2-receptor were determined by Taqman-real time PCR 
and normalized to GAPDH gene expression. Protein expression of GRα and β2-receptors 
were determined by SDS-PAGE/Western blotting and normalized using the expression of 
β-actin.  
 
 
3.3.6 Relationship between GR nuclear translocation and HDAC activity 
In Figure 3.12, HDAC activity was plotted (X axis) against FITC-Dex levels in 
nuclei (Y axis) as an indicator of GR nuclear translocation. X-axis and Y-axis are 
divided by a line showing the lowest values for GR nuclear translocation and 
HDAC activity respectively from a healthy volunteer. Each point shows an 
individual severe asthma patient. There was no correlation between HDAC 
activity and GR nuclear translocation. This figure shows that severe asthma 
patients were distributed in 4 populations. One population shows a defect of 
HDAC activity (blue area). Another one shows a defect of GR nuclear 
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translocation (red area). The third one shows both defects (purple area) and only 
one out of 16 patients did not belong to either HDAC defective or GR nuclear 
translocation defective groups. Theophylline responders distributed into the group 
with a defect in HDAC activity (blue squares) whereas LABA responder (red 
squares) distributed into the group showing a defect in GR nuclear translocation.   
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Figure 3.12 Phenotypes in severe asthma and the selective effect by LABAs and 
theophylline. GR nuclear translocation was plotted (Y axis) against HDAC activity on 
the X axis from severe asthmatics. The lowest values for GR nuclear translocation and 
HDAC activity from a healthy subject were used as arbitrary limits to demarcate both 
phenotypes. PBMCs from severe asthmatics were initially incubated with an add-on 
(formoterol (10-9M), salmeterol (10-7M) or theophylline (10-6M)) for 20 minutes before a 
concentration response with dexamethasone (10-11 – 10-6M) for 1 hour. A final overnight 
TNFα incubation followed by detection of IL-8 ELISA was performed. IC50dex were 
calculated and a patient was considered “responder” when the ratio of IC50dex wo/w 
treatment was superior to a value of “5” (p<0.05). 
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3.3.7 Effect of LABAs on GR phosphorylation in PBMCs from severe asthma  
GR was immuno-precipitated in whole cell extracts and phosphorylated-serine on 
GR was detected using a pan-phospho-serine antibody. Ratio of phospho-GR 
divided by total GR was calculated as an index of GR phosphorylation. As 
Figures 3.13A and 3.13B show, GR is highly phosphorylated in severe asthma 
when compared with healthy volunteers (SA: 0.58±1.90 ratio, n=8 vs. HV: 
0.20±0.12 ratio, n=6; p<0.05). More importantly, when I look at the 
phosphorylation levels of subgroups of severe asthma, G1 was significantly 
higher compared to G2 (G2: 0.37±0.05 ratio, n=5 vs G1: 0.66±0.07 ratio, n=3; 
p<0.05). Interestingly, formoterol at both 10-8M (0.22±0.07 ratio, n=4; p=0.056) 
and 10-9M (0.19±0.12 ratio, n=4; p<0.05) totally de-phosphorylated GR to the 
levels observed in healthy volunteers only by a 20 min incubation (Figure 3.13C). 
 
 
 
 
 
 121
 
0.0
0.2
0.4
0.6
0.8
 Healthy
Volunteer
Severe
Asthma G2 G1
p<0.05 p<0.05
p-
G
R
α  /
G
R
 
0.0
0.2
0.4
0.6
0.8
Normal Severe
Asthma
10-8M 10-9M
Severe asthma
+ Formoterol
0.20
0.58
0.22 0.19
P<0.05 P=0.056
P<0.05
p-
G
R
α  /
G
R
 
Figure 3.13 GR phosphorylation and effect of formoterol. GR was immuno-
precipitated using whole cell extracts and phospho-serine GR was detected using pan-
phospho-protein antibody by Western blotting. Band density was calculated and 
normalized to GR expression level. (A) Membrane representation of three severe 
asthmatics (SA) and two healthy volunteers (N). (B)  Ratio of phospho-GR vs. total GR 
was plotted in healthy volunteers (n=6), severe asthmatics (n=4), and subgroups G1 and 
G2. (C) Formoterol (10-8M, 10-9M) was incubated 20 min with PBMCs from severe 
asthmatics (SA). P<0.05 is significant.  
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3.3.8 IL-2/IL-4 treatment mimics impaired GR function seen in severe 
asthma  
3.3.8.1 IL-2/4 reduces corticosteroid sensitivity 
PBMCs from healthy volunteers were incubated with IL-2 and IL-4 for 48 hours 
as reported by Kam and colleagues (Kam et al., 1993). Cells were then incubated 
overnight with anti-CD3/CD28 in the presence or absence of dexamethasone (10-
6M to 10-11M). IL-2/IL-4 pre-treatment significantly increased IC50dex, suggesting 
that IL-2/4 effectively induced dexamethasone-insensitivity on anti-CD3/CD28-
induced IL-2 in PBMCs obtained from healthy volunteers (IC50dex: 172.2±52.8 
vs. 20.91±6.0; P<0.005, Figure 3.14). The level was similar to that observed in 
PBMCs from severe asthma (IC50dex value: 180.7±111.1 nM, Figure 3.2B). 
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Figure 3.14 Corticosteroid sensitivity in IL-2/4 incubated PBMCs. Effect of 
dexamethasone on anti-CD3/28-induced IL-2 production. PBMCs from healthy 
volunteers, which were stimulated in the presence/absence of IL-2 and IL-4 for 48 hours, 
were incubated with anti-CD3/28 (24 hrs) in the presence of dexamethasone (10-11 – 10-
6M). IC50dex values were calculated from the concentration responsive curve and plotted. 
P<0.05 is significant. N=9 individuals. 
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3.3.8.2 IL-2/4 reduced GR nuclear translocation 
IL-2/IL-4 treatment also reduced GR nuclear translocation after dexamethasone 
treatment as shown in Figure 3.15 in U937 monocytic cell line (NT ratio of 
nuclear translocation= 2.1 vs. IL-2/4 ratio= 1.2, n=3) and Figure 3.16 in HUT78 
lymphocytic cell line (NT ratio of nuclear translocation= 27 vs IL-2/4 ratio= 13, 
n=1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Nuclear translocation in U937 after IL-2/4 treatment. U937 cells were 
incubated with IL-2/IL-4 48 hours and stimulated with dex 10-6M for 1 hour. Nuclear 
protein was extracted and GR was detected by SDS-PAGE/Western blotting. Lamin A/C 
was detected as loading control. Ratio of GR nuclear translocation was calculated 
dividing GR absorbance by Lamin A/C. P<0.05 is significant. NS: non-significant, n=3 
individual experiments. 
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Figure 3.16 Nuclear translocation in HUT78 after IL-2/4 treatment. HUT78 cells 
were incubated with or without IL-2/4 for 48hrs and then exposed with dex (10-7M). 
Nuclear protein was extracted and GR was detected by SDS-PAGE/Western blotting. 
Lamin A/C was detected as a loading control. Ratio of GR nuclear translocation was 
calculated dividing GR absorbance by Lamin A/C. N=1 experiment. 
 
3.3.8.3 IL-2/4 reduced GR transactivation potential 
IL-2/IL-4 incubation in PBMCs also resulted in a non-significant reduction of 
MKP-1 gene induction by GR after 10-6M treatment of dex compared to control 
(p=0.099, n=3, Figure 3.17A). Similarly, two experiments examining GILZ 
mRNA expression show a trend towards a decrease in transcription after 48 hours 
of IL-2/IL-4 pre-treatment (Figure 3.17B). 
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Figure 3.17 GR transactivation in PBMCs after IL-2/4 treatment. PBMCs were 
incubated with or without IL-2/4 for 48hrs and then exposed with dex (10-10M, 10-8M and 
10-6M). mRNA was extracted using Lysis Buffer (Ambion) and One Step-RT-PCR was 
performed. (A) Using mkp-1 primer, its expression was quantified and normalized using 
housekeeping gene GNB2L1. N=3 patients. (B) gilz-1 primer was used; its expression 
was quantified and normalized using housekeeping gene GNB2L1. N=2 patients. Results 
are presented as fold increase over non-treatment (NT). NS: non-significant. 
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3.3.8.4 IL-2/4 incubation results in GR hyperphosphorylation which can be 
prevented by formoterol 
GRs were highly phosphorylated by 48 hrs pre-incubation of IL-2/4 as shown in 
Figure 3.18 when compared to non-treated PBMCs (IL-2/4: 0.39±0.10 ratio, n=4 
vs. NT: 0.16±0.11 ratio, n=4; p<0.05). Incubation of 20 minutes with formoterol 
at 10-8M (For: 0.20±0.08 ratio, n=4, vs. NT: 0.39 ratio; p<0.05) and 10-9M (For: 
0.18±0.12 ratio; n=4, vs. NT: 0.39 ratio; p<0.05) after 48hrs incubation of IL-
2/IL-4 inhibited GR phosphorylation in PBMCs from normal subjects and the 
level was similar to that seen in non-treated PBMCs.    
 
 
 
 
Figure 3.18 Effect of 
formoterol on GR 
phosphorylation. GR was 
immuno-precipitated using 
whole cell extracts and 
phospho-GR was detected 
using pan-phospho-serine 
antibody by Western blotting. 
Band density was calculated 
and normalized to GR 
expression level. Ratio of 
phospho-GR vs. total GR was 
plotted. PBMCs from healthy 
donors were incubated 
with/without IL-2 and IL-4 for 48 hours. Formoterol (10-8M, 10-9M) was incubated 20 
min after 48hrs incubation of IL-2/IL-4 and GR phosphorylation detected. N=4 
independent experiments, p<0.05 is significant. 
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3.3.8.5 Formoterol restores corticosteroid sensitivity in IL-2/4 treated cells 
In the IL-2/IL-4 model, formoterol at 10-9M but not at 10-8M significantly 
(p<0.05) increased dexamethasone sensitivity (IC50dex: 208±99 nM and 197±93 
nM; n=6; respectively) compared to IL-2/IL-4 treated cells (6001±5800 nM) 
(Figures 3.19). 
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Figure 3.19 Corticosteroid sensitivity in IL-2/4 treated PBMCs and formoterol effect. 
PBMCs from healthy volunteers were initially stimulated with/without IL-2 and IL-4 and 
incubated with anti-CD3/28 (24 hrs). Formoterol 10-9M (yellow triangle) and 10-8M (red 
diamont) were incubated 20 mins prior the addition of dexamethasone (10-11 – 10-6M). 
IC50dex values (50% inhibitory concentration) were calculated from a dose response 
curve and plotted. N=6 independent experiments, p<0.05 is significant. 
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3.3.10 Effect of LABAs on kinase phosphorylation    
3.3.10.1 IL-2/IL-4 treatment activated several kinases 
GR was highly phosphorylated in some severe asthmatics, suggesting that kinase 
activation is involved in corticosteroid insensitivity in these patients. Therefore, I 
evaluated kinase activation in IL-2/IL-4 steroid insensitive model. PBMCs were 
incubated in the presence/absence of IL-2/IL-4 for 48 hrs.  Whole cell extracts 
were prepared and the phosphorylation of 21 kinases extracts was detected using 
the Human Phospho-MAPK Array Kit Proteome ProfilerTM (R&D) and density of 
each dot was determined by the Grab-IT software (Figures 3.20A and 3.20B). 
Figure 3.19C shows % change of phosphorylated kinase over baseline. IL-2/4 
increased by more than 25 % the phosphorylation of p38 MAPKs (all isoforms), 
pan-JNK, GSK3α/β, HSP27 and p70S6, but not Akts. 
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Figure 3.20 Kinase profile in IL-2/4 stimulated PBMCs. PBMCs from healthy 
volunteers were incubated with/without IL-2/IL-4 for 48 hours and their cell lysates 
collected on anti-kinase (21 different kinases) coated membrane for measurement of 
intensities. (A) Membrane representation of one experiment. Pairs of dots represent 
phosphorylated kinases. (B) Kinase profiler format of the membranes. (C) % change of 
intensity in phosphorylation over non-treatment was calculated and plotted. All p38 
isoforms, MSK2, HSP27, p70S6kinase, GSK3α/β, GSK3β, RSK2 and pan-JNK have 
increased phosphorylation after IL-2/4 incubation. Data was plotted as means ± SEM, 
n=3 independent experiments.  
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3.3.10.2 Effect of formoterol on IL-2/IL-4 dependent kinase phosphorylation 
Using the same Human Phospho-MAPK Array Kit (R&D), PBMCs treated with 
IL-2 and IL-4 for 48 hrs were incubated 20 minutes with formoterol (1 nM) prior 
whole cell extraction (Figure 3.21A). 
As shown in Figure 3.20C, p38MAPKα is one of the most phosphorylated kinases 
(51% over non-treated cell, n=3; p=0.058). However, formoterol did not reduce 
p38MAPKα phosphorylation induced by IL-2/IL-4 (For: 30.4±27.6 % vs. IL-2/4: 
50.9±30.4 %; ns) (Figure 3.21B). Similarly, formoterol did not restore basal levels 
of p38β (For: 31.1±6.7 % vs. IL-2/4: 46.1±7.1 %; ns). On the other hand, p38γ 
phosphorylation was reduced significantly in the presence of formoterol (For: -
15.9±10.1 % vs. IL-2/4: 26.3±10.7 %; p<0.05) (Figure 3.21B). Formoterol also 
greatly reduced p38δ phosphorylation (For: -6.2±6.3 % vs. IL-2/4: 33.6±9.4 %, 
p=0.12; ns) although this did not reach significance (Figure 3.21B). 
In addition, formoterol significantly inhibited phosphorylation of pan-JNK (For: -
10.9±9.9 % vs. IL-2/4: 33.4±18.3 %; p<0.05), but not individual (JNK1, JNK2, 
JNK3) isoforms. Interestingly, formoterol enhanced Akt phosphorylation (Figure 
3.22). 
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Figure 3.21 Formoterol effect on the p38MAPK family. PBMCs were incubated with 
IL-2/IL-4 for 48hrs and then incubated with formoterol (For: 10-9M) for 20 min. (A) 
Membrane representation of one experiment. (B) Densitometric analysis of kinase 
phosphorylation. Density of each dot was calculated and increased % over non-treatment 
was determined. The densitometric analysis for all p38 isoforms is plotted. Data was 
presented as means ± SEM, n=3 independent experiments, p<0.05 is significant. 
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Figure 3.22 Formoterol effect on pan-JNK and Akt. PBMCs were incubated with IL-
2/IL-4 for 48hrs and then incubated with formoterol (For: 10-9M) for 20 min. Cell 
extracts were used for phospho-kinase profiling (R&D Systems). Density of each dot was 
calculated and percentage change over non-treatment was determined. The densitometric 
analysis for pan-JNK and all Akt isoforms was calculated. Data was plotted as means ± 
SEM, n=3 independent experiments, p<0.05 is significant. 
 
3.3.10.3 Target validation of p38γ on restoration of corticosteroid sensitivity by 
formoterol  
3.3.10.3.1 Role of p38MAPK γ on restoration of corticosteroid sensitivity 
p38γ and p38δ were knocked-down in PBMCs from 7 healthy volunteers by RNA 
interference. A non-specific Scramble oligonucleotide (Scr) was used as control. 
Cells were then incubated for 48 hours in the presence or absence of IL-2 and IL-
4 before stimulation with dexamethasone (10-6M) for 1 hour. Similarly, these 
volunteer’s PBMCs were incubated with IL-2/IL-4 and then treated with 
formoterol (10-9M) or with SB203580 (5x10-6M) for 20 minutes prior dex (10-6M) 
stimulation for 1 hour. IL-2 stimulated by anti-CD3/28 was measured in the 
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supernatant by ELISA. Percent inhibition of IL-2 by dex was determined in the 
presence or absence of formoterol or in p38MAPKγ knocked-down cells. The 
change in the inhibitory % was calculated, as shown in Figure 3.23A, and plotted 
into the graph in Figure 3.23B. Formoterol and p38MAPKγ knocked-down 
enhanced the inhibitory effect of dex (10-6M) in some of patients. However, there 
was a good correlation between improvement by formoterol and improvement in 
p38MAPKγ knocked-down cells, suggesting formoterol efficacy is related to 
p38MAPKγ inhibition. There were no correlations between improvement by 
formoterol and improvement in p38MAPKδ siRNA (data not shown). 
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Figure 3.23 Correlation between p38γ knock-down and formoterol treatment. 
PBMCs from seven healthy volunteers were transfected with short interference RNA of 
p38γ and p38δ and incubated in media for 24 hrs. Cells were then incubated for 48 hours 
in the presence or absence of IL-2 and IL-4 before being stimulated with dex (10-6M) for 
1 hour. PBMCs were also incubated in the presence of formoterol (10-9M) for 20 minutes 
prior treatment of dex. (A) A representative case of the calculation of the increase of % 
inhibition by dex in formoterol and p38γ siRNA treated cells. (B) All 7 sets of results 
were compare to one another and they show to correlate significantly (r=0.937, p<0.01).  
 
A. B. 
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Consequently, in the IL-2/IL4 model of steroid resistance, formoterol and 
p38MAPKγ inhibition improved corticosteroid responsiveness, however 
SB203580 (5x10-6M), a p38MAPKα/β inhibitor, could not restore corticosteroid 
sensitivity in 4 of 5 cases (IC50dex: 415.4±177.4 nM vs. 6001±5800 nM; ns) as 
shown in Figure 3.24. SB203580 alone (4274±941 pg/ml) did not have any anti-
inflammatory effect against anti-CD3/28 induced IL-2 stimulation in IL-2/4 
treated PBMCs (3666±974 pg/ml) (Figure 3.25). 
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Figure 3.24 No effect of SB203580 on corticosteroid sensitivity of IL-2/4 treated 
PBMCs. PBMCs from healthy volunteers were initially stimulated with/without IL-2 and 
IL-4 for 48 hrs and then with anti-CD3/28 (24 hrs). SB203580 (5x10-6M) was incubated 
20 mins prior the addition of dexamethasone (10-11 – 10-6M). IC50dex values (50% 
inhibitory concentration in nM) were calculated from dose responsive curve and plotted. 
P<0.05 is significant. N=6 experiments. 
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Figure 3.25 Anti-inflammatory effects of formoterol and SB203580. PBMCs from 
healthy volunteers were initially stimulated with/without IL-2 and IL-4 and then with 
anti-CD3/28 (24 hrs). SB203580 (5x10-6M) and formoterol (10-9M) were incubated 20 
mins prior IL-2 stimulation. IL-2 in the supernatant was measured using ELISA. Data 
was plotted as means ± SEM, n=6 independent experiments. NS: non-significant. 
 
3.3.10.3.2 Knock-down of p38 γ (but not p38 δ) prevents formation of IL-2/4 
induced steroid resistance in U937  
In the monocytic cell line U937, dexamethasone inhibited TNFα-induced IL-8 
production (IC50dex: 4.6 nM, n=1), but the efficacy is decreased in the presence of 
IL-2/IL-4 (IC50dex: 36nM, n=1). p38MAPKγ knock-down inhibited the 
development of corticosteroid insensitivity under IL-2/IL-4 treatment (IC50dex: 
9.6nM) compared with scrambled oligonucleotides treatment control (IC50dex: 
36nM) (Figure 3.26A). However, p38MAPKδ knock-down did not affect IL-2/IL-
4 induced corticosteroid insensitivity (IC50dex: 21nM vs. 36nM, n=1) (data not 
shown). Furthermore, Western blot analysis (Figure 3.26B) confirmed that 
p38MAPKγ  knock-down prevented GR phosphorylation by IL-2/IL-4. 
 136
pGR
GR
- + - + - +
SCR P38γ
KD
P38δ
KD
U937
48h
Collect
pellets
siRNA p38γ and δ
GR phosphorylation is
prevented by p38γ knock out
IL-2/IL-4
IL-2/IL-4
Dex (-logμM)
-20
0
20
40
60
80
100
p38MAPKγ-KD
Scrambled
-11 -10 -9 -8 -7 -6 -5
%
In
hi
bi
tio
n
 
Figure 3.26 Effect of p38γ and p38δ knock-down (KD) on corticosteroid sensitivity 
in U937 cells. Cells were transfected with siRNAs against p38γ and p38δ or scrambled 
oligonucleotides (scr) as control for 24 hrs. (A) Cells were then treated with IL-2/IL-4 for 
48hrs and stimulated with TNFα (1 ng/ml) in the presence or absence of dexamethasone 
to determine IC50dex. (B) Scrambled oligonucleotides and siRNA for p38MAPKγ 
transfected cells were incubated with IL-2/IL-4 for 48 hrs, and then GR was 
immunoprecipitated in whole cell extracts. Phospho-GR (pGR) and total GR were 
detected by Western blotting. N=1 independent experiment. 
 
3.3.10.3.3 p38 γ indirectly induces GR phosphorylation  
Human recombinant GR was incubated in vitro in the presence of active 
recombinants p38α, p38γ and p38δ with 100 μM ATP. Results did not show any 
increase in phosphorylation of GR (data not shown). This implies that GR might 
not be a direct substrate for any p38MAPK tested. Homogenized cellular extracts 
(CE) in kinase buffer from U937 cells were used as the source of endogenous GR 
A. B. 
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and incubated in the presence of active recombinant p38γ (4 ng/ml). Figure 3.27A 
shows a 26% increase in the phosphorylation of endogenous GR under p38γ 
incubation versus control (p38γ-: 0.393 ratio vs. p38γ+: 0.494 ratio). In the second 
experiment, exogenous GR (hGR (5 μg/ml)) was added to the cellular extracts and 
a 35% increase in the ratio pan-serine phosphorylation/total GR was observed 
between p38γ treated and non-treated assay reactions (p38γ-: 0.332 ratio vs. 
p38γ+: 0.449 ratio) (Figure 3.27B). These data confirm that p38γ related kinases, 
likely downstream, are implicated in the direct phosphorylation of GR. 
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Figure 3.27 P38γ induces GR phosphorylation indirectly. U937 cells were 
homogenized in the presence of a kinase buffer and the cellular extracts (CE) were used 
for an in vitro kinase assay. (A) Cellular extracts (CE) were incubated with/without active 
recombinant p38γ (4 ng/ml) at 30°C for 1 hour. (B) Cellular extracts (CE) were incubated 
in the presence of hrGR (5 μg/ml) with/without active recombinant p38γ (4 ng/ml) at 
30°C for 1 hour. N=1 for both experiments. 
A. B. 
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3.3.10.4 P38γ mRNA expression was increased in the patients with impaired 
nuclear translocation 
Messenger RNA expression of p38MAPKγ was measured by RT-PCR in healthy 
controls, mild asthmatics and severe asthmatics. It was found to be higher in the 
patients with impaired GR nuclear translocation (G1 group) in severe asthma, 
which has been shown responsive to formoterol treatment, when compared with 
those of healthy volunteers (Figure 3.28). In contrast, there were no significant 
mRNA induction of p38MAPKα and δ in G2 or total severe asthma (data not 
shown).   
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Figure 3.28 p38γ mRNA was measured in asthma. Total RNA was extracted from 
PBMCs from severe asthma (SA, n=12; G1 (n=5) and G2 (n=7)), healthy volunteers (HV, 
n=8) and mild asthmatics (MA, n=6) and transcripts of p38MAPKγ was quantified by 
RT-quantitative PCR by ΔCT analysis. The data was normalized to expression of 
GNB2L1, a house keeping gene, p<0.05 is significant. 
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3.4 Discussion 
3.4.1 Molecular phenotyping of severe asthma based on existing compound 
efficacy 
Glucocorticoid sensitivity on TNF-α-induced IL-8 production was reduced in 
severe asthma when compared with healthy subjects and mild asthmatics (Figure 
3.2B). The results suggest that severe asthma is glucocorticoid insensitive at 
cellular and also at systemic level since it was found in PBMCs as supported by 
several reports (Hew et al., 2006; Irusen et al., 2002; Leung et al., 1995; Matthews 
et al., 2004). At a molecular level, glucocorticoid insensitivity on anti-
inflammatory effects was reported to be induced by several mechanisms. In this 
study, I found at least two defective mechanisms in severe asthma, one showing a 
defective GR nuclear translocation and another displaying a reduction in HDAC 
activity.  
Matthews and colleagues also reported that two phenotypes based on the ability of 
GR to translocate into nuclei (Matthews et al., 2004). GR nuclear translocation is 
a critical step for GR action. This is normally detected by immunocytochemistry 
or Western blotting analysis of nuclear proteins, techniques which are time-
consuming, less quantitative or required a high number of cells. For that reason I 
developed a FITC-Dex incorporation assay to evaluate GR nuclear translocation. 
The results from this method correlated well with the result of 
immunocytochemistry (Figure 3.5). In addition, this method is quantitative and 
can be performed quickly. However, the potency of FITC-conjugated Dex is 
about 10 times weaker than intact dexamethasone on repression of IL-8 release. In 
addition this method can not detect GR directly because FITC is conjugated to the 
ligand, not the receptor. FITC-Dex is also distributed into nuclei without receptor 
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binding, which causes a higher background. The FITC-Dex method is better than 
classical methods, but direct detection of GR would be ideal.  
The molecular mechanism of impaired GR nuclear translocation in severe asthma 
is still unknown. Previous research has shown induction of the inactive isoform 
GRβ. This dominant negative isoform was shown to be enhanced by pro-
inflammatory cytokines such as TNFα or by a combination of IL-2/IL-4 (Leung et 
al., 1997). Increased GRβ expression was also seen in severe asthma (Sousa et al., 
2000). However, in my study, GRβ expression was increased in only 3 out of 10 
severe asthmatics, and the expression is considered negligible because the 
transcription level was very low when compared to GRα. In addition, there was 
no correlation between GRβ level and IC50dex and GRβ protein level failed to be 
detected though the antibody detected control GRβ protein. Irusen et al. also 
reported that GRβ overexpression is not critical on glucocorticoid insensitivity in 
severe asthma (Irusen et al., 2002) and instead phosphorylation of serine residues 
in GR might cause defect of GR nuclear translocation.  This is confirmed in this 
thesis by the finding of hyper-phosphorylated cytoplasmic GR in severe asthma. 
Severe asthma patients were temporarily divided into two groups based on ability 
of GR to translocate into nuclei and I was able to prove that both groups behaved 
differently. G1 subgroup shows significant reduction of GR nuclear translocation. 
On the other hand G2 subgroup showed normal GR nuclear translocation but a 
decrease in HDAC2 expression and HDAC activity. Detailed analysis 
demonstrated that PBMCs from severe asthma are characterised by either HDAC 
defect alone or by a defect of GR nuclear translocation alone. About 30 % of 
severe patients evaluated had both defects. Only one patient out of 16 failed to 
show either of these defects (Figure 3.12). 
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Figure 3.12 also demonstrated that the patients displaying an impaired nuclear 
translocation were more responsive to LABAs (formoterol or salmeterol) whereas 
patients with decreased HDAC activity responded better to theophylline in 
restoring glucocorticoid sensitivity. This is supported by the reports that LABA 
enhanced GR nuclear translocation in vivo (Usmani et al., 2005) and that low 
concentration of theophylline enhanced HDAC activity in epithelial cells and 
macrophages (Ito et al., 2002b). 
In consequence, these findings suggest the evaluation of HDAC activity and 
FITC-Dex nuclear incorporation may help to identify LABA or theophylline 
responders. This encourages a tailor-made treatment of severe asthma patients for 
the future.  
 
3.4.2 Effect of LABA on GR phosphorylation 
IL-2, IL-4 and IL-13 mRNA expression is increased in bronchial biopsies (Leung 
et al., 1995) and serum (Lee et al., 2001) from patients with severe asthma. IL-2 
and IL-4 or IL-13 incubation were also reported to decrease glucocorticoid 
sensitivity in PBMCs (Leung et al., 1995; Spahn et al., 1996). In addition, Irusen 
et al. reported that treatment of IL-2 and IL-4 decreased nuclear GR ligand 
affinity (Irusen et al., 2002). In this study, IL-2/IL-4 treatment also reduced 
dexamethasone sensitivity and the ability of cytoplasmic GR to translocate into 
nuclei. The level of defective GR function was similar to that in PBMCs of severe 
asthma patients. In addition, IL-2/IL-4 treatment induced GR phosphorylation, as 
previously observed in PBMCs of severe asthmatics. My study confirms that the 
model of steroid resistance by IL-2/IL-4 treatment can mimic impaired GR 
function observed in severe asthma, particularly in the G1 group. 
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GR is as phospho-protein and altered phosphorylation of GR and its components 
of signal transduction pathway have been implicated in the regulation of 
glucocorticoid binding to GR (Irusen et al., 2002; Wang et al., 2007), GR sub-
cellular localization (Zhou and Cidlowski, 2005), and GR nuclear cytoplasmic 
trafficking through the nuclear pore complex (Galigniana et al., 1999).  
Several kinases such as mitogen protein kinases (MAPK), cyclin-dependent 
kinase (CDK) (Krstic et al., 1997), glycogen synthase kinase-3 (GSK-3) 
(Rogatsky et al., 1998a) and c-Jun N-terminal kinases (JNK) (Itoh et al., 2002; 
Rogatsky et al., 1998b) are reported to phosphorylate GR, each of them having 
distinct specificities for potential phosphorylation residues. Kinase 
phosphorylation array analysis demonstrated that 48hr treatment of IL-2/IL-4 
upregulated phosphorylation of all isoforms of p38MAPK(α,β,γ,δ), RSK1 and 2, 
Akt2 (and pan-Akt), JNK2 and JNK3 (and pan-JNK), MSK1, HSP27, GSK3α/β, 
and p70S6 (Figure 3.20C). Formoterol (10-9M) significantly inhibited only 
phosphorylation of pan-JNK and p38MAPKγ (Figures 3.21 and 3.22). The 
leucine-rich sequence flanking ser246 in rat GR (ser226 of human GR) is reported 
to be directly catalyzed by JNK and its phosphorylation inactivates GR (Rogatsky 
et al., 1998b). Ser226 of human GR is also reported to be involved in nuclear 
export and phosphorylation of this site by JNK may increase GR nuclear export as 
the means of inactivating GR transcriptional enhancement (Itoh et al., 2002). This 
event can eventually result in the accumulation of phosphorylated GR in the 
cytoplasm.  
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3.4.3 P38MAPK gamma (p38γ) as molecular target of formoterol 
Phosphorylation of p38MAPKα and β were upregulated by IL-2/IL-4 but was not 
inhibited by formoterol. In addition, SB203580, a selective p38MAPKα and β 
inhibitor, did not restore corticosteroid sensitivity in IL-2/IL-4 treated PBMCs 
(Figure 3.24). Collectively, the data presented here indicates that p38MAPKα and 
β are not involved in defective GR nuclear translocation. Although Irusen et al. 
reported p38MAPKα/β  as  the kinases which regulate GR phosphorylation, they 
found that GR phosphorylation is involved in a defect of GR ligand affinity in 
nuclear, but not in cytoplasmic GR in severe asthma (Irusen et al., 2002). They 
also looked at a particular cell type in CD2+ T cells. Different kinases may be 
involved in GR phosphorylation in different cell type or in differently localized 
GR. Formoterol also inhibited pan-JNK phosphorylation supporting the 
hypothesis that JNK-dependent GR phosphorylation causes corticosteroid 
resistance as previously shown by Itoh et al. (Itoh et al., 2002). However, 
formoterol did not inhibit specific phosphorylation of either JNK1, 2 or 3, 
suggesting a common serine between all JNK isoforms is a target of formoterol. 
As a result, formoterol likely affects JNK, resulting in inhibition of GR 
phosphorylation. The role of p38 MAPKγ on corticosteroid effect, on the other 
hand, has never been reported. 
P38MAPKγ is one of four isoforms of p38MAPK. This isoform is abundant in 
skeletal muscle (Li et al., 1996) and cardiac myocytes (Court NW et al., 2002) but 
has also recently been found expressed in monocytes and macrophages (Fearns et 
al., 2000; Korb et al., 2006). P38MAPKγ catalyses the phosphorylation of 
proteins which have PDZ domains (Hasegawa et al., 1999), but the function has 
not yet been elucidated. IL-2/IL-4 develops corticosteroid insensitivity on anti-
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CD3/CD28-induced IL-2 release and p38MAPKγ knock-down (KD) in PBMCs 
from some volunteers did not develop corticosteroid insensitivity under IL-2/IL-4 
treatment. Importantly, the improvement of dexamethasone inhibition of anti-
CD3/CD28-induced IL-2 release by formoterol correlated well with those in 
p38MAPKγ knock-down (KD) cells (Figure 3.23). In contrast, p38MAPKδ KD 
did not correlate with formoterol actions. In monocytic cell line, U937, 
dexamethasone inhibited TNFα-induced IL-8 production with an IC50dex of 
4.6nM, but the efficacy was decreased in the presence of IL-2/IL-4 (IC50dex: 
36nM). However p38MAPKγ KD prevented the development of corticosteroid 
insensitivity under IL-2/IL-4 treatment (IC50dex: 9.6nM vs. 36nM with scrambled 
oligonucleotides treatment) whereas p38MAPKδ KD failed to affect IL-2/IL-4 
induced corticosteroid insensitivity (IC50dex: 21nM vs. 36nM with scrambled 
oligonucleotides treatment) (Figure 3.26A). Furthermore, p38MAPKγ KD 
inhibited GR phosphorylation by IL-2/IL-4 (Figure 3.26B). Thus, p38MAPKγ 
may be a key kinase involved in corticosteroid sensitivity, probably by 
phosphorylation of cytoplasmic GR. In fact, mRNA expression of p38MAPKγ 
was higher in the patients with impaired GR nuclear translocation (G2 group) in 
severe asthma, which were also formoterol responsive compared with healthy 
volunteers (Figure 3.28). In contrast, there were no significant mRNA induction 
of p38MAPKα and δ in G2 or in the whole of the severe asthma sample (data not 
shown). Nevertheless, recombinant p38MAPKγ with ATP-magnesium failed to 
demonstrate direct phosphorylation of recombinant human GR, whereas addition 
of recombinant p38MAPKγ into homogenized cellular extracts resulted in 
detectable phosphorylation (Figures 3.27A and B). Although more experiments 
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will be needed to confirm these findings, this data suggests a kinase downstream 
of p38γ might be involved in phosphorylation of GR.  
In our system, formoterol dephosphorylated GR or p38MAPKγ after only 20 min 
incubation following 48 hrs IL-2/IL-4 treatment. This rapid action suggests that 
formoterol may activate phosphatases rather than inhibit kinases. In fact, cAMP 
elevating agents are reported to activate protein phosphatase 2A (PP2A) 
(Feschenko et al., 2002). This also implies that formoterol might not work as a 
direct p38MAPKγ inhibitor, but might work by enhancing a specific phosphatase 
activity to dephosphorylate p38MAPKγ. In fact, formoterol and salmeterol did not 
inhibit p38MAPKγ kinase activity directly (Millipore kinase profiler). The 
phosphatase that specifically dephosphorylates p38MAPKγ has not yet been 
identified. β2-receptor agonists are reported to enhance PP2B activation, which we 
also confirmed in vitro in U937 cells and HUT78 cells (data not shown). 
However, preliminarily results show that PP2B did not dephosphorylate GR or 
p38MAPKγ suggesting that an unknown phosphatase might be involved in 
formoterol action. 
Corticosteroid insensitive severe asthma is heterogeneous, but our study 
demonstrated at least one population with defect of GR nuclear translocation is 
LABA sensitive and p38MAPKγ dependent. This finding gives new insight to 
development of new class of compounds for the treatment of severe asthma 
patients.  
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4. Molecular and pharmacological evaluations of 
heterogeneous corticosteroid insensitive mechanisms in 
severe asthma  
 
4.1 Introduction 
Asthma is a chronic inflammatory disease characterized by its lung function 
reversibility. Overall, the worldwide incidence of asthma has ceased its inexorable 
rise seen over the past 30-40 years (Pearce et al., 2007), however its incidence is 
expected to rise especially in developing countries (Holgate, 2004). Depending on 
the frequency of exacerbations, hospitalizations, lung functions and therapy in use, 
asthmatics are classified into different categories each representing an increasing 
difficulty in containing the disease (ATS, 2000a). Mild asthmatics and moderate 
asthmatics are adequately treated with either β2-agonists or low doses of inhaled 
corticosteroids or in the case of moderate asthmatics, with a combination of 
inhaled corticosteroids with β2-adrenoreceptors. In order to facilitate the 
physician’s job in prescribing the appropriate therapy, guidelines have extensively 
been outlined with a regular reclassification of asthma severity. Current 
guidelines rely mostly on clinical parameters in order to optimize the best therapy 
for each individual patient. Recent guidelines are beginning to look at the 
classification of asthma with a pharmacological approach, separating into those 
who respond to current therapies from those who don’t (GINA, 2007; BTS, 2007). 
Unfortunately severe asthmatics present a considerable management problem with 
an increased likelihood of hospitalization, a higher morbidity rate compared to 
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other groups and with less response to corticosteroids or even to combination 
therapy (Wenzel, 2005). 
Understanding the underlying physiology and molecular mechanism involved in 
severe asthma will ultimately help in characterizing the different phenotypes 
involved in the disease as well as developing more specific, “tailor-made”, 
treatment for each individual.  
 
4.2 Subjects, materials and methods 
4.2.1 Subjects 
Healthy volunteers, mild, moderate and severe asthmatics were recruited from the 
staff and patients of the National Heart and Lung Institute and the Royal 
Brompton Hospital. 
A total of 10 healthy non-smoking volunteers were recruited. Asthma was 
diagnosed by physicians in Professor Fan Chung’s clinic and patients had FEV1 
reversibility of 15% or greater with salbutamol and a methacholine PC20 of less 
than 4mg/ml. Three different asthmatic subgroups were recruited that had been 
characterized using the guidelines of the ATS Workshop on Refractory Asthma 
(ATS, 2000a). Five mild, 9 moderate and 20 severe asthmatics were recruited. 
Severe asthmatics were defined by having at least one of the two major criteria. 
No exclusion criteria were performed regarding ex-smokers or current smokers. 
No exclusion criteria was taken into account when choosing gender neither race 
nor atopy as defined by a positive skin test to common allergen, including house 
dust mite, grass pollen or cat dander. All groups were age matched. 
This study was approved by the Ethics Committee of the Royal Brompton & 
Harefield Hospitals National Health Service Trust, and all subjects gave written 
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informed consent. Some severe asthma patients were still taking inhaled or oral 
glucocorticoids on the day of blood sampling. In severe asthmatics, FEV1 (Figure 
4.1), FEV/FVC and the PEF were significantly lower compared to healthy and 
mild as shown in Table 4.1 
 
Table 4.1 Patients profile.  
 Healthy 
Volunteer 
Mild  
Asthma 
Moderate 
Asthma 
Severe  
Asthma 
Number 10 5 9 20 
Gender (M/F) 3/7 4/1 4/5 6/14 
Age 40.2±4.6 41.2±6.8 44.4±3.0 47.3±3.2 
Atopy 0/10 4/5 9/9 17/20 
FEV1 (% pred) * 98.9±3.4 85.5±4.1 78.1±7.4 § 58.9±4.9 || ** 
FEV/FVC † 99.4±2.3 89.1±6.6 90.1±3.3 80.3±4.2   
(n=19) § 
PEF (L/M) ‡ 469.3±35.4 
(n=9) 
435.6±43.2 393.2±67.3 252.7±27.3  
(n=19) || †† ‡‡ 
Inhaled comb. 
steroid (μg) 
0 40.0 (0) ±40.0 483.3 (400) 
±102.7 †† 
1290 (1000) ±120.9 
§§ 
Prednisilone (mg) 0 0 0 12.1 (10) ±2.5 
Smoking 0 0 0 1 
* FEV1: Forced expiratory volume in one second. 
† FVC: Forced vital capacity 
‡ PEF: Peak expiratory flow 
§ p<0.05 compare to HV 
|| p<0.0005 compare to HV 
** p<0.05 compare to mild asthmatics. 
†† p<0.01 compare to mild asthmatics. 
‡‡ p<0.05 compare to moderate asthmatics. 
§§p<0.001 compare to moderate and mild asthmatics. 
ICS and prednisilone means (and medians) are shown. 
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Figure 4.1 Lung function in asthma. FEV1 (%pred) was measured in healthy volunteers, 
mild, moderate and severe asthmatics. P<0.05 is significant. 
 
4.2.2 Whole Cell extraction  
PBMCs (between 8 to 25x106 cells in 2 ml) were either stimulated in the presence 
or absence of dex at 1 μM and incubated in 6-well plates at 37°C, 5% CO2 in 
RPMI-1640 medium containing 10% FCS and 15 mM glutamine for 4 hours. 
Whole cell extraction was performed using the Active Motif Nuclear Extraction 
kit. PBMCs were washed twice in cold PBS (with 5.5% Phosphatase Inhibitor, 
5,000 x g, for 3 mins at 4°C) and pellet resuspended in 50 μl complete Lysis 
buffer (5 μl 10mM DTT, 0.5 μl Protease Inhibitor cocktail and 44.5 μl of provided 
lysis buffer). Cells were kept in ice and incubated for 10 minutes before vortex for 
30 seconds at the highest setting. Pellets were finally centrifuged at 14,000 x g at 
4°C for 20 minutes and 50 μl of supernatant were transferred in pre-chilled 
microcentrifuge tubes ready for polyacrylamide gel electrophoresis.  
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4.2.3 Western Blot 
Protein samples were electrophoretically size–fractionated using sodium 
dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Precast gels 
were then rinsed in distilled water and opened using a scalpel. The comb like 
section and bottom of the gel was trimmed off and the gel was placed in distilled 
water. The i-Blot™ Dry Blotting System was used. It involves the setting up of an 
i-Blot™ Anode Stack at the bottom of the system consisting of a bottom stack gel 
layer, a Transfer membrane of nitrocellulose and an electrode. The precast gel is 
placed on top of the nitrocellulose membrane and a water soaked filter paper 
placed on top with the subsequent i-Blot™ Cathode Stack  and a i-Blot™ 
disposable sponge. The voltage used for the proteins to be electrophoretically 
transferred to the nitrocellulose membrane was 25 V for a duration of 6 minutes. 
Transferred nitrocellulose membranes were briefly rinsed in TBST. Proteins were 
detected using the primary antibodies shown in Table 4.2. 
 
Table 4.2 Antibodies used for protein detection 
Primary Antibody 
(dilution) 
Company 
(Catalogue n°) 
Secondary Antibody 
(dilution) 
Molecular 
Weight (kDa)
Histone H4, AcK5 
(1:500) 
Serotec (AHP 
962) 
Rabbit (1:3000) 15 kDa 
GR (E-20) (1:700) Santa Cruz (sc-
1003) 
Rabbit (1:3000) 94 kDa 
Lamin A/C (1:700) Santa Cruz (sc-
7292) 
Mouse (1:4000) 60-75 kDa 
HDAC2 (1/1000) Sigma (H2663) Mouse (1:4000) 55 kDa 
β-actin Abcam (ab8226) Mouse (1:4000) 45 kDa 
kDa: kilo Dalton 
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4.2.4 One-Step quantitative RT-PCR 
4.2.4.1 RNA extraction from stimulated PBMCs 
Total cellular RNA was extracted using the Cell-to-Signal Lysis buffer (Applied 
Biosystems) following the manufacturer’s instructions. Briefly, PBMCs (0.2x106 
cells/ml) were plated in 6-well plates and stimulated in the presence/absence of 
dexamethasone (10-6M) for 4 hours. PBMCs were then washed twice in ice-cold 
200 μl PBS (5000 x g, for 3 mins at 4°C) and the RNA extracted by incubating 
cell pellets with 100 μl of Lysis buffer for two minutes with gentle agitation. 
RNA extracts were immediately stored at -80°C. 
 
4.2.4.2 One-Step RT-PCR 
The One-Step RT-PCR Master Mix Reagents kit (Applied Biosystems) was used 
to perform the reverse transcription and polymerase reaction in the same tube. 25 
μl volume per well for each reaction, was performed using MicoAmp® optical 
96-well reaction plate with barcode. In each well, the equivalent RT-PCR reaction 
mix for each primer was put together as followed: 12.5 μl of 2 x Master Mix 
without UNG, 0.625 μl of 10 x Multiscribe and RNase Inhibitor Mix, 0.75 μl of 
primer, 5 μl of total RNA previously extracted and 6.125 μl of DNase free water.  
Transcripts were quantified using the ABI PRISM® 7700 Sequence Detection 
System using the following thermal cycling parameters: 30 minutes at 48°C to 
allow reverse transcription to take place followed by the activation of AmpliTaq 
Gold activation at 95°C for 10 minutes before 55 cycles of denaturing (15 seconds 
at 95°C) and annealing (1 minute at 60°C).  
Transcripts of MKP-1 and GILZ were used with the housekeeping gene, guanine 
nucleotide binding protein beta polypeptide 2-like 1 (GNB2L1). The results are 
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presented as the threshold cycle or CT value which is the cycle at which a 
statistically significant increase in detected transcripts takes place. Results are 
quantified using a previously constructed standard curve for threshold for 
GAPDH and the initial copy number. 
 
4.2.5 ELISA  
PBMCs (1x106 cells/ml) were plated into 96-well plates and stimulated with 
either formoterol (10-9M), SB203580 (5x10-6M), IMD0354 (2x10-6M), 
theophylline (10-6M), LY294002 (10-8M), erythromycin (10-5M) or EM703 (10-
5M) for 30 minutes before being exposed to serial dilutions of dexamethasone (10-
11M -10-6M) for 1 hour. Cells were subsequently transferred into a 96-well plate 
coated with anti-human CD3 (10µg/ml) and CD28 antibodies (8µg/ml) and TNFα 
(1 ng/ml) overnight at 37°C, 5% CO2. IL-2, IL-4 and IL-8 released into the 
supernatant were detected by ELISA. 
 
4.2.6 Immunocytochemistry of GR 
Cytospined PBMCs, previously incubated 4 hours with/without dexamethasone (1 
μM), were fixed using IntraPrep™ Reagent 1 (Beckman Coulter) containing 
formaldehyde for 15 minutes at RT. Slides were washed twice with PBS and 
permeabilized with IntraPrep™ Reagent 2 (Beckman Coulter) containing 
saponine for 15 minutes at RT. After the washing step, slides were blocked using 
a 2% bovine serum albumin (BSA) in PBS for 20 minutes and subsequently 
incubated overnight at 4°C with an affinity purified polyclonal antibody to GRα 
(Affinity Bioreagents) diluted in blocking solution (20 μg/ml). Cells were washed 
and then incubated with donkey anti-rabbit IgG, F(ab,)2-cy3 conjugated secondary 
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antibody (24 μg/ml) (Jackson Laboratories) for 2 hours and after a wash with PBS 
(0.1 % Tween-20) the nuclei were counterstained with 750 μM Cy5/TO-PRO®-3 
(Invitrogen) for one hour. Slides were mounted using VectaShield® mounting 
medium (Axxora) and analyzed by confocal microscopy (Leica) with imaging 
analysis software Leica Confocal Software Lite™ (Leica). The data is presented 
as the ratio of mean fluorescence between the GR signals (cy3 channel) in a fixed 
area of the nuclei divided by the nuclear signal (cy5 channel) of this area. The 
ratio change in the presence of dexamethasone was calculated between slides of 
an individual patient in order to quantify the GR nuclear translocation potential. 
Ten cells were randomly selected in each slide and the average calculated. 
 
4.2.7 Statistical analysis 
Difference between patients’ groups has been analysed using the statistical 
analysis previously described in Materials and Methods (section 2.2.13). The 
effect of an add-on treatment was calculated using Wilcoxon matched pair test. 
On each graph, the number of healthy volunteers (n=10), mild (n=5), moderate 
(n=9) and severe asthmatics (n=20) is the same as mentioned in Table 4.1. Where 
different number of patients is used, this is indicated in brackets. 
 
4.3 Results 
4.3.1 Molecular background of severe asthma 
4.3.1.1 IL-8 production and glucocorticoid sensitivity  
The basal levels of IL-8 production were 537.7±289.0 pg/ml in PBMCs from 
healthy volunteers (n=10), 421.1±242.7 pg/ml in mild asthmatics (n=5), 
638.5±225.9 pg/ml in moderate asthmatics (n=9) and 468.0.6±158.6 pg/ml in 
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severe asthmatics (n=20) and there was no difference between groups (Figure 
4.2A).    
TNFα alone stimulated IL-8 production by 3-5 times more than basal level, and 
there was no significant difference in IL-8 levels between the groups: healthy 
volunteers 2780±584.6 pg/ml (n=8), mild asthmatics 2107±395.6 pg/ml (n=5), 
moderate asthmatics 3075±499.7 pg/ml (n=4) and severe asthmatics 2349±344.1 
pg/ml (n=15) (Figure 4.2B). 
In this section, a double stimulation with anti-CD3/28 and TNFα was performed 
to stimulate lymphocytes and monocytes together and enable to detect IL-2 and 
IL-8 together. IL-8 released in the supernatant was subsequently measured using 
ELISA. TNFα and anti-CD3/28 double stimulation induced 3 times more IL-8 
production than TNFα stimulation alone, although no significant differences 
between patient groups were observed: healthy volunteers 8639±996.0 pg/ml 
(n=10), mild asthmatics 7324±662.9 pg/ml (n=5), moderate asthmatics 
9022±468.7 pg/ml (n=9) and severe asthmatics 8894±606.0 pg/ml (n=20) (Figure 
4.2C). The ratio of anti-CD3/28 and TNFα stimulation over TNFα stimulation 
alone is not significantly different between patient groups: healthy volunteers 
5.3±1.9 (n=8), mild asthmatics 4.1±0.9 (n=5), moderate asthmatics 3.2±0.6 (n=4) 
and severe asthmatics 4.6±0.6 (n=15) (Figure 4.2D). 
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Figure 4.2 IL-8 production in asthma. (A) Baseline IL-8 production in PBMCs from 
healthy volunteers, mild, moderate and severe asthmatics. IL-8 production was 
determined by ELISA. (B) PBMCs were stimulated with TNFα (1 ng/ml), anti-human 
CD3 (10 µg/ml) and CD28 antibodies (8 µg/ml) for 24 hours. (C) PBMCs were 
stimulated with TNFα (1 ng/ml) and incubated overnight. (D) The ratio increase between 
TNFα and anti-CD3/28 against TNFα alone was measured and compared between each 
patient group. NS: not significant. Data was plotted as means ± SEM. 
 
Glucocorticoid sensitivity was determined by calculating 50% inhibitory 
concentration of dexamethasone (IC50dex). The IC50dex values of TNFα-induced 
IL-8 in PBMCs were 21.1±9.2 nM (n=7) in healthy volunteers, 13.7±2.7 nM 
(n=4) in mild asthmatics, 39.8±3.0 nM (n=4) in moderate asthmatics and 
77.3±44.2 nM (n=14) in severe asthmatics. The PBMCs from the severe 
asthmatics were more corticosteroid resistant to IL-8 inhibition relative to healthy 
volunteers (p<0.05) and mild asthmatics (p<0.05). Moderate asthmatics also 
A. B. 
C. D. 
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showed a significant increase of IC50dex over healthy controls or mild asthmatics 
(p<0.05) (Figure 4.3). 
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Figure 4.3 Effect of dexamethasone on TNFα-induced IL-8 production. PBMCs from 
8 healthy volunteers, 4 mild, 4 moderate and 14 severe asthmatics were stimulated 
overnight with TNFα in the presence of dexamethasone (10-11 – 10-6M) for 1 hour. 
IC50dex values (50% inhibitory concentration) were calculated from concentration 
responsive curve and plotted. P<0.05 is significant 
 
In this double stimulation system, IC50dex values could not be calculated in some 
patients in the range of dexamethasone concentrations used. In this case, I 
arbitrarily used 10-4M as maximal quantifiable data for IC50dex. The IC50dex of 
anti-CD3/28 and TNFα-induced IL-8 in PBMCs from healthy volunteers was 
13.2±9.9 μM (n=10), becoming 650 times higher than IC50dex of TNFα-induced 
IL-8 production alone. IC50dex values of mild asthmatics and moderate asthmatics 
were 3.1±2.0 μM (n=5) and 23.6±14.5 μM (n=7), respectively. IC50dex values 
tend to increase but not significantly in severe asthmatics (32.2±10.2 μM) 
compared to the other groups (Figure 4.4). 
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Figure 4.4 Effect of dexamethasone on anti-CD3/28 and TNFα-induced IL-8 
production. PBMCs were stimulated overnight with anti-CD3/28 and TNFα in the 
presence of dexamethasone (10-11 – 10-6M). IC50dex values (50% inhibitory 
concentration) were calculated from concentration responsive curves and plotted. Some 
patients became completely resistant to dexamethasone and their IC50dex could not be 
calculated. They were given a nominal value of 10-4M. 
 
There was a significant correlation between FEV1 and % inhibition by 
dexamethasone of TNFα/anti-CD3/CD28 induced IL-8 production at 1 μM 
(r=0.568, p<0.01) and 0.1 μM (r=0.534, p<0.05) (Figures 4.5A and B) in severe 
asthma only. Interestingly, the IC50dex from the severe asthmatics also correlated 
with FEV1 (r=-0.556, p<0.05, n=14, Figure 4.6). This is the first time that lung 
function has been associated with a decrease in corticosteroid sensitivity in 
PBMCs. 
 
 158
20 40 60 80 100
0
20
40
60
80 r=0.534
p<0.05
FEV1 (%Pred)
%
 in
hi
bi
tio
n 
of
 IL
-8
 b
y 
D
ex
 0
.1
μM
20 40 60 80 100
0
20
40
60
80 r=0.568
p<0.01
FEV1 (%Pred)
%
 in
hi
bi
tio
n 
of
 IL
-8
 b
y 
D
ex
 1
μ M
 
Figure 4.5  Correlation between corticosteroid sensitivity to IL-8 inhibition and lung 
function in severe asthma. (A) Correlation between enhancement of GR inhibitory 
potential of IL-8 at dexamethasone (0.1 μM) and lung function by FEV1 (%pred). (B) 
Correlation between enhancement of GR inhibitory potential of IL-8 at dexamethasone (1 
μM) and lung function by FEV1 (%pred). p<0.05 is significant, n=20 severe asthmatics. 
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Figure 4.6 Correlation between IC50dex and lung function in severe asthma. 
Correlation between IC50dex for IL-8 lung function by FEV1 (%pred). p<0.05 is 
significant, n=14 severe asthmatics. 
 
4.3.1.2 IL-2 production and glucocorticoid sensitivity 
Moderate asthmatics (28.3±23.0 pg/ml, n=10) showed an increase of basal IL-2 
production compare to mild (0.8±0.6 pg/ml, n=5) and healthy volunteers (1.0±0.5 
A. B. 
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pg/ml, n=10) although it did not reach significance. Only in severe asthmatics was 
the increase significant (18.8±6.9 pg/ml, n=10; p<0.05, Figure 4.7A).  
Anti-CD3/CD28 stimulation of IL-2 production was not significantly different 
between groups: healthy volunteers 1185±340 pg/ml (n=6), mild asthmatics 
1624±574 pg/ml (n=5), moderate asthmatics 1739±230 pg/ml (n=4) and severe 
asthmatics 1625±326 pg/ml (n=12) (Figure 4.7B). 
Anti-CD3/28 and TNFα double stimulation induced a similar pattern of IL-2 
production compared to anti-CD3/28 alone with no significant difference between 
patient groups (healthy volunteers 1276±242 pg/ml (n=10), mild asthmatics 
2071±602 pg/ml (n=5), moderate asthmatics 1533±189 pg/ml (n=9) and severe 
asthmatics 2118±411 pg/ml (n=20) (Figure 4.7C). Interestingly, although the 
increase of IL-2 by anti-CD3/28 is similar to the stimulation of both anti-CD3/28 
and TNFα, there is a significant ratio increase in severe asthmatics (1.54±0.08 
ratio, n=12) over healthy volunteers (1.05±0.14 ratio, n=6, p<0.05) which is not 
observed with moderate and mild asthmatics (1.59±0.33 ratio, n=5 and 0.99±0.20 
ratio, n=5 respectively) (Figure 4.7D).  
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Figure 4.7 IL-2 production in severe asthma. (A) Baseline IL-2 production in PBMCs 
from healthy volunteers, mild, moderate and severe asthmatics. IL-2 production was 
determined by ELISA. (B) PBMCs were stimulated with anti-human CD3 (10 µg/ml) and 
CD28 antibodies (8 µg/ml) overnight. (C) PBMCs were stimulated with TNFα (1 ng/ml), 
anti-human CD3 (10 µg/ml) and CD28 antibodies (8 µg/ml) for 24 hours. (D) The ratio 
increase between anti-CD3/28 and TNFα against anti-CD3/28 alone was measured and 
compared between each patient group. NS: non-significant. P<0.05 is significant. Data 
was plotted as means ± SEM. 
 
IC50dex values on anti-CD3/28 and TNFα-induced stimulation of IL-2 were 
90.8±46.4 nM (n=10) in healthy volunteers, 286.2±253.8 nM (n=5) in mild 
asthmatics, 44.2±22.4 nM (n=9) in moderate asthmatics and 280.8±111.2 nM 
(n=20) in severe asthmatics. The IC50dex values in severe asthma were over 3 
times higher than that of healthy volunteer, but the difference was not statistically 
significant although severe asthmatics show four patients with a higher 
A. B. 
C. 
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insensitivity to dexamethasone compared to normal and moderate groups (Figure 
4.8). In contrast to IL-8 inhibition, the loss of lung function did not correlate with 
a loss of dexamethasone inhibition of IL-2. Interestingly, there was a very 
significant correlation between % inhibition of IL-2 and IL-8 by dexamethasone 
(0.1 μM) in all patients except in severe asthmatics (p<0.0001) where there is no 
significant correlation (data not shown). 
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Figure 4.8 Effect of dexamethasone on anti-CD3/28 and TNFα-induced IL-2 
production. PBMCs were stimulated overnight with anti-CD3/28 and TNFα in the 
presence of dexamethasone (10-11 – 10-6M). IC50dex values (50% inhibitory 
concentration) were calculated from concentration response curves and plotted. NS: non-
significant. 
 
4.3.1.3 GRα expression 
GRα protein expression was determined individually in whole cell extracts by 
Western blotting. Although GR molecular weight is around 94 kDa, the main 
product detected was the partially degraded GR at about 65 kDa. In A549 cells, 
this partially degraded protein was observed after dexamethasone treatment. This 
implies that the bands observed are not non-specific products. This degradation 
might be due to endogenous glucocorticoid stimulation or to freezing at -80°C of 
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samples before extraction. In fact, un-degraded 94 kDa sizes were observed in the 
two cases that PBMCs were freshly collected. However, I would need to compare 
results with the same sample stored at -80C for different periods of time to 
confirm this.  There was no significant difference in partially degraded GRα 
normalized with β-actin in the different patients groups (healthy volunteers 
0.052±0.014 ratio (n=8), mild asthmatics 0.051±0.028 ratio (n=5), moderate 
asthmatics 0.077±0.081 ratio (n=9) and severe asthmatics 0.059±0.014 ratio 
(n=18)) (Figures 4.9A and B). 
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Figure 4.9  GRα protein expression levels in asthma. (A) Protein expression of 
degraded GRα was determined by SDS-PAGE/Western blotting and normalized using the 
expression of β-actin in healthy volunteers (n=8), mild, moderate and severe asthmatics 
(n=18). (B) Representative blot of three patients from whole cell extracts performed on 
previously stored PBMCs in -80°C (N: non-treatment, D: dex (1 μM)). Only ‘N’ samples 
are shown in the graph.  
 
4.3.1.4 GR nuclear translocation  
GR was visualized by immunocytochemistry using anti-GR antibody in the 
presence or absence of dexamethasone (1 μM) (Figure 4.10). The intensity of the 
GR signal in the nuclei was compared between patients and used as a marker of 
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GR nuclear translocation. Furthermore, the ratio of nuclear GR in the presence of 
dexamethasone and compare to the signal in the absence of dexamethasone was 
calculated as the marker of the steroid efficacy. This semi-quantitative analysis 
showed that the ratio of GR nuclear translocation after dexamethasone treatment 
in severe asthma (1.96±0.33 ratio, n=19) tended to be decreased when compared 
with those of healthy volunteers (2.41±0.33 ratio, n=9; p=0.184), mild asthmatics 
(3.25±0.76 ratio, n=5; p=0.076) and moderate asthmatics (3.30±1.01 ratio, n=8; 
p=0.144) althought no significant change between groups was observed (Figure 
4.11). However, as found in Chapter 3, two populations were visibly present, 
some with a defect of GR nuclear translocation and those with normal GR nuclear 
translocation (Figure 3.4). 
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Figure 4.10 Immunocytochemistry of GR nuclear translocation in asthma. Nuclear 
translocation was assessed by Immunocytochemistry of PBMCs treated with 
dexamethasone (1 μM) for 4 hrs. PBMCs were cytospined into slides and air dried. GR 
was detected using an anti-GR antibody with a secondary cy3-conjugated antibody (red). 
The nucleus was counter-stained using a cy5 To-Pro-3 (blue). A fixed area was drawn 
and used to measure the intensities of the red and blue channels in the nucleus. Ten cells 
per experiment were counted and the ratio cy3/cy5 used as the representation of nuclear 
GR which was normalized for dexamethasone treatment. Four patients’ pictures from 
confocal microscopy are shown. (A); non-treatment, (B); dexamethasone (1 μM) for 4 hrs 
(1) K045 is a healthy volunteer with ratio of nuclear translocation = 4.23; (2) K043 is a 
moderate asthmatic with a ratio of nuclear translocation = 2.42; (3) K020 is a severe 
asthmatic with a ratio of nuclear translocation = 1.20; (4) K019 is a severe asthmatic with 
a ratio of nuclear translocation = 1.25.  
 
  
4A 4B 
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Figure 4.11 Ratio of GR nuclear translocation in asthma. Ratio of nuclear 
translocation was measured by immunocytochemistry in PBMCs treated for 4 hours with 
dexamethasone (1 μM) in healthy volunteers (n=9), mild (n=5), moderate (n=8) and 
severe asthmatics (n=19). NS: non-significant 
 
When comparing the % inhibition of IL-8 with 1 μM and 0.1 μM dexamethasone 
and the ratio of GR nuclear translocation in severe asthmatics there was a 
significant positive correlation for both values of dexamethasone (r=0.593, n=19; 
p<0.01 and  r=0.621, n=19; p<0.005 respectively, Figures 4.12A and B). This 
correlation is confirmed when comparing the IC50dex for IL-8 and the ratio of GR 
nuclear translocation in severe asthmatics (r=-0.789, n=14; p<0.001, Figure 
4.12C). Furthermore, there was a good correlation between FEV1 (%pred) and GR 
nuclear translocation (r=0.486, p<0.05), suggesting that the patients who show a 
defective GR nuclear translocation are more severe and less corticosteroid 
sensitive (Figure 4.12D). IL-2 did not correlate with the ratio of GR nuclear 
translocation in severe asthmatics (r=-0.414, p=0.078). 
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Figure 4.12 Relationship between GR nuclear translocation, corticosteroid 
sensitivity and lung function in severe asthma. Correlation between GR nuclear 
translocation ratio after 1 μM dexamethasone as measured by immunocytochemistry and 
(A) enhancement of GR inhibitory potential of IL-8 with dexamethasone (1 μM) (n=19), 
(B) enhancement of GR inhibitory potential of IL-8 with dexamethasone (0.1 μM) (n=19), 
(C) IC50dex for IL-8 (n=13), (D) lung function as measured by FEV1(%pred) in severe 
asthma (n=19). P<0.05 is significant. 
 
4.3.1.5 HDAC2 expression 
HDAC2 protein expression was measured in whole cell extracts of PBMCs from 
the different group of patients and normalized with β-actin. A small but not 
significant reduction was observed in severe asthmatics (0.081±0.015 ratio, n=18) 
compare to healthy volunteers (0.174±0.061 ratio, n=8; p=0.192) and moderate 
A. B. 
C. D. 
 168
asthmatics (0.160±0.039 ratio; n=9; p=0.085) whereas mild asthmatics had a 
similar level of expression (0.117±0.035 ratio; n=5) (Figure 4.13). I did not have 
enough samples for the detection of HDAC activity. 
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Figure 4.13 HDAC2 protein expression in asthma. HDAC2 protein expression was 
determined by SDS-PAGE/Western blotting and normalized using the expression of β-
actin in healthy volunteers (n=8), mild (n=5), moderate (n=9) and severe asthmatics 
(n=18). (A) A representation blot showing results from four patients. Only ‘N’ samples 
are shown in the graph. (N= non-treatment, D=dex (1 μM)). (B) Basal HDAC2 protein 
expression is shown in the graph. 
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4.3.1.6 Histone-4 K5 acetylation as marker of GR transactivation 
Previously, Ito et al. (Ito et al., 2000) have reported that Histone-4 K5 acetylation 
is a marker of GR transactivation and Matthews et al. (Matthews et al., 2004) 
found that PBMCs obtained from some severe asthmatics showed a defect in 
Histone-4 lysine-5 acetylation after dexamethasone.  
PBMCs were treated in the presence or absence of 1 μM dexamethasone for 4 
hours and Histone-4 lysine-5 acetylation was determined in whole cells extracts 
from the different groups by Western blot, and was normalized to lamin A/C. The 
ratio between dexamethasone treatment and non-treatment was calculated using 
band density. The data confirmed a significant reduction of Histone-4 lysine-5 
acetylation in severe asthmatics (0.64±0.06 ratio, n=7) compared with mild 
(1.31±0.18 ratio, n=5; p<0.01) and healthy volunteers (1.47±0.35 ratio, n=5; 
p<0.05) (Figure 4.14). Moderate asthmatics showed a similar trend to severe 
asthmatics (0.86±0.13 ratio, n=6) but results did not reach significance. 
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Figure 4.14 Ratio of Histone-4 lysine-5 acetylation in asthma. Histone-4 lysine-5 (K5) 
acetylation was determined by incubating PBMCs with/without 1 μM of dexamethasone 
for 4 hours. Whole cell extracts from healthy volunteers (n=7), mild (n=5), moderate 
(n=6) and severe asthmatics (n=7) were run in SDS-PAGE/Western blotting and 
normalized using the expression of lamin A/C. The induction of H4 K5 acetylation by 
dexamethasone was calculated. (A) Representative blot of results from three patients 
using whole cell extracts from isolated PBMCs (N= non-treatment, D=dex (1 μM)). (B) 
Basal ratio of Histone-4 K5 acetylation after 1 μM dexamethasone treatment is shown in 
the graph. P<0.05 is significant. NS: non-significant. 
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4.3.1.6 GILZ and MKP-1 mRNA expression as markers of GR transactivation 
The expressions of MKP-1 and GILZ mRNA by 1 μM dexamethasone were 
measured as markers of GR transactivation by using the One-Step qRT-PCR 
method. Both transcripts were normalized to GNB2L1, the housekeeping gene, 
and values were shown as fold-increase (ratio) of GILZ/MKP-1 expression by 1 
μM dexamethasone over non-treatment (NT). Severe asthmatics (14.9±2.3 ratio, 
n=20) showed a similar transactivation ratio of GILZ when compared to healthy 
volunteers (15.4±2.0 ratio, n=9), mild (17.6±6.9 ratio, n=5) and moderate 
asthmatics (14.3±3.9 ratio, n=9) (Figure 4.15A).  
In contrast, the ability of dexamethasone (1 μM) to enhance MKP-1 expression 
was significantly reduced in severe asthmatics (4.5±0.9 ratio, n=20) when 
compared with mild (17.3±7.6 ratio, n=5; p<0.05) and moderate asthmatics 
(13.6±6.7 ratio, n=9; p<0.05) but not when compared to healthy volunteers 
(4.8±1.0 ratio, n=9; p=0.383; ns). Although there was a good correlation between 
GILZ and MKP-1 induction by 1 μM dexamethasone when excluding severe 
asthmatics (p<0.05) (Figure 4.15C), there was no correlation between GILZ and 
MKP-1 in severe asthmatics alone (Figure 4.15D). This implies that different 
mechanisms may regulate the induction of MKP-1 and GILZ mRNA expression 
in severe asthma.   
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Figure 4.15 MKP-1 and GILZ mRNA expression in asthma. PBMCs were initially 
incubated 4 hours with/without 1 μM dexamethasone and mRNA extracted using Cell-to-
Signal Lysis Buffer (Ambion). Specific primers for (A) mkp-1 and (B) gilz were used in 
a One-Step-qRT-PCR. Levels of transactivation by dexamethasone (1 μM) were 
calculated as a ratio over non-treatment (NT). GNB2L1 was used as a housekeeping gene. 
(C) Correlation between GILZ and MKP-1 induction by dexamethasone (1 μM) 
treatment in healthy, mild and moderate subjects. (D) Correlation between GILZ and 
MKP-1 induction by dexamethasone (1 μM) treatment in severe asthmatics. P<0.05 is 
significant. 
 
Similarly, there was a good negative correlation between transactivation by 
dexamethasone (GILZ fold-induction) and GR transrepression by dexamethasone 
A. B. 
C. D. 
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(% inhibition of IL-8 production by 0.1 μM dexamethasone) in patients when 
excluding severe asthmatics (p<0.005), suggesting the patients showing lower 
transrepression have higher transactivation (Figure 4.16A). However, when 
including severe asthmatics, the relationship was no longer significant (p=0.194; 
ns) (Figure 4.16B). The same conclusions were drawn when comparing 1 μM 
dexamethasone inhibition of IL-8 and GILZ transactivation (data not shown). 
 
 
0 20 40 60 80
10
20
30
40
50
r=-0.635
 p<0.005
% inhibition of IL-8 by dex (0.1 μM)
R
at
io
 o
f d
ex
 (1
μM
) a
ct
iv
at
ed
 G
IL
Z
ov
er
 N
T 
(n
or
m
al
iz
ed
 w
ith
 G
N
B
2L
1)
0 25 50 75 100
10
20
30
40
50
r=-0.303
ns (p=0.194)
% inhibition of IL-8 by dex (0.1 μM)
R
at
io
 o
f d
ex
 (1
μM
) a
ct
iv
at
ed
 G
IL
Z
ov
er
 N
T 
(n
or
m
al
iz
ed
 w
ith
 G
N
B
2L
1)
 
Figure 4.16 Correlation between corticosteroid sensitivity and GILZ transactivation 
in asthma. The ratio of 1 μM dexamethasone activation of GILZ was plotted (Y axis) 
against the % inhibition by dex (0.1 μM) (X axis). (A) Correlation in healthy, mild and 
moderate asthmatics, N=23 patients. (B) Correlation in severe asthmatics alone. P<0.05 is 
significant. NS: non-significant. 
 
4.3.1.7 Basal IL-2 and IL-4 
Basal levels of IL-8 were not significantly different between the patient groups 
(Figure 4.2A). When the basal levels of IL-2 was determined, severe asthmatics 
(18.8±6.9 pg/ml, n=10; p<0.05) showed significantly higher IL-2 levels than 
healthy volunteers (1.0±0.5 pg/ml, n=10) and mild asthmatics (0.8±0.6 pg/ml, 
A. B. 
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n=5). IL-2 levels from moderate asthmatics (28.3±23.0 pg/ml, n=10) were as well 
high but not significantly different to any other patient group (Figure 4.17A). 
The basal level of IL-4 in severe asthmatics (3.99±1.17 pg/ml, n=20) was also 
higher than those of healthy volunteers (0.27±0.27 pg/ml, n=10; p<0.01), mild 
(0.06±0.06 pg/ml, n=5; p<0.01) and moderate asthmatics (0.30±0.26 pg/ml, n=9; 
p<0.01) (Figure 4.17B). 
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Figure 4.17 Baseline levels of IL-2 and IL-4 in asthma. (A) IL-2 and (B) IL-4 were 
measured by ELISA in healthy volunteers (HV, n=10), mild (n=5), moderate (MA, n=9) 
and severe asthmatics (SA, n=20). PBMCs were previously seeded in 96-well plates and 
left overnight before collecting supernatant for ELISA IL-2 and IL-4. P<0.05 is 
significant. Data was plotted as means ± SEM. NS: non-significant. 
 
4.3.1.9 Severe asthmatics can be divided into sub-phenotypes with different 
sensitivities to glucocorticoids 
Further analysis using data of GR nuclear translocation and GR transactivation 
suggested that severe asthmatic patients can be divided into four sub-groups. 
Previoulsy, a cut-off line of 1.5x standard deviation (SD) in Chapter 3 was used, 
however, because we used a different method to detect GR nuclear translocation 
in Chapter 4, confocal microscopy, there are outliers in normal and mild groups 
and this results in a bigger standard deviation. Also, some variation might be due 
A. B. 
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to the different profile of patients compared to the first study. For this reason, I 
cannot use same criteria as the previous Chapter. To identify the point falling 
outside of 68-70% confidential range, I decided to use 1xSD to divide the group. 
The criterion is shown below: 
“GR nuclear translocation” 
Levels of GR nuclear translocation in severe asthmatics were assessed as normal 
(√) if they were above the average of the healthy volunteers minus the standard 
deviation (SD) and defective (×) in the case the levels were below.  
- Nuclear translocation in healthy volunteer = 2.41 
- Standard deviation (SD) = 1.00 
- Borderline: 2.41-1.00 = 1.41 
- Positive<1.41<Negative 
 
“GR transactivation” 
By the same principle, levels of transactivation by MKP-1, GILZ and His-4 K5 
activation in severe asthmatics were assessed as positive if they were above the 
average of the healthy volunteers minus the standard deviation (SD) and defective 
in the case the levels were below: 
- GILZ levels: Positive<9.42<Negative 
- MKP-1 levels: Positive<1.89<Negative 
- His4-K5 levels: Positive<0.53<Negative 
As shown in Figure 4.18, severe asthmatics were grouped into (A): patients with 
both normal GR nuclear translocation and normal GR transactivation, (B): 
patients with normal GR nuclear translocation and abnormal GR transactivation 
marker, (C): patients with defective GR nuclear translocation and normal GR 
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transactivation and (D): patients showing both of the defects. Figure 4.18 also 
indicates the % inhibition of IL-8 production by 1 μM dexamethasone. 
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Figure 4.18 Sub-phenotypes of severe asthma. Severe asthmatics were divided into 
four subgroups by their ability of dexamethasone to translocate GR into the nucleus and 
its transactivation potential efficacy. (A) Normal GR nuclear translocation and GR 
transactivation (n=3). (B) Normal GR nuclear translocation and defective GR 
transactivation (n=5). (C) Defective GR nuclear translocation and GR normal 
transactivation (n=7). (D) Defective in both GR nuclear translocation and GR 
transactivation (n=4). 
 
Interestingly the sub-phenotyping of severe asthmatics revealed that defective GR 
nuclear translocation is most associated with a reduced inhibition of IL-8 by 1 μM 
dexamethasone (Figure 4.19). Patients with defective GR nuclear translocation 
only and with both defects are less responsive to IL-8 suppression by 
dexamethasone compared to patients with a defect in GR transactivation only 
A. B.
C. D.
 177
(14.4±8.9 %; p<0.01 (n=7) and 32.4±6.5 %; p<0.05 (n=4) vs. 80.6±12.1 % 
(n=5) respectively). The group of severe asthmatics with no defects (54.2±
20.2 % (n=3)) were as responsive to IL-8 suppression as patients with defective 
GR transactivation only and no significantly different from patients with GR 
nuclear translocation defect. This is partly due to one individual with very low 
response to IL-8 inhibition by dex (15.1%) which might be caused by a defective 
GR mechanism of action not characterized in this study.  
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Figure 4.19 Corticosteroid sensitivity in severe asthma sub-phenotypes. 
Corticosteroid sensitivity, as calculated by dexamethasone (1 μΜ) % inhibition of IL-8, 
was measured in severe asthmatics with different response to GR nuclear translocation 
and GR transrepression (GILZ, MKP-1 or His-4 K5). (A) Normal GR nuclear 
translocation and transrepression (n=3). (B) Normal GR nuclear translocation but 
defective GR transrepression (n=5). (C) Defective GR nuclear translocation but normal 
transrepression (n=7). (D) Defective GR nuclear translocation and transrepression (n=4). 
P<0.05 is significant. Data was plotted as means ± SEM. 
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Short summary 
Table 4.3 Molecular profile of healthy volunteers, mild, moderate and severe asthma. 
 Healthy 
Volunteer 
Mild  
Asthma 
Moderate 
Asthma 
Severe  
Asthma 
Number 10 5 9 20 
Basal IL-2 (pg/ml) 1.0±0.5 0.8±0.6 28.3±30.0 18.8±6.9 ** 
Basal IL-4 (pg/ml) 0.3±0.3 0.1±0.1 0.3±0.3 4.0±1.2 § 
Basal IL-8 (pg/ml) 537.7±289.0 421.1±247.7 638.5±225.9 460.9±158.6 
GILZ activation 
(dex/NT) † 
15.4±2.0 
(n=9) 
17.6±6.9 14.3±3.9 15.0±2.3 
MKP-1activation 
(Dex/NT) † 
4.8±1.0 
(n=9) 
17.3±7.6 13.6±6.7 4.5±0.9 || 
H4 K5 acetylation 
(Dex/NT) † ‡  
1.47±0.35 
(n=7) 
1.31±0.18 
(n=5) 
0.86±0.14 
(n=6) 
0.64±0.06 
(n=7) ** 
GRα protein (β-
actin normaliz.) 
0.052±0.014 
(n=8) 
0.051±0.028 0.077±0.081 0.059±0.014 
(n=18) 
HDAC2 protein 
(β-actin normaliz.) 
0.174±0.061 
(n=8) 
0.117±0.035 0.160±0.039 0.081±0.017 
(n=18) 
IC50dex of 
IL-8 (TNFα) (nM) 
21.1±9.2 
(n=9) 
13.7±2.2 
(n=5) 
39.8±3.0 
(n=7) ** 
77.3±4.4 
(n=14) ** 
Ratio of CI/CS * 
(TNFα/anti-
CD3/28) 
1/10 0/5 2/9 6/20 
GR nuclear 
translocation 
(Dex/NT) † 
2.41±0.33 
(n=9) 
3.25±0.76 
(n=5) 
3.30±1.01 
(n=8) 
1.90±0.32 
(n=19) 
* CI (corticosteroid insensitive; IC50dex>10-4M) and CS (corticosteroid sensitive IC50dex<10-4M) 
as measured after anti-CD3/28/TNFα stimulation of IL-8. 
† Dex: dexamethasone, NT: Non-treatment 
‡ H4 K5: Histone-4 lysine-5 acetylation 
§ p<0.01 compare to healthy volunteers, mild and moderate asthmatics. 
|| p<0.05 compare to mild and moderate asthmatics.  
** p<0.05 compare to healthy volunteers and mild asthmatics. 
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Severe asthmatics showed:  
• Significant increase in basal IL-2 and IL-4. 
• Significant decrease in the ability of dexamethasone to inhibit TNFα-induced 
IL-8 release (defect of transrepression). 
• Significant decrease in ability of dexamethasone to induce Histone-4 K5 
acetylation and MKP-1 gene (defect of transactivation). 
• That some patients showed defect of GR nuclear translocation. 
• That lower lung function patients had a decrease ability of dexamethasone to 
inhibit anti-CD3/28/TNFα-induced IL-8 release. 
• They can be divided into 4 phenotypes based on the data of GR nuclear 
translocation and GR dependent transactivation. 
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4.3.2 Pharmacological phenotyping of severe asthma 
4.3.2.1 List of compounds used  
SB203580 (SB) (Calbiochem): p38MAPKα/β inhibitor, IC50= 20 nM for enzyme 
assay, IC50= 0.6-1.5 μM in cell based assay (Company information). 
Concentration used: 5 μM. 
IMD-0354 (IM) (IMMD, Institute of Medicinal and Molecular Design): IKK2 
active form inhibitor, IC50= 250 nM for enzyme assay, IC50: <1 μM in cell based 
assay (Company information). Concentration used: 2 μM. 
LY294002 (LY) (Calbiochem): non-selective PI3K inhibitor, IC50= 1.4 μM for 
enzyme assay (Company information). IC50: 3.3 nM in cell based assay (In house). 
Concentration used: 10 nM. 
Formoterol (For) (AstraZeneca): long-acting beta agonist, pEC50= 9.13 
(Inhibition of electrically induced contraction (Battram et al., 2006)). 
Concentration used: 1 nM. 
Erythromycin (EM): antibiotics-macrolide, at 10 μM showed 72.4% inhibition 
of PMA induced IL-8 (Desaki et al., 2004). Concentration used 10 μM.  
EM-703 (E7) (Kitazato Institute): non-antibiotic macrolide, IC50dex= 72.7 μM 
for anti-CD3/28 induced IL-2 in PBMCs. At 10 μM showed 77.5% inhibition of 
PMA induced IL-8 (Desaki et al., 2004). Concentration used 10 μM. 
Theophylline (Theo) (Sigma): Phosphodiesterase inhibitor at high concentration 
(150 μM), PI3Kδ inhibitor at 75 μM, HDAC2 inducer at 1-10 μM (Ito et al., 
2007b), PI3K (pAkt phosphorylation) in cell based assay: IC50: 0.1-1 μM (in 
house). Concentration used: 1 μM. 
 
 
 181
4.3.2.2 IL-8 release and glucocorticoid sensitivity on IL-8 production 
4.3.2.1.1 Effect of add-on treatments on basal IL-8 production 
Different add-on treatments were incubated 30 minutes before the addition of 
increasing concentrations of dexamethasone in PBMCs and overnight stimulation 
with anti-CD3/28 and TNFα. As shown in Figure 4.20, SB203580 showed a 
significant decrease in basal IL-8 production when compared to non-treatment 
(SB: 57±24 pg/ml vs. NT: 468±158 pg/ml, n=20; p<0.005). On the other hand, 
IMD0354 showed a significant increase in basal IL-8 production compared with 
non-treatment (IMD: 967±298 pg/ml vs. NT: 468±158 pg/ml, n=20; p<0.01). The 
other add-on treatments showed no significant change in basal IL-8.          
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Figure 4.20 Add-on effect on baseline IL-8. Baseline IL-8 was measured by ELISA in 
supernatant of PBMCs incubated 30 minutes in the presence or absence of formoterol (1 
nM), IMD0345 (2 μM), theophylline (1 μM), LY294002 (10 nM), EM (10 μM), EM703 
(10 μM) or SB203580 (5 μM). Data was plotted as means ± SEM. P<0.05 is significant. 
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4.3.2.1.2 Effect of add-on treatments on anti-CD3/CD28 and TNFα-induced IL-8 
production 
Similar to what was observed with baseline IL-8, SB203580 significantly reduced 
anti-CD3/28/TNFα stimulated IL-8 production (SB: 5754±506 pg/ml vs. NT: 
8894±606 pg/ml, n=20; p<0.0001, Figure 4.21). IMD0354 also showed a 
significant reduction when compared to non-treatment (IMD: 6406±553 pg/ml vs. 
NT: 8934±637 pg/ml, n=19; p<0.0001). EM703 had a smaller but significant 
reduction of IL-8 production (E7: 8277±614 pg/ml vs. NT: 8894±606 pg/ml, 
n=20; p<0.05).  
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Figure 4.21 Anti-inflammatory effects of add-on treatments on anti-CD3/CD28/TNF 
α-stimulated IL-8 release. Anti-CD3/28/TNFα stimulation of IL-8 was measured by 
ELISA in supernatant of PBMCs previously incubated for 30 minutes with either 
formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM,) LY294002 (10 nM), EM (10 
μM), EM703 (10 μM) or SB203580 (5 μM). Data was plotted as means ± SEM. P<0.05 is 
significant. 
 
4.3.2.1.3 Effect of add-on treatments on dexamethasone sensitivity 
The IC50dex in the presence of SB203580 on anti-CD3/28 and TNFα-induced IL-
8 production was 5.3±5.0 μM, and significantly less than the IC50dex without 
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add-on treatment (32.0±10.2 μM; p<0.0001) in cells from patients with severe 
asthma. Addition of LY294002 (28.5±9.7 μM), theophylline (26.4±9.8 μM), 
and IMD0354 (30.1±10.1 μM, n=19) had no significant effect on IC50dex. 
However, 5 out of 20 patients were LY294002 responders (ratio of IC50dex with 
treatment/ IC50dex without treatment > 2) (Figure 4.22). Five out of 20 patients 
were also theophylline responders and very interestingly, 4 of LY294002 
responders are identical with theophylline responders. IMD0354 restored 
corticosteroid sensitivity in 6/19 severe asthmatics with respect to IL-8 inhibition 
(significant when ratio > 2). Surprisingly in this study, severe asthmatics’ IC50dex 
with formoterol showed a significant increase (of 50.9±11.3 μM; p<0.0005). EM 
(37.0±10.7 μM) and EM703 (40.9±11.1 μM) add-on treatment had no effect on 
IC50dex. However, EM703 had a capacity for restoring corticosteroid sensitivity 
in 3 patients (ratio > 2). 
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Figure 4.22 Effect of add-on treatments on dexamethasone suppression of IL-8 
release in severe asthma. PBMCs were stimulated with increasing concentrations of 
dexamethasone (10-11 – 10-6M) for 1 hr in the presence or absence of 30 minutes pre-
incubation with formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM), LY294002 
(10 nM), EM (10 μM), EM703 (10 μM) or SB203580 (5 μM) before stimulation with 
anti-CD3/28 and TNFα overnight. IL-8 production was measured by ELISA and IC50dex 
calculated. P<0.05 is significant. NS: non-significant. 
 
4.3.2.2 IL-2 release and glucocorticoid sensitivity on IL-2 production 
4.3.2.2.1 Effect of add-on treatments on basal IL-2 production 
Different add-on treatments were incubated 30 minutes before the addition of 
increasing concentration of dexamethasone and overnight stimulation with anti-
CD3/28 and TNFα. The anti-inflammatory effect of each add-on on their own and 
their effect on the IC50dex on IL-2 release in PBMCs were studied.  
Formoterol and IMD0345 showed a significant decrease in basal IL-2 production 
when compared to non-treatment (For: 1.5±0.7 pg/ml vs. NT: 18.8±6.9 pg/ml, 
n=20; p<0.0005 and IMD: 3.2±2.2 pg/ml vs. 19.5±7.3 pg/ml, n=19; p<0.05 
respectively). Both theophylline (46.1±8.8 pg/ml; p<0.05) and LY294002 
(62.0±10.2 pg/ml, n=20; p<0.005) showed a significant increase in basal IL-2 
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production in comparison to non-treatment. The other add-on treatments showed 
no significant effect in basal IL-2 level (Figure 4.23).         
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Figure 4.23 Effects of add-on treatment on baseline IL-2 release. Baseline IL-2 was 
measured in the supernatant of PBMCs incubated in the presence or absence of 30 
minutes of formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM,) LY294002 (10 
nM), EM (10 μM), EM703 (10 μM) or SB203580 (5 μM). IL-2 was detected by ELISA. 
Data was plotted as means ± SEM. P<0.05 is significant. 
 
4.3.2.2.2 Effect of add-on treatments on anti-CD3/CD28 and TNFα-induced IL-8 
production 
As illustrated in Figure 4.24, many of the add-on treatments showed a significant 
reduction of anti-CD3/28- and TNFα-induced IL-2 (2118±412 pg/ml): formoterol 
(1833±357 pg/ml; p<0.0005), EM (1894±371 pg/ml; p<0.005), EM703 
(1272±263 pg/ml; p<0.0001), SB203580 (1130±225 pg/ml; p<0.0005) and 
IMD0354 (1102±264 pg/ml; p<0.0005, n=18). LY294002 and theophylline did 
not show any inhibition.  
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Figure 4.24 Anti-inflammatory effects of add-on treatments on anti-
CD3/CD28/TNFα-stimulated IL-2 release. IL-2 stimulation was measured in the 
presence of different treatments. Anti-CD3/28 and TNFα stimulation of IL-2 was 
measured in supernatant of PBMCs previously incubated for 30 minutes in the presence 
of either formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM,) LY294002 (10 nM), 
EM (10 μM), EM703 (10 μM) or SB203580 (5 μM). Data was plotted as means ± SEM. 
P<0.05 is significant. 
 
4.3.2.2.3 Effect of add-on treatments on dexamethasone sensitivity 
The IC50dex on IL-2 stimulation in severe asthma was 280±111 nM. Add-on 
treatment with theophylline (IC50dex: 122±41 nM; p=0.12), LY294002 (IC50dex: 
226±92 nM; p=0.08), formoterol (209±78 nM), and SB203580 (IC50dex: 123±
40 nM) reduced the IC50dex, although this did not reach significance. In addition, 
EM (606±259 nM) and EM703 (464±190 nM) also had no effect on the IC50dex. 
In contrast, IMD0354 (2476± 1560 nM; p=0.0002) reduced dexamethasone 
sensitivity (Figure 4.25). 
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Figure 4.25 Effect of add-on treatments on dexamethasone suppression of IL-2 
stimulated release in severe asthma. PBMCs were stimulated with increasing 
concentrations of dexamethasone (10-11 – 10-6M) for 1 hr in the presence or absence of 30 
minutes pre-incubation with formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM), 
LY294002 (10 nM), EM (10 μM), EM703 (10 μM) or SB203580 (5 μM) before 
stimulation with anti-CD3/28 and TNFα overnight.. IL-2 production was measured by 
ELISA and IC50dex was calculated. P<0.05 is significant. NS: non-significant. 
 
4.3.2.3 Relationship between clinical parameters/molecular abnormalities and 
pharmacological effects 
4.3.2.3.1 Relationship with anti-inflammatory action of drugs 
The relationship between anti-inflammatory effect (% inhibition of anti-
CD3/CD28/TNFα-induced IL-8 production) and clinical parameters/molecular 
abnormalities are summarized in Table 4.4. Significant correlations are indicated 
(p<0.05). Positive correlations were observed between the anti-inflammatory 
effect of theophylline and lung function as measured by FEV1 and FEV1/FVC 
although theophylline did not posses a significant anti-inflammatory effect 
(Figure 4.21). A positive correlation was also found between the anti-
inflammatory effect of erythromycin and LY294002 and baseline IL-8 production 
which cannot be explained. The relationship between age and the anti-
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inflammatory effect of erythromycin also remains inexplicable. Overall the anti-
inflammatory effects of the different add-on treatments in severe asthma account 
for little information about the disease. 
 
Table 4.4 Correlations between anti-inflammatory effects of drugs and clinical and 
molecular parameters. 
Anti-infl. LY 
294002 
SB 
203580 
IMD 
0354 
EM EM703 For Theo 
FEV1 (%pred) ns ns ns ns ns ns 
+ve 
p<0.05 
FEV1/FVC 
(%pred) 
ns ns ns ns ns ns 
+ve 
p<0.05 
Age ns ns ns 
+ve 
p<0.05 
ns ns ns 
GRα ns ns ns ns ns ns ns 
HDAC2 ns ns ns ns ns ns ns 
GILZ ns ns ns ns ns ns ns 
MKP1 ns ns ns ns ns ns ns 
H4K5 ns ns ns ns ns ns ns 
GR nuclei ns ns ns ns ns ns ns 
IL-8 
+ve 
p<0.05 
ns ns 
+ve 
p<0.05 
ns ns ns 
 
- Compounds used: formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM,) LY294002 (10 
nM), EM (10 μM), EM703 (10 μM) and SB203580 (5 μM). 
- FEV1: Forced Expiratory Volume in 1 second. FVC: Forced Vital Capacity. 
- Dex % inh 0.1 μM. The % inhibition of IL-8 at 0.1 μM of dexamethasone. 
- GR nuclei: GR nuclear translocation value. 
- H4K5: Ratio of Histone-4 Lysine-5 acetylation after dexamethasone (1 μM) incubation of 4 hrs.  
- “+ve”= positive correlation, “-ve”= negative correlation, ns= not significant. P<0.05 is 
significant. 
 
4.3.2.3.2 Relationship with add-on treatment’s effect on corticosteroid sensitivity  
The relationship of each add-on treatment effect on corticosteroid sensitivity 
(IC50dex values on anti-CD3/CD28/TNFα-induced IL-8 production) and clinical 
parameters/molecular abnormalities are summarized in Table 4.5. The % 
inhibition of IL-8 production by dexamethasone at 0.1 μM was chosen as an 
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alternative reading for corticosteroid sensitivity as some severe asthmatics 
become totally refractory to dexamethasone after anti-CD3/CD28/TNFα 
stimulation and the IC50dex could not be calculated (Table 4.6). The statistically 
significant results are detailed below. 
 
Table 4.5 Correlations between add-on effect on IC50dex and molecular/clinical 
parameters  
 
- Compounds used: formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM,) LY294002 (10 
nM), EM (10 μM), EM703 (10 μM) and SB203580 (5 μM). 
- FEV1: Forced Expiratory Volume in 1 second. FVC: Forced Vital Capacity. 
- IC50: Dexamethasone concentration that causes 50% inhibition of IL-8 or IL-2. 
- Dex % inh 0.1 μM. The % inhibition of IL-8 at 0.1 μM of dexamethasone. 
- H4K5: Ratio of Histone-4 Lysine-5 acetylation after dexamethasone (1 μM) incubation of 4 hrs. 
- GR nuclei: GR nuclear translocation value. 
- “+ve”= positive correlation, “-ve”= negative correlation, ns= not significant. P<0.05 is 
significant. 
 
 
 
IC50dex LY 
294002 
SB 
203580 
IMD 
0354 
EM EM703 For Theo 
FEV1 (%pred) 
-ve 
p<0.05 
-ve 
p<0.05 
ns ns ns ns ns 
FEV/FVC 
(%pred) 
ns ns ns ns ns ns ns 
Age ns ns ns ns ns ns ns 
IL-8 IC50 (steroid 
sensitivity) 
ns 
+ve 
p<0.0001 
+ve 
p<0.05 
ns ns ns ns 
IL-2 IC50 (steroid 
sensitivity) 
+ve 
p<0.05 
ns ns ns ns ns ns 
Dex % inh 0.1 μM 
(steroid 
sensitivity) 
ns 
+ve 
p<0.05 
ns ns ns 
-ve 
p<0.05 
ns 
GRα ns ns ns ns ns ns ns 
HDAC2 ns ns ns ns ns ns ns 
GILZ ns ns ns ns ns ns ns 
MKP1 ns ns ns ns ns ns ns 
H4K5 ns 
+ve 
p<0.05 
ns ns ns ns ns 
GR nuclei ns 
-ve 
p<0.005 
ns ns ns ns ns 
IL-8 ns ns ns ns ns ns ns 
 192
Table 4.6 Correlations between add-on effect on % inhibition of IL-8 inhibition at 
0.1 μM of dexamethasone and molecular/clinical parameters  
 
- Compounds used: formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM,) LY294002 (10 
nM), EM (10 μM), EM703 (10 μM) and SB203580 (5 μM). 
- FEV1: Forced Expiratory Volume in 1 second. FVC: Forced Vital Capacity. 
- IC50: Dexamethasone concentration that causes 50% inhibition of IL-8 or IL-2. 
- Dex % inh 0.1 μM. The % inhibition of IL-8 at 0.1 μM of dexamethasone. 
- H4K5: Ratio of Histone-4 Lysine-5 acetylation after dexamethasone (1 μM) incubation of 4 hrs. 
- GR nuclei: GR nuclear translocation value. 
- “+ve”= positive correlation, “-ve”= negative correlation, ns= not significant. P<0.05 is 
significant. 
 
 
 
 
 
 
 
% Impro 
dex(0.1μM) 
LY 
294002 
SB 
203580 
IMD 
0354 
EM EM703 For Theo 
FEV1 (%pred) ns ns ns ns ns ns 
-ve 
p<0.005 
FEV1/FVC 
(%pred) 
ns ns ns ns ns ns 
-ve 
p<0.05 
Age ns ns ns ns ns ns ns 
IL-8 IC50 ns ns ns ns ns ns ns 
IL-2 IC50 ns ns ns ns ns ns ns 
Dex % inh 0.1 μM ns ns 
-ve 
p<0.05 
ns ns ns 
-ve 
p<0.005 
GRα ns ns ns ns ns ns ns 
HDAC2 ns ns ns ns ns 
-ve 
p<0.05 
ns 
GILZ 
+ve 
p<0.05 
ns ns ns 
+ve 
p<0.05 
ns ns 
MKP1 ns ns ns ns ns ns 
+ve 
p<0.05 
H4K5 ns ns ns ns ns ns ns 
GR nuclei ns 
-ve 
p<0.05 
ns ns ns ns ns 
IL-8 ns 
-ve 
p<0.05 
-ve 
p<0.005 
-ve 
p<0.05 
ns ns ns 
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Vs. Treatment with high dose of corticosteroid 
Table 4.7 summarizes the patients’ use of inhaled and oral corticosteroid and the 
efficacy of add-on treatment on improvement of dexamethasone sensitivity in 
vitro. There was no significant correlation between use of corticosteroid therapy 
and the efficacy of add-on treatment although looking at the patients having the 
10 highest doses of corticosteroid therapy (oral and inhaled, highlighted as 
orange), 9/10 were SB203580 responders, 5/10 IMD0354 responders, 4/10 
theophylline responders and 4/10 LY294002 responders. Thus, severe asthmatics 
using the highest corticosteroid doses are more likely to be responder to one or 
more of SB203580, LY294002, theophylline or/and IMD0354. This data confirms 
that in severe asthmatics, the use of high doses of corticosteroid therapy can 
potentially be reduced by the use of an add-on treatment. 
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Table 4.7 Relationship between responders to theophylline, SB203580, IMD0354 or 
LY294002 and steroid therapy in severe asthma. 
Severe 
Asthmatics 
Inhaled CS 
(µg) 
Oral CS 
(mg) 
SB203580 
(ratio>5) 
IMD0354 
(ratio>2) 
Theophyill. 
(ratio>2) 
LY294002 
(ratio>2) 
K013 2000 30 + - - - 
K028 2000 30 + - - - 
K026 2000 15 + + - - 
K022 2000 10 - - - - 
K023 2000 10 + + - - 
K029 2000 6.25 - - - - 
K021 2000 0 + + + - 
K031 1000 15 + + + + 
K040 1000 15 + - + + 
K032 1000 5 - - - - 
K001 1000 0 + - - - 
K002 1000 0 - - - - 
K003 1000 0 - - - - 
K024 1000 0 + - - + 
K020 800 35 + + + + 
K019 800 27.5 + - + + 
K016 800 20 + + - - 
K030 800 10 - - - - 
K012 800 7.5 - - - - 
K025 800 5 - - - - 
- 10 highest (highlighted in orange) corticosteroid users and the lowest by looking at the overall 
inhaled and oral therapy.  
- The ratio of IC50dex without add-on treatment divided by the ratio with treatment (IC50dex 
wo/IC50dex w) was used to measure “responder” and “non-responder” to therapy. For SB203580; 
a ratio>5 means “responder”. For IMD0354, LY294002 and theophylline, a ratio>2 means 
“responder”. (+) responder, (-) non-responder. 
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Vs. HDAC2 expression  
No correlations were observed between the improvement of corticosteroid 
sensitivity by theophylline or LY294002 and the basal levels of HDAC2 protein 
expression in severe asthma. When patients “responder” to an add-on treatment 
were defined as increasing corticosteroid sensitivity by two fold decrease in 
IC50dex to IL-8 (ratio IC50dex without treatment/ IC50dex with treatment > 2), it 
was found that 4 out of 5 severe asthmatics “responder” to LY294002 and 5 out 
of 5 “responder” to theophylline have lower than average HDAC2 expression. 
Figure 4.26A shows that HDAC2 expression from theophylline “responders” 
(0.041±0.012 ratio, n=5) vs. “non-responder” (0.097±0.019 ratio, n=13) is lower 
although not significantly (p=0.26). Incidentally, “responders” to theophylline 
also show a lower but not significant reduction in corticosteroid sensitivity as 
measured by dexamethasone (0.1 μM) % inhibition of IL-8 vs. “non-responder” 
(Responder: 16.2±8.7 %, n=5 vs. Non-responder: 29.0±7.9 %, n=15; p=0.38) 
(Figure 4.26B). This result may imply that the restoration of corticosteroid 
sensitivity by PI3Ks inhibitors does not depend only on the HDAC2 protein levels 
but also on its activity as previously observed in Chapter 3.   
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Figure 4.26 Theophylline “responders” and HDAC2 expression and corticosteroid 
sensitivity. PBMCs were pre-treated with theophylline (1 μM) for 30 minutes prior to 
addition of dexamethasone (0.1 μM) and anti-CD3/28/TNFα stimulation of IL-8. (A) 
HDAC2 protein expression from “responders” (n=5) to theophylline (ratio IC50dex 
without treatment/ IC50dex with treatment > 2) were compared to “non-responders” 
(n=13). (B)  Corticosteroid sensitivity as measured by the % of IL-8 inhibition by 0.1 μM 
dexamethasone was compared between “responders” (n=5) and “non-responders” (n=15) 
to theophylline. Data was plotted as means ± SEM. NS: non-significant. 
 
Short summary 
Anti-inflammatory action 
• A p38MAPKα/β inhibitor (SB203580), an IKK2 inhibitor (IMD0354) and a 
non-antibiotic macrolide (EM703) were able to inhibit anti-CD3/CD28/TNFα-
induced IL-8 production in PBMCs from patients with severe asthma. 
• SB203580, IMD0354, macrolides (erythromycin and EM703) and formoterol 
alone could inhibit anti-CD3/CD28/TNFα-induced IL-2 production in PBMCs 
from patients with severe asthma, whereas theophylline and LY294002 did not. 
 
 
A. B. 
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Corticosteroid sensitivity 
• Only the p38MAPKα/β inhibitor (SB203580) significantly restored 
dexamethasone sensitivity in anti-CD3/CD28/TNFα-induced IL-8 production in 
PBMCs from patients with severe asthma. 
• SB203580, LY294002 and theophylline were more effective at restoring 
dexamethasone sensitivity in the patients with lower FEV1. 
• SB203580 was also more effective in the patients with reduced 
dexamethasone sensitivity and defective GR nuclear translocation. 
• Theophylline and IMD0354 were more effective in the patients with lower 
corticosteroid sensitivity 
• Basal IL-8 production may affect the ability of IMD0354 on restoration of 
dexamethasone sensitivity. 
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4.3.3 Individual evaluation of abnormality and restoration 
Table 4.8 summarizes the individual profiles of each severe asthmatic and Table 
4.9 summarizes the co-morbidities associated with each severe asthmatic. 
 
Table 4.8 Individual clinical profile of severe asthmatics 
Patient Sex Rac Age Atop FEV1 
(% pre) 
FEV/ 
FVC 
(%pre) 
FEV1 
(L) 
PEF 
L/M 
Inh. 
steroid 
(ug) 
Oral 
steroid 
(mg) 
Smoking 
History 
K001 F Cau 75 Y 85.0 114.8 1.30 161.5 1000 0.0 N 
K002 M Cau 63 Y 22.3 44.3 0.73 121.5 1000 0.0 Ex 
K003 M Cau 37 Y 100.9 103.5 4.04 557.6 1000 0.0 Ex 
K012 F Cau 69 Y 35.3 52.9 0.54 110.3 800 7.5 N 
K013 M Cau 35 Y 40.7 61.0 1.69 310.1 2000 30.0 Ex 
K016 F Cau 37 Y 62.6 92.2 1.90 261.1 800 20.0 12pack/yr 
(20yr) 
K019 F Cau 32 Y 45.2 79.0 1.41 195.9 800 27.5 N 
K020 F Cau 56 Y 37.1 73.2 0.90 121.2 800 35.0 Ex 
K021 F Cau 57 N 66.6 86.2 1.53 281.7 2000 0.0 Ex 
K022 M Cau 36 Y 74.1 92.6 2.90 458.9 2000 10.0 N 
K023 M Asi 45 Y 46.2 70.6 1.84 243.5 2000 10.0 N 
K024 F Cau 40 Y 51.9 82.9 1.35 212.0 1000 0.0 N 
K025 F Cau 51 Y 100.5 102.0 2.86 354.1 800 5.0 N 
K026 F Cau 34 Y 69.9 82.2 2.12 235.7 2000 15.0 N 
K028 F Cau 32 Y 70.8 95.5 2.04 376.1 2000 30.0 N 
K029 F Cau 41 N 76.0 NP 2.93 NP 2000 6.3 N 
K030 F Cau 61 Y 61.9 78.3 1.43 228.9 800 10.0 Ex 
K031 F Asi 57 Y 35.0 55.7 0.78 136.5 1000 15.0 N 
K032 F Cau 63 Y 53.6 80.1 1.27 173.5 1000 5.0 N 
K040 M Cau 35 N 41.6 78.1 1.56 261.2 1000 15.0 N 
- F/M: Female, Male 
- FEV1: Forced Expiratory Volume in 1 second (% predicted of L; litters). FVC: Forced Vital 
Capacity. PEF: Peak Expiratory Flow 
- Atopy: Yes, No 
- Race: Caucasian, Asian 
- Smoking: Never, Ex-smoker or x pack/year 
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Table 4.9 Co-morbidities associated with severe asthmatics 
Patient Co-morbidities 
K001 Hypertension (controlled), Eczema 
K002 No 
K003 Pancreatitis (dec 05) 
K012 Osteoporosis 
K013 Sleep Apnoea (13 years of asthma) 
K016 Rhinosinusitis grade 1 polyps, Myopathy (steroid induced), Osteoporosis (steroid 
induced) 
K019 Left vocal cord paralysis, Gastro-oesophageal reflux (GER), Rhinosinusitis, Hay 
fever, Eczema 
K020 High B/P 
K021 Rhinitis, Hiatus hernia 
K022 Sleep Apnoea-on CPAP 
K023 Anxiety, Allergic rhinitis, Vitiligo 
K024 PMH: Cholinergic urticaria and angioedema 
K025 Rheumatoid arthritis, Psoriasis, Pulmonary Sterosis 
K026 Eczema, Gastro-oesophageal reflux 
K028 No 
K029 Asthma Aspirin induced, Protein S deficiency 
K030 Nasal polyposis 
K031 Aortic valve & root replacement (Jul 06), Hypertension, Osteoporosis 
K032 Osteoporosis, Gastro-oesophageal reflux, Rhinosinusitis 
K040 Osteoporosis 
 
The individual case report is the pinnacle of the pharmacological phenotyping. 
The construction of “heat-maps” between each patient and the various levels of 
response of each add-on treatment on its own or in combination with 
dexamethasone has the task of achieving the prediction of “tailor-made” 
treatments for each individual. Two different “heat-maps” have been constructed; 
 200
one shows the anti-inflammatory effects of each drug by itself in severe 
asthmatics (Table 4.10). The other shows the pharmacological parameter of ratio 
increase of IC50dex (Table 4.11). The “heat-maps” for IL-8 and not IL-2 were 
built as IL-8 was shown to be more resistant to dexamethasone therapy and linked 
with a reduction in FEV1. 
 
4.3.3.1 “Heat-map” of anti-inflammatory effect 
The anti-inflammatory effect of each add-on treatment was calculated as the % 
inhibition of the TNFα and anti-CD3/28 stimulated IL-8.  
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Table 4.10 “Heat-map” of anti-inflammatory effect 
Anti-
inflammation 
 
SB203580 
 
 
IMD0354 
 
 
  Theophy 
 
 
LY294002 
 
 
EM 
 
 
EM703 
 
 
Formot 
 
K001 22.8 n/a 5.4 18.5 15.2 17.4 18.2 
K002 13.9 8.1 -13.8 12.6 30.6 24.6 4.7 
K003 55.9 26.5 -12.2 -18.5 -12.7 -9.3 -10.9 
K012 27.7 20.5 -9.5 -16.2 -7.6 -1.0 -0.9 
K013 10.7 19.1 -5.2 -9.5 -7.8 1.3 3.8 
K016 30.1 24.8 -1.8 -2.0 -1.1 5.6 -8.3 
K019 52.1 34.9 -12.6 -2.7 -13.2 17.2 -9.4 
K020 26.7 41.9 -3.3 4.1 1.7 11.7 -5.8 
K021 35.0 15.5 -1.7 -6.1 -5.5 -4.2 -14.5 
K022 72.7 15.3 0.9 2.6 -1.4 6.6 -3.3 
K023 53.1 36.3 -3.5 -6.4 -6.0 3.3 -4.9 
K024 41.6 46.5 -4.8 10.7 13.3 17.1 1.3 
K025 -1.2 39.8 -2.4 2.2 0.2 9.7 -16.5 
K026 42.1 29.6 -5.9 -15.1 -12.4 -5.7 -6.8 
K028 7.8 17.9 2.6 -11.9 -15.4 -7.5 -2.2 
K029 58.5 46.7 20.7 15.3 -1.6 15.9 -2.6 
K030 27.7 28.5 2.9 -4.3 -0.4 5.8 -4.4 
K031 26.9 24.6 -6.0 13.2 7.1 19.2 -2.5 
K032 51.7 65.3 1.1 -1.9 -15.6 23.4 -5.8 
K040 36.4 24.8 -2.0 -9.1 -9.4 -1.2 -0.3 
- IMD0345 (2 μM), theophylline (1 μM), LY294002 (10 nM), EM (10 μM), EM703 (10 μM), 
formoterol (1 nM) and SB203580 (5 μM). Effect measured in % inhibition of anti-CD3/28/TNF-α 
induced IL-8. 
- () % inhibition < -10  
- () -10 <% inhibition < +10  
- () +10 <% inhibition < +20 
- () +20 <% inhibition < +50 
- () % inhibition > +50.  
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4.3.3.2 “Heat-map” of add-on effect on corticosteroid sensitivity by IC50dex 
The improvement on corticosteroid sensitivity was assessed for each add-on 
treatment and was calculated by using the ratio (fold) change of IC50dex before 
and after treatment.  
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Table 4.11 “Heat-map” of add-on effect on corticosteroid sensitivity by IC50dex 
IC50dex 
 
SB203580 
 
 
IMD0354 
 
 
  Theophy 
 
 
LY294002 
 
 
EM 
 
 
EM703 
 
 
Formot 
 
K001 RT RT* NP NP NP NP NP 
K002 NP NP NP NP NP NP NP 
K003 4.93 1.68 0.59 1.05 1.65 1.04 0.12 
K012 RT NP NP NP NP NP NP 
K013 RT NP NP NP NP NP NP 
K016 22.21 33.89 NE NE NE NE NE 
K019 6.65 1.22 2.61 2.75 0.70 2.79 1.08 
K020 RT RT RT RT NP NP NP 
K021 306.89 6.45 3.52 0.55 7.06 2.19 NE 
K022 1.34 0.29 0.47 0.27 0.42 0.43 0.33 
K023 41.79 4.29 0.72 0.54 1.58 0.72 0.63 
K024 17.72 1.27 0.41 3.06 1.93 0.47 NE 
K025 1.02 0.55 0.49 0.72 0.41 0.48 0.46 
K026 23.96 2.18 0.48 0.33 0.43 0.61 0.11 
K028 5.14 0.08 0.88 0.36 0.06 2.93 0.92 
K029 3.84 1.32 0.45 0.49 0.66 1.14 0.89 
K030 4.32 NE 0.16 0.88 0.69 1.41 0.17 
K031 RT RT RT RT NP NP NP 
K032 4.42 0.64 0.83 1.54 0.83 1.32 0.65 
K040 80.31 NE 4.33 5.39 1.47 NE NE 
 
- IMD0345 (2 μM), theophylline (1 μM), LY294002 (10 nM), EM (10 μM), EM703 (10 μM), 
formoterol (1 nM) and SB203580 (5 μM) 
- Ratio: IC50dex without treatment/IC50dex with treatment of anti-CD3/28/TNF-α induced IL-
8 inhibition. 
- () Ratio<0.5  
- () 0.5<Ratio<1.99 
- () 2.0<Ratio<2.99 
- () 3.0<Ratio<9.99 
- () 10<Ratio 
- NP: not possible to calculate, NE: Negative effect. RT: Restores corticosteroid sensitivity 
- (*) A different IKK2 inhibitor was used (AS602868 from Merck Serono International SA, 
Geneva, Switzerland). 
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4.3.3.3 Corticosteroid sensitivity is restored in nearly all severe asthmatics and 
these can be divided according to their pharmacological profile 
Using the results from the “Heat-map” of add-on effect on corticosteroid 
sensitivity by improvement of IC50dex, a map of the positive response of each 
patient (IC50dex wo/ IC50dex w >2) to corticosteroid sensitivity was constructed. 
Responders to IMD0354, theophylline, LY294002, SB203580, EM and EM703 
were grouped as responders to IKK2 inhibition, responder to PI3K inhibition 
(theophylline included), responders to p38α/β inhibition and responders to 
macrolides respectively (Figure 4.27). Interestingly, corticosteroid sensitivity is 
restored in nearly every severe asthmatic displaying a reduction in corticosteroid 
responsiveness except for one patient (K002). All responders to macrolides, PI3K 
and IKK2 inhibition also responded to SB203580. 
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K002
K022
K025
K001
K012
K013
K026
K023
K016
K028
K019
K021
K020
K024
K040K003
K029
K030
K032
P38α/β inhib Macrolide
PI3K inhib
IKK2 inhib
K031
No effect
K*** Corticosteroid insensitive
 
Figure 4.27 Pharmacological phenotypes of severe asthma. Severe asthmatics were 
mapped in four pharmacological groups corresponding to responders to each treatment 
(ratio of IC50dex without treatment/ IC50dex with treatment > 2). Responders to IKK2 
inhibition (IMD0354), responders to p38α/β inhibition, responders to PI3K/Akt inhibition 
(theophylline and LY294002) and macrolides responders (EM and EM703) were defined. 
Underlined are the patients that were corticosteroid insensitive (IC50dex>10-4M) 
 
4.3.3.4 Individual case report 
Table 4.12 summarizes the individual results found for different markers of GR 
transactivation, GR transrepression and nuclear translocation in severe asthma and 
compares it to the average in healthy volunteers, mild and moderate patients. 
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Table 4.12 Summary of the results of 20 severe asthmatics for markers of 
inflammation.  
 
Severe 
Asthmatics 
IC50dex for IL-
8 (μM) 
Ratio of nuclear 
translocation 
GILZ ratio incr. 
at dex 1μM 
 Ratio His-4 K5 
at dex 1μM 
 MKP-1 
at dex 1μM 
K001 SR _ 12.6 0.6 3.6 
K002 SR 2.2 6.7 0.4 3.6 
K003 0.14  6.2 13.8 0.5 0.9 
K012 SR 1.1 34.0 _ 2.8 
K013 SR 1.3 10.4 _ 5.4 
K016 10.0 0.9 30.1 _ 3.4 
K019 0.36 1.2 16.6 _ 15.1 
K020 SR 1.2 11.5 _ 5.2 
K021 9.5 1.1 9.9 0.8 1.6 
K022 0.02 2.8 5.9 _ 3.1 
K023 2.1 0.8 22.7 _ 12.5 
K024 3.7 0.8 8.4 0.6 2.3 
K025 0.06 2.2 2.2 _ 1.2 
K026 0.89 1.1 6.1 0.9 1.6 
K028 1.4 2.6 10.1 _ 1.7 
K029 0.12 4.2 15.2 _ 4.6 
K030 0.41 2.1 9.7 0.7 13.2 
K031 SR 1.1 39.9 _ 2.1 
K032 0.07 3.4 24.5 _ 3.3 
K040 12.0 0.9 8.9 _ 2.5 
HV average _ 2.4 15.4 1.5 4.8 
Mild A. 
average _ 3.3 17.6 1.3 17.3 
Mod. A. 
Average _ 3.3 14.3 1.0 13.6 
- HV: Healthy Volunteers. 
- SR: steroid resistant for IL-8 inhibition (IC50dex > 10-4M) 
- In “orange” the patients where the IC50dex was superior to 1 μM.  
- GILZ transactivation levels in severe asthma (in green the highest levels which correlated with 
osteoporosis (p<0.05)). 
- (-) No values available. 
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4.4 Discussion 
Molecular abnormalities in severe asthma 
Severe asthma is characterized clinically by total or partial loss of corticosteroid 
sensitivity for the control of asthma symptoms (Chanez et al., 2007). Even at 
cellular level, macrophages (Goleva et al., 2006) and epithelial cells (Hamilton et 
al., 2003) obtained from severe asthmatics have been reported to be corticosteroid 
insensitive in vitro. I have also shown that PBMCs from severe asthmatics were 
more corticosteroid insensitive to TNFα-induced IL-8 release, confirming the 
previous results from Chapter 3. I used combination of TNFα and anti-CD3/CD28 
as a stimulant to stimulate lymphocytes and monocytes together, which resulted in 
2-3 times stronger induction of IL-8 production and over 600 times more steroid 
insensitivity than with TNFα alone. In fact, anti-CD3 and anti-CD28 have been 
shown to synergistically stimulate TNFα and IL-8 in T cells which may explain 
the stronger induction in IL-8 (Schafer et al., 1999; Wechsler et al., 1994). Under 
this stimulation, PBMCs tended to be dexamethasone insensitive in severe asthma 
when compared with healthy volunteers and mild asthmatics. Furthermore, it was 
found that the reduction in corticosteroid responsiveness correlated with a 
decrease in lung function, suggesting that patients with less corticosteroid 
sensitivity in PBMCs in vitro displayed a more severe clinical phenotype. A 
reduction in lung function is often associated with severe asthmatics although it is 
not always the case. This reduction in lung function has been reported to be 
associated with a systemic increase in IL-8 and TNFα in blood serum (Silvestri et 
al., 2006) and circulating (Silvestri et al., 2006) and infiltrated neutrophils in the 
airways (Lamblin et al., 1998; Little et al., 2002; Shannon et al., 2007; Shaw et al., 
2007) from severe asthmatics. Neutrophilic inflammation in the lung in turn is 
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associated with increased lung damage which could result in airway 
hyperresponsiveness (Bai and Knight, 2005) and severe exacerbations (Fahy et al., 
1995). Neutrophilic inflammation is thought to be corticosteroid resistant in the 
airway (Barnes, 2004). Basal IL-8, a neutrophil chemoattractant, has been shown 
to be increased in BAL and sputum from severe asthmatics (Lamblin et al., 1998; 
Little et al., 2002; Shaw et al., 2007) although this was not the case in PBMCs 
analysed in this study. However, a systemic reduction in dexamethasone-
dependent inhibition of TNFα/anti-CD3/CD28-induced IL-8 production suggests 
the existence of neutrophilic inflammation in these patients indirectly. In fact, 
patients with steroid-dependent asthma have also been shown to be prednisolone 
naïve against circulating neutrophils and IL-8 in the whole blood (Mann and 
Chung, 2006). Similarly, TNFα/anti-CD3/CD28 induced IL-2 production tended 
to be more dexamethasone insensitive, even if it did not reach significant levels. 
Nevertheless, there was no correlation between dexamethasone sensitivity to IL-2 
release and lung function. Anti-CD3/CD28 dependent IL-2 production did not 
result in an increase of dexamethasone insensitivity in severe asthma when 
compared to healthy volunteers and mild asthmatics, underlying that monocytes 
are more involved in corticosteroid insensitive inflammation. This is confirmed 
by Hew et al. who found monocytes to be responsible for corticosteroid 
insensitivity to various cytokines including IL-8 (Hew et al., 2006). It is possible 
that other mediators from lymphocytes might be better markers of corticosteroid 
insensitive inflammation. In fact, basal IL-4 level was significantly increased in 
severe asthma. 
GR nuclear translocation after ligand binding is an active and initial process 
crucial for steroid action. In this project, GR nuclear translocation was assessed 
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by immunocytochemistry using confocal microscopy. FITC-Dex nuclear 
translocation was used in Chapter 3 as a quantitative and relatively simple 
laboratory technique.  However, it remains inadequate because it involves indirect 
detection of GR localization. Furthermore, abnormalities in the metabolism of 
steroids might affect the result. Immunocytochemistry is usually time-consuming 
for the analysis and biased, yet the software used was semi-quantitative for data 
analysis, reducing biased results. Severe asthmatics in this study showed a 
tendency for a reduction of GR nuclear translocation as observed in their PBMCs 
compared to healthy volunteers, moderate and mild asthmatics. Two patterns were 
detected; one showing a defect in GR nuclear translocation and another with a 
normal GR nuclear shuttling. These results confirmed previous findings on two 
phenotypes defined by GR nuclear translocation in Chapter 3 as well as data 
reported by Matthews et al. (Matthews et al., 2004). PBMCs from the patients 
with impaired GR nuclear localization also showed a decrease of corticosteroid 
sensitivity for IL-8 inhibition only in severe asthmatics (Figures 4.12A, B, C). 
This was not the case when comparing to IL-2 implying that lymphocytes are less 
affected than monocytes.  
In addition, severe asthmatics with a low GR nuclear translocation also showed a 
reduced lung function (Figure 4.12D). This is the first time that a reduction in 
nuclear translocation has been correlated to a clinical marker of disease severity. 
Several studies have demonstrated that treatment with IL-2/IL-4 can mimic the 
corticosteroid insensitivity seen in severe asthma (Irusen et al., 2002; Kam et al., 
1993; Larsson et al., 1999). According to the results in Chapter 3, IL-2/IL-4 
treatment induced defective GR nuclear translocation by hyperphosphorylation of 
GR. These data supports that IL-2 and IL-4 are key factors in the defect of GR 
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nuclear translocation. As shown in Figure 4.17, basal IL-2 and IL-4 levels are 
significantly increased in severe asthma. Previous studies have also revealed that 
both cytokines are increased in blood serum of this patient group (Leung et al., 
1995) and are associated with increased corticosteroid resistance in PBMCs (Kam 
et al., 1993). The study by Kam et al. also shows that the incubation of PBMCs 
with IL-2 and IL-4 has helped in maintaining this phenotype but the washout of 
the cytokines results in restoration of corticosteroid sensitivity (Kam et al., 1993). 
After translocation into nuclei, activated GR transrepression was measured by IL-
8/IL-2 inhibition by dexamethasone. Dexamethasone also induces dimerization of 
nuclear GR, acting as a transcription factor binding to DNA in a process described 
as GR transactivation (Ito et al., 2006a). Three different markers of transactivation 
were evaluated in the different patient groups; Histone-4 lysine-5 acetylation, 
MKP-1 gene induction and GILZ (Glucocorticoid induced leuzine zipper) gene 
induction. Histone-4 lysine-5 acetylation was reported to be normally associated 
to the transcriptional initiation by activated GR considered a marker of steroid-
dependent transactivation (Ito et al., 2000; Matthews et al., 2004). Matthews et al. 
found that PBMCs from steroid resistant patients showed a defect in Histone-4 
lysine-5 acetylation after dexamethasone treatment. My data also supports a 
reduction of Histone-4 lysine-5 acetylation in severe asthmatics over mild 
asthmatics and healthy volunteers (p<0.05) (Figure 4.14).  
GILZ is a transactivation product of GR with a role as an endogenous inhibitor of 
transcription factors such as AP-1 and NF-κB by interacting directly with their 
subunits (Di Marco et al., 2007; Mittelstadt and Ashwell, 2001). AP-1 and NF-κB 
are transcription factors regulating IL-8 production. There was no significant 
reduction of dexamethasone-induced GILZ expression in severe asthma (Figure 
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4.15B). However, all patients showed an interesting correlation where 
dexamethasone either strongly induced GILZ activation but transrepressed IL-8 
weakly IL-8 or vice-versa (Figure 4.16A). This mutually exclusive trend was not 
significant in severe asthmatics any more where a small subgroup showed both a 
low level of GILZ transactivation and a low inhibitory potential of IL-8 (Figure 
4.16B). This reduction in GILZ expression by dexamethasone was shown to be 
due to a decrease of GR nuclear translocation. Interestingly, GILZ transactivation 
potential was correlated with the basal levels of IL-8 in severe asthma (Table 
4.13), which might indicate that high levels of baseline of IL-8 are related to 
underlying inflammation due to reduction of endogenous transcription factor 
inhibitor-GILZ. Similarly, Eddleston et al. found that baseline levels of IL-8 
expression were slightly increased in knock-down studies using GILZ siRNA, in 
cells compared with controls, suggesting that decreased levels of GILZ within the 
cell might initiate an inflammatory response through the induction of chemotactic 
cytokines (Eddleston et al., 2007).  
MKP-1, known as “dual-specific phosphatase”, is an endogenous p38MAPK 
inhibitor able to dephosphorylate this kinase (Clark et al., 2003). MKP-1 is part of 
a group of 10 to 100 dexamethasone inducible anti-inflammatory genes (Chivers 
et al., 2006). The transactivation levels of MKP-1 were significantly reduced in 
severe asthmatics when compared with those of mild and moderate asthmatics. As 
dexamethasone-induced GILZ expression was not reduced significantly in severe 
asthma, dexamethasone-induced GILZ and MKP-1 expression might be 
controlled by different molecular mechanisms, such as different co-activators 
recruitment. In fact, GILZ promotor region is known to posses several GRE 
elements whereas MKP-1 does not (Chinenov and Rogatsky, 2007). Additionally, 
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GILZ promoter region is also regulated by forkhead response elements (FHRE) 
where GR and transcription factor FoxO3 play a regulatory role (Asselin-Labat et 
al., 2005) whereas MKP-1 expression does not require the formation of GR 
dimers (Newton and Holden, 2007). Also, Kaur et al. have shown that cAMP 
elevating agents enhance dexamethasone-induced transcription of MKP-1 but not 
GILZ (Kaur et al., 2008). Actually, the transcription of both mRNA products 
correlated in all patients except for severe asthmatics. Further investigations will 
be required to reveal the different molecular mechanisms involved. My data 
implies that MKP-1 might be a better marker to determine the ability of steroids 
to induce transactivation in severe asthma. 
Few studies have investigated phenotypes of severe asthma at a molecular level. 
Defective GR nuclear translocation and GR transactivation were seen in severe 
asthmatics as well as defective GR transrepression. Analysis using data of GR 
nuclear translocation and GR transactivation divided severe asthmatics into 4 
subgroups in Figure 4.18. Matthews et al. were not able to see any difference 
between the transrepression effect from patients with a defective GR nuclear 
translocation from those with a defective Histone-4 K5 acetylation (Matthews et 
al., 2004). I have found that patients with either double defect of GR nuclear 
translocation and GR transactivation or only defective GR nuclear translocation 
were the most corticosteroid insensitive subgroups for IL-8 suppression (Figure 
4.19) In fact, if we divide in only two groups, as in Chapter 3, by comparing 
defective GR nuclear translocation versus normal, we observe that defective GR 
nuclear translocation is the main factor in the reduction of corticosteroid 
sensitivity (A/B: 70.7 ± 10.9% vs C/D: 20.8 ± 6.5%; p<0.005). Defective GR 
nuclear translocation group (C/D) also showed a significant reduction in lung 
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function determined by FEV1 (% pred) as compared to control (A/B) (A/B: 70.0 ± 
9.0% vs C/D: 48.9 ± 3.8%; p<0.05) and higher use of oral prednisilone (A/B: 8.3 
± 3.4% vs C/D: 15.9 ± 3.5%). This is not observed when comparing defective GR 
transactivation versus normal suggesting that GR nuclear translocation plays a 
more important role in systemic corticosteroid insensitivity and reduced lung 
function. Thus, the findings from the in vitro study were matched with clinical 
measurements in severe asthma suggesting this in vitro phenotyping might be 
useful in understanding the level of steroid sensitivity. However additional 
phenotyping would be needed to confirm this. 
Table 4.13  Correlations in severe asthma 
 
IL-8 IC50 
IL-8 % 
inh 
0.1μM 
Dex 
GRα HDAC2     GILZ (dex/nt) 
MKP1 
(dex/nt) 
H4K5 
(dex/nt) 
GR 
 nuclei 
IL-8 
(Basal) 
FEV1 
(%pred) 
IL-8- 
IC50 
 R=-0.92 P<0.0001 ns ns ns ns ns 
R=-0.80 
P<0.001 ns 
R=-0.56 
P<0.05 
IL-8 % 
inh 
0.1μM 
Dex 
R=-0.92 
P<0.0001  ns ns ns ns ns 
R=0.59 
P<0.005 ns 
R=0.53 
P<0.05 
GRα ns ns  ns ns ns ns ns ns ns 
HDAC2 ns ns ns  ns ns ns ns ns ns 
GILZ 
(dex/nt) ns ns ns ns  ns ns ns 
R=-0.64 
P<0.005 ns 
MKP1 
(dex/nt) ns ns ns ns ns  ns ns ns ns 
H4K5 
(dex/nt) ns ns ns ns ns ns  ns ns ns 
GR 
nuclei 
R=-0.80 
P<0.001 
R=0.59 
P<0.005 ns ns ns ns ns  ns 
R=0.49 
P<0.05 
IL-8 ns ns ns ns R=-0.64 P<0.005 ns ns ns  ns 
FEV1 
(%pred) 
R=-0.56 
P<0.05 
R=0.53 
P<0.05 ns ns ns ns ns 
R=0.49 
P<0.05 ns  
- GR nuclei: ratio of GR nuclear translocation after dex treatment. 
- H4K5: Ratio of Histone-4 lysine-5 acetylation after dex treatment. 
- FEV1: Forced Expiratory Volume in one second. 
- IL-8 % inh 0.1 μM Dex: The % inhibition of TNFα/anti-CD3/CD28 induced IL-8 by 
dexamethasone at 0.1 μM. 
- P<0.05 is significant. 
- ns: non-significant 
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Pharmacological assessment of abnormalities in severe asthma 
In this study, an IKK2 inhibitor, a p38MAPKα/β inhibitor, a PI3K inhibitor and 
macrolides (antibiotic and non-antibiotic) were used as examples of novel add-on 
treatments whereas formoterol and theophylline were used as examples of drugs 
currently used in the treatment of severe asthma.   
The most effective add-on treatment was the p38MAPKα/β inhibitor: SB203580. 
The inhibition of basal and TNFα/anti-CD3/CD28 stimulated IL-8 by SB203580 
in PBMCs shows the importance of the p38α/β pathway in the pro-inflammatory 
cytokine regulation. The IL-8 promoter is regulated by transcription factors such 
as AP-1 and NF-κB (Roebuck, 1999), and p38MAPK is known to activate these 
transcription factors either by driving direct phosphorylation (Saatian et al., 2006) 
or indirectly by the phosphorylation of kinases responsible for the activation of 
transcription factors (Choi et al., 2007; Saatian et al., 2006). In addition, p38α-
dependent phosphorylation of MSK results in the phosphorylation of Histone-3 
(H3) leading to the recruitment of NF-κB and the transcriptional regulation of IL-
8 and other inflammatory cytokines (Saccani et al., 2002). Furthermore 
p38MAPK enhances the stability of pro-inflammatory cytokine mRNA by 
phosphorylation of an AU-rich element in mRNA (Kumar et al., 2003).  
Notably, SB203580 was the only add-on treatment able to restore corticosteroid 
sensitivity for IL-8 inhibition in all severe asthmatics underlying the importance 
of the p38α/β pathway in inflammation for restoration of corticosteroid sensitivity. 
This restoration of corticosteroid sensitivity by SB203580 was shown to correlate 
with a defect in GR nuclear translocation (Tables 4.5 and 4.6). Irusen et al. 
demonstrated that p38MAPKα and β have the potential to phosphorylate GR 
leading to a defect of GR function (Irusen et al., 2002). Studies have also 
 215
demonstrated that p38MAPKα phosphorylated GR indirectly (Szatmary et al., 
2004) in contrast to JNK, which was shown to directly phosphorylate GR at a 
specific serine residue (Rogatsky et al., 1998a). SB203580 did not work in my IL-
2/IL-4 induced steroid insensitive model in Chapter 3, and a mechanism other 
than that induced by IL-2/IL-4 might be involved in the defect of GR nuclear 
translocation in SB203580 responders. Analysis also revealed that SB203580 was 
more effective in the patients with lower lung function (Table 4.5). P38MAPKα/β 
inhibition might be effective in more severe patients. As I discussed above, an 
increased effect of SB203580 was correlated with higher corticosteroid resistance 
to IL-8 inhibition implying that patients with neutrophilic inflammation, more 
affected by decreased lung function, are p38MAPKα/β inhibitor responders. 
Further analysis of neutrophil counts in peripheral blood and airway will be 
required. 
IMD0354 was equally effective as SB203580 in reducing IL-8 and IL-2 
production in TNFα/anti-CD3/CD28 stimulated PBMCs. This suggests that NF-
κB signaling is also important in IL-8 and IL-2 gene expression. In fact, NF-κB 
binding sites on the IL-2 gene promoter region are reported in literature (Kim et 
al., 2006) and Cosio et al. (Cosio et al., 2004a) have shown that another IKK2 
inhibitor (AS602868) reduces LPS induced IL-8 in asthmatics macrophages. 
Overall the IKK2 inhibitor did not restore corticosteroid sensitivity with regards 
to IL-8 production, and decreased corticosteroid sensitivity with regards to IL-2 
production. The mechanisms of the latter remain unknown.   
All add-on treatments had either “responder” or “non-responder” individuals in 
severe asthma. IMD0354 responders were the patients with lower corticosteroid 
sensitivity (Tables 4.5 and 4.6). Overexpression of NF-κB is reported to induce 
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corticosteroid insensitivity (Gagliardo et al., 2003) possibly by sequestering active 
GR and preventing GR anti-inflammatory effects (McKay and Cidlowski, 1998), 
although this mechanisms remains controversial. Sequestration of GR by NF-κB 
however could result in reduction of GR-dependent Iκ-B expression, a molecule 
known as the endogenous inhibitor of NF-κB signalling, leading to hyper-
activation of NF-κB. This vicious circle might be involved in the IKK2-inhibitor 
responder subgroup of patients. In fact, IKK2 activation is reported to be 
enhanced in severe asthma (Gagliardo et al., 2003). “Responders” to IKK2 
inhibition were not associated with a defect in GR nuclear translocation although 
all patients had a low nuclear translocation. It is possible that IMD0354 relieves 
the inhibition of NF-κB on GR in these patients which in turn produce lower 
levels of dexamethasone induced Iκ-B expression due in part to poor GR nuclear 
translocation. In this case transactivation of Iκ-B by dexamethasone should be 
investigated and further studies would be necessary to understand the mechanism 
by which NF-κB inhibition enhances corticosteroid sensitivity in some severe 
asthmatics.  One particularity of this group was that the highest response to IKK2 
was measured in the only current smoker. Smoking asthmatics are also 
characterized by resistance to corticosteroid therapy. It has been suggested by 
Thompson et al. that smoking might contribute to the development and 
manifestations of severe asthma, and that they have more symptoms and frequent 
exacerbations (Thomson et al., 2006). A reduced response to steroids and a more 
rapid decline in pulmonary function has also been reported. These patients might 
be responders to IKK2 inhibitor. Further analysis using smoking asthmatics will 
be required. 
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Ito et al. have shown a reduction in HDAC2 expression in smoker’s BAL 
macrophages compared to non-smoking asthmatics (Ito et al., 2001). Interestingly, 
the only current smoker in this study showed the lowest HDAC2 protein 
expression levels. I found no reduction in HDAC2 protein expression in the 
samples from ex-smokers. The impact of cigarette smoke on ex-smokers is not 
fully understood. Further phenotyping in smoker asthmatics would be necessary 
to clarify the real impact of smoking on disease severity.  
Theophylline is an old drug used as a bronchodilator in asthma (Barnes, 2003). Its 
use is declining due to side-effects and the development of more potent 
bronchodilators such as LABAs (Barnes, 2003). Recently low-dose theophylline 
has been reported to have anti-inflammatory efficacy and enhance corticosteroid 
action both clinically and in vitro (Evans et al., 1997; Ito et al., 2002b; Ukena et 
al., 1997). The molecular mechanism of low-dose theophylline is still unclear, yet 
low concentration of theophylline is reported to restore corticosteroid sensitivity 
by enhancing HDAC2 activity via inhibition of PI3K signaling (To Y., 2007). In 
fact, there were “responders” and “non-responders” for the add-on treatment of 
theophylline in this in vitro study. The responders of theophylline were almost 
identical to responders of LY294002, a known non-specific PI3K inhibitor (Table 
4.11). In Chapter 3, HDAC activity was shown to be reduced in steroid insensitive 
patients with a normal pattern of nuclear translocation and restored by 
theophylline although overall HDAC2 mRNA levels were similar compare to 
healthy volunteers. In this study a slight reduction in HDAC2 protein expression 
is found in mild asthmatics which is reversed to the levels seen healthy volunteers 
in moderate asthmatics. This trend has been found to be significant in a study 
from Ito and colleagues which reported that HDAC2 protein expression 
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upregulation in moderate asthmatics might be the result of ICS therapy (Ito et al., 
2002a). The same could be said about this study. Severe asthmatics however 
showed a near significant reduction in HDAC2 expression compare to moderate 
asthmatics (p=0.085) despite oral prednisilone use combined with higher doses of 
ICS. Interestingly, theophylline and LY294002 induced corticosteroid 
responsiveness in 5/5 and 4/5 severe asthmatics respectively with low levels of 
HDAC2 protein expression (Figure 4.26A). In the case of theophylline, 
“responders” also showed a decrease in corticosteroid sensitivity (Figure 4.26B). 
Similar results were obtained, although with more significance, when looking at 
the effect of IL-2, hence in lymphocytes (data not shown). Cosio et al. have 
previously demonstrated that changes in HDAC activity and expression are the 
same between monocytes and lymphocytes in PBMCs population (Cosio et al., 
2004a). However, this study fails to find a significant relationship with HDAC2 
protein levels decrease and PI3K/Akt inhibitory effect on steroid sensitivity 
supporting that HDAC activity is mainly responsible for the loss of steroid 
sensitivity in some severe asthmatic patients as shown in Chapter 3. 
PI3K inhibition is reported to restore HDAC2 expression reduced under oxidative 
stress (To Y., 2007). The patients with high levels of endogenous oxidative stress 
might be responders to PI3K signal modifiers. Correlation with oxidative stress 
markers, such as isoprostane, nitrotyrosine or hydroxynonenal (HNE) will be 
interesting to study. Sub-phenotyping analysis also suggested responders to 
theophylline and LY294002 were type D, showing double defect of GR nuclear 
translocation and GR transactivation. 
Macrolides are known to have anti-inflammatory action in airway diseases (Oishi 
et al., 1994; Sakito et al., 1996). EM703 was discovered by Kitazato institute as a 
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non-antibiotic macrolide derivative from erythromycin (EM). Recently, EM and 
its derivate EM703 have shown to be able to inhibit IL-8 and IL-6 from human 
epithelial cells (Desaki et al., 2004). In this study, EM703 inhibited IL-2 and IL-8 
production, and was more potent than EM. Although EM703 is reported to inhibit 
NF-κB signaling, there was no correlation with the effects of IKK2 inhibitors on 
anti-inflammatory actions and the restoration of corticosteroid sensitivity. 
Another mechanism might be involved in the macrolide pathway of action. 
Macrolides are reported to inhibit mTOR (mammalian target of rapamycin, a 
regulatory of cell cycle arrest) acting as an immunosuppresor resulting in 
inhibition of IL-2 (Brennan et al., 1999). Recently it was found in our laboratory 
that EM703 inhibits Akt signaling by inhibition of phosphorylation. Maybe 
macrolides act as PI3K signaling modifiers similar to LY294002 and (low dose) 
theophylline. In fact, both the anti-inflammatory and steroid enhancing effects of 
LY294002 and EM703 correlated very significantly (p<0.0005) in severe asthma.  
In Chapter 3, formoterol and salmeterol were effective on restoration of 
corticosteroid sensitivity in almost half of the severe asthmatics recruited. 
However, formoterol was less effective in this study. The patients used in Chapter 
3 were under inhaled corticosteroid therapy but LABA-naïve, whereas in this 
study, all patients except one were on daily doses of combination inhaler (CS + 
LABA) and on high doses of combination inhaler and/or oral corticosteroids. 
Reduced efficacy of formoterol on restoration of corticosteroid sensitivity might 
be due to desensitization of β2-adrenoreceptor or by an unknown mechanism 
connected to long-term use of LABA. Formoterol was able to enhance 
corticosteroid suppression of IL-2 in three patients showing that β2-
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adrenoreceptor desensitization might not be so important with regards to the 
steroid response in lymphocytes.  
All together, this pharmacological analysis has helped to bridge the gap between 
the clinical observations and the molecular profile of these subjects. 
 
Case report 
Many good correlations between clinical and molecular parameters or the effect 
of add-on treatments were observed in healthy volunteers, mild and moderate 
asthmatics when excluding severe asthmatics. The reason for this might be the 
heterogeneous nature of severe asthma. This marks the limit of the grouping of 
the phenotypes and points out at the importance of individual analysis for 
enabling tailor-made treatment. 
The construction of heat-maps facilitates the reading of each individual patient 
response with the anti-inflammatory effect or steroid sparing effects of a 
particular compound as shown in Tables 4.10 and 4.11. Although most patients 
responded positively to the anti-inflammatory role of the p38α/β, SB203580 failed 
to show an anti-inflammatory potential in only two patients, one being the only 
psoriasis and rheumatoid arthritis sufferer. The effect of add-on treatment could 
also be affected by co-morbidity, such as in the case of patients with hypertension, 
patients with aspirin-induced asthma and psoriasis. The occurrence of co-
morbidities such as hypertension, osteoporosis and myopathy, whether steroid-
induced or not, play an important part in deciding the correct add-on treatment in 
addition to the markers of individual molecular abnormalities shown in Table 4.12.  
The ubiquitous nature of SB203580 represents a dilemma. Whitebread et al. has 
proposed that the achievement of exquisite pharmacological selectivity is the 
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Holy Grail of the pharmacological industry, however, when the disease seems to 
be of polygenic origin, some degree of promiscuity might be advantageous 
(Whitebread et al., 2005). In this case, the many effects of SB203580 might not 
give us a treatment for one, but for more than one defective phenotype in severe 
asthma. Barnes has mentioned that for new treatment to have a major clinical 
impact it need not to be so specific and target more than one pathway (Barnes, 
2006c). Various p38α/β inhibitors with promising in vitro effect have proved to 
have toxicity effects in clinical trials (Adcock et al., 2006; Sweeney and Firestein, 
2006). The reason behind is the same as its success, too many targets makes it 
prone to the induction of side-effects. However, SB203580 was the most 
succesfull add-on treatment for reversing corticosteroid resistance in those 
patients with an in vitro corticosteroid insensitive phenotype except for only one 
severe asthmatic (Figure 4.27). In fact, all responders to IMD0354, 
theophylline/LY294002 and macrolides are also responder to SB203580 which   
underlines that more than one pathway might be involved in the loss of 
corticosteroid sensitivity and also that these inflammatory pathways are connected. 
The benefit of IKK2 inhibition for certain patients underlines the important role of 
this pro-inflammatory factor in the severe asthma. The low proportion of 
responders to theophylline compared to Chapter 3 implies that the group of severe 
asthmatics used in this study is biased towards prevalence for defective GR 
nuclear translocation. In fact, all PI3K inhibitor responders also have a low 
nuclear translocation but PI3K does not clearly contribute to a more defective 
transrepression by GR. 
Restoring corticosteroid responsiveness might result in an increase in lung 
function. In the case of patients with better lung function, it is thought that 
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maintaining this level might be achieved with a steroid-sparing agent leading to a 
reduction of overall corticosteroid use. The reduction of steroid use is important 
in order to achieve a reduction in side-effects (Schacke et al., 2002). In fact, Table 
4.7 shows that the majority of severe asthmatics taking the highest doses of oral 
corticosteroids in conjunction with inhaled corticosteroids responded to at least 
one of SB203580, IMD0354, theophylline or LY294002. Molecular and 
pharmacological phenotyping by one blood sampling could be useful to determine 
the best add-on treatments although almost all of the compounds I used in this 
project are in development stage and not available in clinics.  
The benefits of the “tailor-made” treatment are obvious for both patient and 
physician. A simple blood sample will be enough to pharmacologically phenotype 
the best combination therapy for any severe asthmatic and would help also in 
preventing the incidence of side-effects. 
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5. Effect of nortriptyline on restoration of corticosteroid 
sensitivity in severe asthma 
5.1 Introduction 
CombinatoRx Ltd. is a venture company implicated in finding novel add-on 
treatments to enhance corticosteroid sensitivity. They successfully detected a 
compound called nortriptyline hydrochloride (NH) in their In-house screening. 
Nortriptyline (Figure 5.1) is a second-generation tricyclic antidepressant (TCA) 
that inhibits the re-uptake of serotonin, and to a lesser extent, norepinephrine 
(noradrenalin) (Prochazka et al., 1998). It has also been used as a non-nicotine 
drug for smoking cessation in COPD patients (Borson et al., 1992). Aside the 
improvements in mood and physical symptoms, patients have shown a marked 
improvement in certain respiratory symptoms (Borson et al., 1992). Nortriptyline, 
known for its anti-depressant properties also has anti-histamine activity. It is 
thought to contain other anti-inflammatory properties. In fact, CombinatorRx has 
developed a compound combining low doses budesonide with NH (CRx-170) 
which in clinical trials revealed to improve FEV1 when both drug had no 
significant effect on their own (CombinatoRx, 2006). The steroid-sparing effect of 
NH was studied ex vivo in PBMCs from patients with asthma and the molecular 
mechanism involved studied in cell-based assays.  
 
 
 
 
 224
 
Nortriptyline 
 
 
 
 
 
 
 
 
Figure 5.1 Nortriptyline molecular structure. Nortriptyline is also known as 3-(10,11-
dihydro-5H-dibenzo[a,d] cyclohepten-5-ylidene)- N-methyl-1-propanamine with the 
following molecular formula: C19H21N.  
 
5.2 Subjects, materials and methods 
5.2.1 Subjects 
The same 10 healthy volunteers, 5 mild, 9 moderate and 19 severe asthmatics that 
were recruited from the staff and patients form the National Heart and Lung 
Institute and the Royal Brompton Hospital for the pharmacological phenotyping 
study in Chapter 4 were utilized.  
 
5.2.2 ELISA of stimulated PBMCs in the presence of NH 
PBMCs (106 cells/ml) were seeded in 96-well plates and stimulated with NH 
(5x10-7M) for 30 minutes prior stimulation with serial dilutions of dexamethasone 
(10-6M to 10-11M) for 1 hour. Cells were subsequently transferred into a 96-well 
plate coated with anti-human CD3 (10 µg/ml) and CD28 antibodies (8 µg/ml) and 
TNFα (1 ng/ml) overnight at 37°C, 5% CO2. The same ELISA protocol that was 
described previously was used for IL-2 and IL-8 cytokine quantification. 
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5.2.3 Construction of Isobologram 
The study of combinatory effect of two drugs was performed by construction of 
an Isobologram. PBMCs (106 cells/ml) extracted from a healthy volunteer were 
previously stimulated for 48 hours with IL-2 and IL-4 and were plated in 96-well 
plate as previously described. Combination of budesonide (100 nM, 10 nM, 1 nM, 
and 0.1 nM) with NH (33 μM, 10 μM, 3.3 μM and 1 μM) was assessed for the 
study of CRx-170. PBMCs were initially stimulated with NH for 30 minutes 
before the addition of budesonide for one hour at 37°C, 5% CO2. Controls were 
used where neither NH nor budesonide were present. After incubation, cells were 
transferred in 96-well plates pre-incubated with or without anti-human CD3 
(10µg/ml) and CD28 antibodies (8µg/ml) overnight at 37°C, 5% CO2. 
Supernatants were collected for IL-2 ELISA as previously described.  
 
5.2.4 One-Step RT-PCR 
PBMCs (2x105 cells/ml) extracted and stimulated with IL-2 and IL-4 from the 
previously used healthy volunteer were plated in 6-well plates and were either 
stimulated with budesonide alone (10 nM), with NH alone (1 μM) or in 
combination for 4 hours at 37°C, 5% CO2. IL-2/4 stimulated and non-stimulated 
PBMCs were also cultured alone as controls for 4 hours. Total mRNA was 
extracted using the previously described Cell-to-Signal Lysis buffer (Applied 
Biosystems) following the manufacture’s instructions. 
The One-Step RT-PCR Master Mix Reagents kit (Applied Biosystems) was used 
to perform the reverse transcription and polymerase reaction in the same tube as 
previously described using GILZ primer and housekeeping gene GNB2L1 for 
normalization. 
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5.2.5 pAkt cell-based assay 
U937 were seeded (106 cells/ml) in 6-well plates using RPMI-1640 (minus phenol 
red), with 1% FCS and 15mM glutamine and left for an hour at 37°C, 5% CO2. 
NH (10 μM, 3.3 μM and 1 μM) was added for 30 minutes and cells were 
subsequently stimulated with H2O2 (200 μM) for 7 minutes. Phosphatase Inhibitor 
(Active Motif) was warmed to 37°C and 5% was added to each well. Cells were 
immediately transferred to a 2 ml eppendorf and centrifuged (5,000 x g, for 3 
minutes) before washing twice with PBS and performing a whole cell extraction 
using the Nuclear Extraction kit (Active Motif) as previously described. Protein 
concentration from whole cell extracts were determined using Bradford Bio-Rad 
protein Assay® kit as previously described. 
 
5.2.6 Detection of phosphorylated Akt Western Blotting  
5.2.6.1 Polyacrylamide gel electrophoresis and I-blot protein transfer 
Protein samples were electrophoretically size–fractionated using sodium 
dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Precast 
NuPAGE® Novex Bis-Tris Gel (10%) (Invitrogen) was rinsed with deionised 
water and set up in the Xcell SuperLock Mini-Cell tank (Invitrogen Carlsbad, 
CA). Reservoir in the tank was filled with MOPS SDS Running Buffer 
(Invitrogen Ltd, Paisley, UK). Protein samples (30 μg) were mixed with one third 
volume of 4 x Laemmli buffer as previously described. Samples were boiled at 
100ºC for 5 min. Protein was loaded onto the gels and run at 200 Volts, 120 mA, 
25 Watts for 35 mins.  
The i-Blot™ Dry Blotting System was used for a quick protein transfer as 
previously described. 
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5.2.6.2 Protein detection 
Protein detection was performed as previously described with the antibodies cited 
in Table 5.1.  
 
Table 5.1 List of antibodies used for the pAkt based assay 
Primary Antibody 
(dilution) 
Company 
(Catalogue n°) 
Secondary 
Antibody 
(dilution) 
Molecular 
Weight (kDa)
Phospho-Akt1 (S473) 
(1:1000) 
Upstate (05-669) Mouse (1:3000) 60 kDa 
Akt1/PKBα  
(1:2000) 
Upstate (07-416) Rabbit (1:2500) 60 kDa 
kDa: kilo-Daltons 
 
5.2.7 HDAC activity  
HDAC activity was measured in 1 μl from U937 cells and normalized with 
protein concentrations. The activity assay is the same as previously described 
based on a fluorescent derivative of epsilon-acetyl lysine (Fluor de Lys™) from 
the HDAC fluorescent Activity Assay kit (Biomol). 
 
5.2.8 Statistical analysis 
Data are expressed as mean ± SEM. Statistical analysis was performed using the 
PC analysis package Graph Pad Prism Software. Results were analyzed using 
Kruskal Wallis analysis of variance and if significant, comparisons were made 
using Mann-Whitney U-test. The efficacy of NH was assesed by Wilcoxon 
matched pairs test. Correlation was analysed by non-parametric Spearman method. 
A p value < 0.05 was considered statistically significant.   
Paired t-test was used for hydrogen peroxide stimulation on U937s and multiple 
comparisons were made between the means from each individual treatment group 
by Dunnett’s test to measure the effect of NH.  
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5.3 Results 
5.3.1 Effect of NH on anti-CD3/CD28/TNFα-induced IL-8 production and 
glucocorticoid sensitivity  
5.3.1.1 Add-on effect on baseline and anti-CD3/28/TNFα production of IL-8 
No differences were observed in severe asthmatics’ baseline production of IL-8 in 
the presence of NH (0.5 μM) (Figure 5.2A). Instead, a small but significant 
reduction in IL-8 was observed in anti-CD3/28/TNFα stimulation of PBMCs 
when incubated 30 minutes with NH compared to non-treatment (NH: 8072±637 
pg/ml vs. NT: 8934±637 pg/ml; P<0.005, n=19) (Figure 5.2B). 
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Figure 5.2 Effect of NH on baseline and anti-CD3/28/TNFα-stimulation of IL-8. (A) 
Baseline IL-8 was measured by ELISA in supernatant of PBMCs incubated in the 
presence or absence of NH (0.5 μM) for 30 minutes. (B) PBMCs were stimulated in the 
presence or absence of 30 minutes pre-incubation of NH (0.5 μM) prior anti-
CD3/28/TNFα stimulation of IL-8 and ELISA. NS: not significant. Data was plotted as 
means ± SEM. P<0.05 is significant. 
 
5.3.1.2 Effect of NH on dexamethasone sensitivity for IL-8 
The IC50dex on anti-CD3/CD28/TNFα-stimulation of IL-8 production in severe 
asthma was 28.5±10.1 μM (n=19) and no significant change in the overall 
A. B. 
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corticosteroid sensitivity was observed after the pre-incubation with NH (27.5±
10.2 μM, Figure 5.3A). Although NH showed no significant reduction in the 
IC50dex, five severe asthmatics were responder to NH (ratio>2). Figure 5.3B 
shows the effect on restoration of dexamethasone sensitivity by NH on a severe 
asthmatic patient (K003) by means of IC50dex. 
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Figure 5.3 Effect of NH on dexamethasone sensitivity to IL-8 inhibition in severe 
asthma. (A) PBMCs were stimulated with serial dilutions of dexamethasone (0.1 nM to 1 
μM) in the presence or absence of 30 minutes pre-incubation of nortriptyline (NH) (0.5 
μM) before induction with anti-CD3/28 and TNFα overnight. (B) An example of one 
experiment done with a severe asthmatic (K003) where the values of dexamethasone 
needed to inhibit IL-8 by 50% (IC50dex) were calculated in the absence (Nt= 141 μM) or 
presence of NH (NH= 52.4 μM). IL-8 production was measured by ELISA and IC50dex 
IL-8 calculated. NS= non-significant. P<0.05 is significant. 
 
5.3.2 Effect of NH on anti-CD3/CD28/TNFα-induced IL-2 production and 
glucocorticoid sensitivity  
5.3.2.1 Effect of NH on baseline and anti-CD3/28/TNFα production of IL-2 
IL-2 baseline production remained unchanged after NH stimulation (NH: 16.5±
7.2 pg/ml vs. NT: 19.5±7.2 pg/ml, n=19) (Figure 5.4A). NH showed a significant 
A. B.
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anti-inflammatory effect for IL-2 in anti-CD3/28/TNFα stimulation (NH: 1797±
353 pg/ml vs. NT: 2189±427 pg/ml, n=19; p<0.0005) (Figure 5.4B). 
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Figure 5.4 Effect of NH on anti-CD3/28/TNFα-stimulated IL-2 production. (A) 
Baseline IL-2 and (B) anti-CD3/28/TNFα stimulated IL-2 were measured in supernatant 
of PBMCs incubated in the presence or absence of 30 minutes pre-incubation NH (0.5 
μM). ELISA was used for IL-2 quantification. Data was plotted as means ± SEM. NS: 
non-significant. P<0.05 is significant. 
 
5.3.2.2 Effect of NH on dexamethasone sensitivity for IL-2 
The IC50dex in anti-CD3/28/TNFα stimulation of IL-2 production in severe 
asthma was 294±116 nM (n=19) and no significant change in the overall 
corticosteroid sensitivity was observed after the incubation with NH (303±119 
nM, n=19) (Figure 5.5). Although NH showed no significant reduction in the 
IC50dex, 3/19 severe asthmatics were “responder” to NH (ratio>2). Only one 
patient “NH responder” to IL-2 was also a responder to IL-8. 
 
 
A. B. 
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Figure 5.5 Effect of NH on dexamethasone sensitivity to IL-2 inhibition in severe 
asthma. PBMCs were stimulated with serial dilutions of dexamethasone (0.1 nM to 1 
μM) in the presence or absence of 30 minutes pre-incubation of NH (0.5 μM) before 
being incubated with anti-CD3/28 and TNFα overnight. IL-2 production was measured 
by ELISA and IC50dex calculated. NS: non-significant. 
 
5.3.3 Relationship of NH with clinical parameters 
The relationship between anti-inflammatory effect of NH (% inhibition of anti-
CD3/CD28/TNFα-induced IL-8 production) and clinical parameters/molecular 
abnormalities are summarized in Table 5.2. The relationship of each add-on 
treatment effect on corticosteroid sensitivity (IC50dex values on anti-
CD3/CD28/TNFα-induced IL-8 production or % inhibition of IL-8 production by 
0.1 μM dexamethasone) and clinical parameters/molecular abnormalities are 
summarized also in Table 5.2. Significant correlations are indicated (p<0.05). 
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Summary 
 
Table 5.2 Relationship of NH’s anti-inflammatory and steroid inducing effects on 
IL-8 inhibition in asthma. 
 Anti-inflammatory Improvement of  steroid sensitivity 
Age +ve; p<0.05 (SA) - 
Hypertension Increased response (SA) - 
FEV1 +ve; p<0.05 (MA+SA) - 
FEV/FVC +ve; p<0.01 (MA+SA)  
Atopy - Increased response (SA) 
GILZ 
transactivation 
- 
+ve; p<0.01 
(SA) 
MKP-1 
transactivation 
- - 
H4 K5 - - 
GR nuclear 
translocation 
- - 
- Anti-inflammatory effect: % inhibition of anti-CD3/28/TNFα-stimulated IL-8. 
- Improvement of steroid sensitivity: 1) Ratio IC50dex without treatment/ IC50dex with treatment 
2) % change in 0.1 μM dexamethasone inhibition of anti-CD3/28/TNFα-stimulated IL-8 by NH. 
- H4 K5: Ratio of Histone-4 K5 acetylation after dexamethasone treatment. 
- (-ve): negative correlation, (+ve): positive correlation. 
- (-): no correlation 
- MA: Moderate asthmatics, SA: Severe asthmatics 
- P<0.05 is significant 
- FEV1: Forced expiratory volume in one second. 
- FVC: Forced vital capacity 
 
 
5.3.4 Relationship of NH with efficacy of other compounds 
Table 5.3 summarizes all correlations between NH and the different add-ons. The 
best association is found with LY294002 which is in the order of p<0.0001 for all 
patients, for severe asthmatics and healthy, mild and moderates alone (r=0.726, 
p<0.0001; r=0.853, p<0.0001; r=0.669, p<0.0001 respectively). Although 
LY294002 does not have an anti-inflammatory effect; PI3K/Akt inhibition might 
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be a common pathway of action. This is partly confirmed by a similar correlation 
with theophylline in all subjects (r=0.447, p<0.005).  
 
Table 5.3 NH’s IL-8 anti-inflammatory relationship with other compounds 
IL-8 inhibition All Subjects 
 
Severe 
Asthma 
Normal 
Mild & Moderate 
SB208530 r=0.364, p<0.05  r=0.581, p<0.005 
IMD0354 r=0.460, p<0.005  r=0.580, p<0.005 
Theophylline r=0.445, p<0.005 r=0.447, p<0.05  
LY294002 r=0.726, p<0.0001 r=0.853, p<0.0001 r=0.699, p<0.0001 
Erythromycin r=0.346, p<0.05 r=0.605, p<0.01  
EM703 r=0.689, p<0.0001 r=0.786, p<0.0001 r=0.662, p<0.0005 
Formoterol    
 
Correlations of anti-inflammatory effects for anti-CD3/28 and TNFα-stimulated IL-8 of NH (0.5 
μM) with formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM), LY294002 (10 nM), EM (10 
μM), EM703 (10 μM) and SB203580 (5 μM) measured in all subjects, severe asthmatics, and 
healthy, mild and moderate. P<0.05 is significant. 
 
When the anti-inflammatory effect of LY294002 and theophylline were compared 
against NH for IL-2 inhibition I found that there is only a correlation with 
LY294002 in all patients except severe asthmatics (r=0.490, p<0.05). NH was 
previously shown to have anti-inflammatory activity against IL-2 in severe 
asthma as well as in in the other patient groups. Nevertheless, NH showed a 
significant correlation in all patients except severe asthmatics against formoterol 
(r=0.523, p<0.01). The significance was higher in all subjects together (r=0.332, 
p<0.005). Formoterol has shown in literature to have anti-inflammatory action 
against IL-2 (Steinke et al., 2006), which was confirmed the previous chapter. It is 
possible that NH shows a similar mode of action (Table 5.4).  
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Table 5.4 NH’s IL-2 anti-inflammatory relationship with other compounds 
Red: IL-2 inh 
 
All Subjects 
 
Severe 
Asthma 
Normal 
Mild & Moderate 
SB208530    
IMD0354 r=0.326, p<0.05   
Theophylline    
LY294002   r=0.468, p<0.05 
Erythromycin r=0.370, p<0.05  r=0.479, p<0.05 
EM703 r=0.332, p<0.05 r=0.544, p<0.05  
Formoterol r=0.473, p<0.005  r=0.523, p<0.01 
 
Correlations of anti-inflammatory effects for anti-CD3/28 and TNFα-stimulated IL-2 of NH (0.5 
μM) with formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM), LY294002 (10 nM), EM (10 
μM), EM703 (10 μM) and SB203580 (5 μM) measured in all subjects, severe asthmatics, and 
healthy, mild and moderate. P<0.05 is significant. 
 
When comparing the IC50dex ratio of the theophylline and LY294002 to NH for 
IL-8 inhibition, it was observed that NH and theophylline had no significant 
correlation in all patients. However, there was a positive correlation in severe 
asthmatics (r=0.797, p<0.005). This was also confirmed when looking at the % 
inhibition by dexamethasone (0.1 μM) (r=0.477, p<0.05) in the same patient 
group although it was also significant in all patients except for severe asthmatics 
(r=0.577, p<0.005).  In the case of NH and LY294002, all patients showed a 
positive correlation when looking at the fold change by IC50dex (r=0.481, p<0.01) 
which was not significant in all patients except severe asthmatics. However, when 
comparing the % inhibition by 0.1 μM dexamethasone, it was found to be very 
significant in all patients and in severe asthmatics only (r=0.586, p<0.0001 and 
r=0.795, p<0.0001 respectively) (Table 5.5).  
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Table 5.5 Relationship of NH improvement on steroid sensitivity for IL-8 inhibition 
with other compounds 
All Subjects 
 
Severe 
Asthma 
Normal 
Mild & Moderate 
IL-8 inhibition 
IC50 
Impro 
% Impro 
at 0.1μM 
dex 
IC50 
Impro 
% Impro 
at 0.1μM 
dex 
IC50 
Impro 
% Impro 
at 0.1μM 
dex 
SB208530        
IMD0354       
Theophylline  
r=0.542, 
p<0.0005 
r=0.797, 
p<0.005 
r=0.477, 
p<0.05 
 
r=0.555, 
p<0.005 
LY294002 
r=0.481, 
p<0.01 
r=0.586, 
p<0.0001 
 
r=0.795, 
p<0.0001 
r=0.546, 
p<0.05 
 
Erythromycin    
r=0.470, 
p<0.05 
r=0.637, 
p<0.01 
 
EM703  
r=0.499, 
p<0.001 
r=0.629, 
p<0.05 
r=0.577, 
p<0.01 
 
r=0.406, 
p<0.05 
Formoterol    
 
 
  
 
IC50dex ratio and the % improvement of IL-8 inhibition at 0.1 μM dexamethasone were correlated 
between NH (0.5 μM) and formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM), LY294002 
(10 nM), EM (10 μM), EM703 (10 μM) or SB203580 (5 μM) after anti-CD3/28 and TNFα 
stimulation. Associations were measured in all subjects, severe asthmatics, and healthy, mild and 
moderate. P<0.05 is significant. 
 
When the IC50dex ratio for IL-2 inhibition was compared between NH with 
theophylline and LY294002, it correlated significantly only in severe asthmatics 
(r=0.861, p<0.0001 and r=0.617, p<0.005 respectively). From the 3 respondents 
to NH (ratio>2) all responded also to theophylline and LY294002. The overall 
potency of NH (ratio IC50dex=1.410) was lower than that of theophylline (ratio 
IC50dex=3.52) and LY294002 (ratio IC50dex=3.96). Similarly, NH also showed a 
very positive correlation in severe asthma with formoterol and IMD0354 (r=0.728, 
p<0.0005 and r=0.645, p<0.005 respectively) (Table 5.6). This confirms that the 
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PI3K/Akt is an important target for NH. But it also implies that a formoterol 
mechanism of action might also be involved with NH action on corticosteroid 
responsiveness.   
 
Table 5.6 Relationship of NH improvement on steroid sensitivity for IL-2 inhibition 
with other compounds 
 
IC50dex ratio and the % improvement of IL-2 inhibition at 0.1 μM dexamethasone were correlated 
between NH (0.5 μM) and formoterol (1 nM), IMD0345 (2 μM), theophylline (1 μM), LY294002 
(10 nM), EM (10 μM), EM703 (10 μM) or SB203580 (5 μM) after anti-CD3/28 and TNFα 
stimulation. Associations were measured in all subjects, severe asthmatics, and healthy, mild and 
moderate. P<0.05 is significant. 
 
 
 
 
 
 
All Subjects 
 
Severe 
Asthma 
Normal 
Mild & Moderate 
IL-2 inhibition 
IC50 
Impro 
% Impro 
at 0.1μM 
dex 
IC50 
Impro 
% Impro 
at 0.1μM 
dex 
IC50 
Impro 
% Impro 
at 0.1μM 
dex 
SB208530       
IMD 
r=0.448, 
p<0.005  
r=0.645, 
p<0.005 
   
Theophylline 
r=0.501, 
p<0.001 
 
r=0.645, 
p<0.005 
   
LY294004 
r=0.420, 
p<0.005 
 
r=0.617, 
p<0.005 
   
Erythromycin   
 
 
 
 
 
 
 
 
EM703    
 
 
  
Formoterol 
r=0.512, 
p<0.0005 
 
r=0.728, 
p<0.0005 
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5.3.5 Molecular mechanism of NH action 
From the correlation studies, it is hypothesized that NH mechanism of action is 
related the PI3K/Akt pathway. Since the associations were very significant in the 
inhibition of IL-8, the molecular mechanism of NH was studied in vitro using a 
monocytic cell line; U937. 
 
5.3.5.1 H2O2 induced Akt1 phosphorylation is prevented by NH  
U937s stimulated for 7 minutes with 200 μM hydrogen peroxide (H2O2) showed a 
3.4 fold significant increase in pAkt1 although (p<0.01, n=3). Interestingly, the 
pre-incubation of 30 minutes of NH at 10 μM (p<0.05, n=3) and 1 μM (p<0.05, 
n=3) was enough to prevent the phosphorylation of Akt1 by H2O2 even if at 3.3 
μM it was not significant (Figure 5.6). 
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Figure 5.6 Effect of NH on hydrogen peroxide induced phosphorylation of Akt1. 
U397 were pre-incubated 30 minutes with NH (10, 3.3 and 1 μM) and subsequently 
stimulated 7 minutes with 200 μM H2O2. Whole cell extracts were used to measure pAkt1 
and Akt1 by Western blot. Results are presented as fold induction of phosphorylation 
(pAkt/Akt). N=3 independent experiments. Data was plotted as means ± SEM. P<0.05 is 
significant. 
 
5.3.5.2 H2O2 reduced HDAC activity is prevented by NH  
The same samples from the previous experiment were tested for HDAC activity. 
A significant decrease in HDAC activity has been previously observed after 
hydrogen peroxide (200 μM) (data not shown) although at n=3 in these samples, a 
40% reduction of HDAC in activity was not yet significant (p=0.296, n=3). 
However, at 1 μM pre-incubation of NH, HDAC activity levels were restored 
significantly (p<0.05, n=3), even if it not the case for 3.3 μM and 10 μM (Figure 
5.7). 
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Figure 5.7 Effect of NH on hydrogen peroxide reduction of HDAC activity. U397 
were pre-incubated 30 minutes with NH (10, 3.3 and 1 μM) and subsequently stimulated 
7 minutes with 200 μM H2O2. Whole cell extracts were used to measure HDAC activity. 
Results are presented as fold induction of HDAC activity over non-treatment. N=3 
independent experiments. Data was plotted as means ± SEM. P<0.05 is significant. 
 
5.3.6 Isobologram of CRx170 
Isobologram is a method used to measure the effect of the combination of two 
drugs. An isobologram is a graph of equally effective dose pairs (isoboles) for a 
single effect level which allows detecting if two drugs behave either in an 
antagonistic, additive of synergistic effect (Tallarida, 2001). The synergistic effect 
will determine if two drugs are targeting different downstream targets.  
 
 240
5.3.6.1 Budesonide and NH act synergistically in restoring corticosteroid 
sensitivity in steroid resistant model 
PBMCs from a healthy volunteer were incubated with IL-2/IL-4 for 48 hrs in 
order to make them corticosteroid insensitive as shown in Chapter 3. The 
inhibition of IL-2 was measured by ELISA after anti-CD3/28 stimulation and pre-
incubation of different combinations of budesonide and NH. Results shown in 
Table 5.7 illustrate a budesonide concentration dependent inhibition of IL-2 on its 
own or in combination with increasing doses of NH. IC50 values were calculated 
because the maximum effect of NH is nearly at 40%. 
 
Table 5.7 CRx-170 % inhibition of IL-2 
100 72.0 67.6 77.1 76.3 79.9
10 61.9 63.9 70.5 73.5 79.2
1 21.1 26.9 27.6 40.3 59.3
0.1 2.7 12.9 14.6 18.2 41.2
0 0 -7.6 1.8 10.3 39.0
B
ud
es
on
id
e 
(n
M
) 
 
0 1 3.3 10 33
CRx-170 Nortriptyline (μM) 
Values represent the % inhibition of anti-CD3/28 stimulation of IL-2 by NH and/or budesonide in 
an IL-2/4 steroid-resistant PBMC model. 
 
For CRx-170, 50% inhibition of the maximum was chosen as representing the 
maximum inhibition of IL-2 by NH that gives this effect. All the doses from both 
drugs that give this effect are then plotted in a Cartesian plot (Figure 5.8). The 
straight line connecting budesonide and NH at the locus of points (dose-pairs) 
would produce this effect in a simple additive combination. In the case of the two 
drugs, their combined effects are super additive or synergistic as they clearly 
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stand well under this straight line. We can conclude that the combination of 
budesonide and NH taken at 50% inhibition of IL-2 have a synergistic effect in 
the IL-2/4 steroid insensitive model making CRx-170 a potential drug for severe 
asthma. 
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Figure 5.8 Isobologram for CRx-170. The doses from budesonide (Y axis) and NH (X 
axis) that resulted in 50 % inhibition of IL-2 were plotted in a Cartesian plot. The straight 
line (red) connecting both drugs at the locus of points (dose pairs) would produce this 
effect in a simple additive combination. Antagonistic effect would result in a connecting 
curve above the straight line. Synergism occurs when the curve is below the straight line. 
 
5.3.6.2 CRx-170 induces a stronger GILZ expression than budesonide or NH 
alone 
The combined effect of budesonide and NH on the levels of GILZ transcription 
was measured by One-Step qRT-PCR. IL-2/IL-4 induced “steroid resistant” 
PBMCs used in the previous study were used for this study. Budesonide (10 nM) 
and NH (1 μM) were incubated either alone or in combination for 4 hours and 
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after mRNA extraction, samples were used to detect transcripts levels of GILZ. 
Housekeeping gene GNB2L1 was also measured and results were presented as 
GILZ log copy number divided by GNB2L1 log copy number. The data shows 
that in the IL-2/4 steroid resistant model, budesonide alone increases GILZ 
expression 8.3 times over non-treated cells (Bude: 48.2±7.8 ratio vs. NT: 5.8±0.8 
ratio, n=3; p<0.05). NH (7.4±1.1 ratio) has no effect (x 1.3) although in 
combination with budesonide (127.9±21.8 ratio) it potentiates an increase of 21.9 
times over NT. This results in an increase of 2.7 times of transactivation potential 
by the combination treatment (CRx-170) over budesonide alone (p<0.05) (Figure 
5.9).  
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Figure 5. 9 NH enhances budesonide stimulation of GILZ in IL-2/4 steroid resistant 
model. PBMCs were incubated with or without IL-2/4 for 48hrs and then exposed to 
budesonide (10 nM) and/or NH (1 μM). mRNA was extracted using Lysis Buffer 
(Ambion) and One Step-RT-PCR was performed. GILZ primer was used and its 
expression was quantified and normalized using housekeeping gene GNB2L1. Results 
are presented as log copy numbers of GILZ divided by GNB2L1. N=3 independent 
experiments from the same patients’ PBMCs. Data was plotted as means ± SEM. P<0.05 
is significant. Ns: non-significant. 
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5.4 Discussion 
The heterogeneous nature of severe asthma coupled with its reported reduction in 
corticosteroid sensitivity in some patients paves the way for the development of 
new therapies necessary to control the defective phenotypes by inducing an 
optimal steroid function. NH is the example of a known compound with potential 
anti-inflammatory effects in asthma. Although NH is currently under clinical 
trials, not much is known about it’s mechanisms of action. 
In this thesis, the molecular mechanism of NH was speculated by analysis of 
correlation with other add-on treatments with characterized pathway of action. 
This has helped in determining that NH behaves similarly to theophylline but 
especially to LY294002, suggesting its mechanism of action could be through the 
targeting and inhibition of the PI3K/Akt pathway. NH association with PI3K 
inhibitors for IL-8 control was confirmed when looking at the effect of the 
combination of steroids with NH in a monocytic cell-line under oxidative stress. 
Hydrogen peroxide is set to mimic the effect of reactive oxygen species (ROS) 
resulting from the cellular environment such as inflammatory cells through 
NADPH oxidase or the environment such as cigarette smoke (Rahman et al., 
2004). ROS have been implicated in initiating inflammatory responses in the lung 
through the activation of NF-κB and AP-1 via the activation of MAPKs and the 
PI3K pathway (Rahman et al., 2004). In fact, Akt1 phosphorylation at serine 473 
(S473) has been identified as the site of activation under hydrogen peroxide in 
vitro (Lahair et al., 2006), which was confirmed in Figure 5.6. This 
phosphorylation was completely prevented by the pre-incubation with PI3K 
inhibitor LY294002 (To Y., 2007). It was also confirmed that NH inhibited 
phosphorylation of Akt1 induced by H2O2 when pre-incubated for 30 minutes.  
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Oxidative stress and redox status in the cell can also regulate nuclear chromatin 
remodelling by histone acetylation and deacetylation. HDAC activity can be 
regulated by post-translational mechanism and its activity has been shown to be 
decreased in COPD patients (Ito et al., 2005). Oxidative stress has been confirmed 
to decrease activity and expression of these proteins which play an important role 
in GR transrepression (Ito et al., 2000). Reduced HDAC activity was shown to be 
associated with oxidative stress in monocytes with hyperphosphorylation at S473. 
NH was able, at the same concentration as the one used to reduce pAkt, to restore 
HDAC activity (Figure 5.7). Results confirm that NH could restore corticosteroid 
sensitivity via the restoration of HDAC activity. For this reason, NH could be 
more effective in COPD where high level of oxidative stress has been reported 
(Rahman and Adcock, 2006). 
NH also showed an association with formoterol hinting at a possible mechanism 
via cAMP stimulation for the control and inhibition of IL-2. The isobologram 
results confirmed that the CombinatoRx combination of budesonide and NH 
(CRx-170) had a synergistic effect on the inhibition of IL-2 steroid resistant 
PBMCs. NH was also able to synergise with budesonide to significantly increase 
GILZ activation over the steroid dose alone. Co-treatment of IL-2 and IL-4 was 
previously shown to mimic the reduction in nuclear translocation observed in 
some severe asthmatics. NH was shown to correlate with formoterol actions only 
for the steroid sensitivity to IL-2 inhibition in severe asthma. In Chapter 3, 
formoterol was shown to induce nuclear translocation via inhibition of p38γ. In 
addition, NH actions did not correlate with SB203580. Results show a possible 
association although more experiments would be needed to confirm this. 
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Severe and moderate asthmatics with a lower lung function were shown to have 
more anti-inflammatory effects against NH. Preliminary results from the clinical 
study using CRx-170 had shown that the combination of the drugs but neither 
drug alone achieved a reduction in lung function by FEV1 (%pred) in asthmatics. 
It is possible that NH is able to reduce IL-8 production effectively, resulting in the 
inhibition of the recruitment of neutrophils to the lung and improving lung 
function.  
Thus, the mechanism of NH’s action seems to be through the inhibition of the 
PI3K pathway possible through the restoration of HDAC activity in deficient 
patients. This is the first case of identification of a target molecule using analysis 
of correlation with known inhibitors in clinical samples from asthmatics.  
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6. Conclusion  
Asthma guidelines describe severe asthma as a disease characterized by poorly 
controlled symptoms with the commonly used drugs (Barnes and Woolcock, 
1998), sometimes with augmented exacerbations (Moore et al., 2007), other times 
with airway remodelling resulting in increased morbidity (ENFUMOSA, 2003). 
Physiologically, the disease is characterized by a heterogeneous nature, where 
Th2 and Th1 cells might coexist (Truyen et al., 2006) and where the airways 
inflammation might also present both eosinophil and neutrophil infiltration (Wark 
and Gibson, 2006). Reduced responses to therapeutics, especially steroids, define 
a clinical occurrence which is referred as ‘steroid resistance’ (Lee et al., 1996). 
This results in increased dosage of steroids with a plethora of side-effects. Add-on 
treatments such as LABAs, theophylline and leukotriene antagonist have proven 
to be beneficial in some severe asthmatics as well as resulting in the use of lower 
doses of corticosteroids (Kankaanranta et al., 2004). The problem remains in 
many patients were the optimal add-on treatment is not applied and the disease 
remains uncontrolled. About 50% of the total health care cost in asthma is the 
result of sub-optimal treatment of severe asthma when the disease accounts for a 
mere 5-10% of total asthmatics (Barnes and Woolcock, 1998; Chung et al., 1999; 
Sorkness et al., 2007). 
Poor adherence and poor absorption of steroids in the lung or in the cell might 
result in a decreased therapeutic response to steroids (Barnes, 2004). I have found 
that baseline production of IL-2 and IL-4 are significantly increased from PBMCs 
from severe asthmatics. These cytokines have been also shown to induce 
corticosteroid resistance in in vitro models (Irusen et al., 2002; Kam et al., 1993). 
The cause of this increase in baseline IL-2 and IL-4 is still unknown. An IL-4 
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genetic polymorphism is thought to be linked to the increase in baseline 
production in asthmatics (Chiang et al., 2007; Wenzel et al., 2007).  
Corticosteroid insensitivity was observed in severe asthmatics’ PBMCs 
confirming that the clinical observations are also reflected systemically. This 
association of clinical parameters with systemic corticosteroid sensitivity was 
only observed when PBMCs were stimulated with anti-CD3/CD28 and TNFα. 
The combined effect on both lymphocytes and monocytes induce endocrine 
changes that might reflect better the disease. It was interesting to observe that 
corticosteroid resistance was only significant for IL-8 inhibition, but not for IL-2, 
underlying the importance of monocytes as previously observed (Hew et al., 
2006). Although IL-2 release from lymphocytes was not corticosteroid insensitive, 
four patients showed an increased resistance which has been reported in T 
lymphocytes from steroid-resistant asthmatics (Corrigan and Kay, 1991; Kam et 
al., 1993). Kam et al. showed that IL-2 and IL-4 affected only lymphocytes (Kam 
et al., 1993) but not monocytes although we showed that U937 monocytes 
incubated with IL-2/4 was sufficient to induce a more steroid resistant phenotype. 
While it has been previously confirmed that severe asthmatics with steroid-
resistant or -dependent phenotypes also show a systemic relationship in ex vivo 
models (Corrigan et al., 1988), it is the first time that steroid sensitivity evaluaton 
ex vivo in PBMCs is associated with a reduction in lung function. Asthma is 
known to be a Th2 disease leading to recruitment of eosinophils in the lung. In 
severe asthma, continuous presence of eosinophils can results in airway 
hyperresponsiveness (ten Brinke et al., 2001) and airway remodelling (Fabbri et 
al., 2003). Increasingly, research groups have been finding neutrophils coexisting 
with eosinophils in the lung (Wenzel et al., 1999; Jatakanon et al., 1999) or 
 248
sometimes exclusively (Lamblin et al., 1998; Little et al., 2002; Shannon et al., 
2007; Shaw et al., 2007). In fact a decrease in lung function has been associated 
with an increase in IL-8 in severe asthma (Silvestri et al., 2006). IL-8 is a 
chemokine known to attract neutrophils and the failure of steroids to inhibit this 
chemokine can results in a progressive loss of lung function (Bai and Knight, 
2005). Contrary to eosinophils, corticosteroids are thought to enhance survival of 
neutrophils in the airway (Cox, 1995; Meagher et al., 1996).  
I showed here that in PBMCs from all individuals, corticosteroids will either 
direct a strong transactivation of GILZ or transrepression of IL-8. GILZ is also 
known to be an NF-κB and AP-1 inhibitor (Di Marco et al., 2007; Mittelstadt and 
Ashwell, 2001). This illustrates possibly innate differences in the anti-
inflammatory pathway used between individuals but unrelated to the disease. 
However, it was not the case in severe asthmatics where many patients had a 
reduction in GILZ transactivation as well as in IL-8 transrepression. Other 
transactivation markers, such as Histone-4 lysine-5 acetylation, and MKP-1 were 
also shown to be defective in severe asthma after dexamethasone stimulation 
proving to be ideal markers for defective GR transactivation. A reduction in 
nuclear translocation also correlated with a reduction in FEV1 underlying the 
importance of this mechanism for corticosteroid responsiveness. Patients with 
both low nuclear translocation and transactivation had the lowest systemic 
response to steroids and the lowest lung function. We confirmed heterogeneous 
abnormalities in severe asthma patients. Each abnormality is known but this is the 
first report to look at all possible abnormalities in the same patients at the same 
time. 
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We examined the effects of several compounds on the restoration of 
corticosteroid sensitivity and found “responders” and “non-responders” for each 
treatment. Severe asthma patients displaying lower corticosteroid sensitivity are 
all p38MAPKα/β inhibitor “responders”, confirming the importance of the kinase 
in this disease. The degree of response to p38MAPKα/β inhibition treatment also 
correlated with levels of corticosteroid sensitivity and nuclear translocation, 
showing that p38MAPKα/β phosphorylation of GR might be responsible for 
reduced nuclear translocation and subsequent transrepression of IL-8. 
Interestingly, all reponders to IKK2 inhibition (IMD0354), PI3K inhibition 
(theophylline and LY294002) or macrolides also responded to p38MAPKα/β 
inhibition underlying that many pathways might be involved and also that these 
could overlap. IKK2 inhibition results in NF-κB failure to translocate into the 
nucleus and prevents the transcriptional activation of IL-8. Overexpression of NF-
κB is also known to reduce corticosteroid effects in the cell, making it an 
important target for severe asthma (Gagliardo et al., 2003). In Chapter 3, 
theophylline was also shown to restore corticosteroid sensitivity only in patients 
with a reduced HDAC activity. Both theophylline and LY294002 act as PI3K/Akt 
inhibitors and are known to enhance HDAC2 activity (To Y., 2007). The activity 
of this histone deacetylase has been previously shown to be decreased in COPD 
or in vitro under conditions of oxidative stress (Kirkham and Rahman, 2006). 
Some severe asthmatics could develop intracellular oxidative stress from the 
action of macrophages or neutrophils leading to a reduction of steroid action due 
to a reduction in HDAC2 activity (Rahman and Adcock, 2006). Cigarette smoke 
could also result in en environmental exposure to other oxidant and nitrate stress 
resulting in a reduced response to steroids (Ito et al., 2004). By setting up a 
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system to rapidly evaluate GR function in a single blood sample we were able to 
produce an individual fingerprint of GR abnormalities. This suggests that it may 
be possible to rapidly screen patients in clinic and therefore provide an optimal 
tailor-made treatment for each severe asthmatic patient. 
Using the same system of one blood sampling we studied the effect of a novel 
add-on treatment; nortriptyline hydrochloride (NH), currently in clinical trials as 
add-on treatment to enhance corticosteroid responsiveness. Correlation studies 
with drugs of known molecular pathways proved to be a novel approach to 
discovering the potential mechanism of new compounds. NH association with 
LY294002 and theophylline was further investigated in vitro under an oxidative 
stress model in a monocytic cell line. As previously observed with LY294002 (To 
Y., 2007), NH was able to prevent phosphorylation of serine 473 in Akt1, a 
known marker of activation by oxidative stress (Lahair et al., 2006). Interestingly, 
NH also prevented the dowregulation of HDAC activity by hydrogen peroxide 
confirming the findings that NH acts as a PI3K inhibitor to enhance corticosteroid 
responsiveness in severe asthma. The system of one blood sampling resulted in 
useful information for the identification of new add-on treatments.  
In vitro IL-2 and IL-4 incubation of healthy volunteers’ PBMCs was shown to 
mimic the impaired steroid response observed in severe asthma. Severe 
asthmatics were shown to have a decreased steroid sensitivity to IL-8 release in 
TNFα-induced PBMCs. This was revealed to be caused by a hyperphosphorylated 
GR in some patients resulting in defective GR nuclear translocation. These 
patients were defined as formoterol “responder” whereas the other subgroup 
“responded” to theophylline and were shown to have a reduction in HDAC2 
mRNA expression and HDAC activity. Formoterol incubation for 20 minutes was 
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enough to reduce GR serine phosphorylation to basal levels, increase nuclear 
translocation and restore corticosteroid responsiveness in these patients. LABAs 
have already been shown to increase GR nuclear translocation in vitro (Eickelberg 
et al., 1999) and in vivo (Usmani et al., 2005) after corticosteroid treatment. The 
same results were confirmed in IL-2/4 steroid resistant PBMCs. Formoterol was 
found to act through the inhibition of p38MAPKγ, which could be responsible for 
the activation of a downstream kinase that directly or indirectly phosphorylates 
GR. The short time period by which formoterol acts suggests that a phosphatase 
such as PP2A/B could be activated rather than it acting through a kinase inhibitor 
directly. Increased p38γ expression levels were observed in severe asthmatics 
with a low nuclear translocation making it possible that overexpression of this 
kinase plays an important role in corticosteroid resistance. These findings give 
new insight into the pharmacological properties of LABAs as well as contributing 
to new opportunities for drug development. Future work will be needed to 
establish the identity of the downstream kinase from p38γ responsible for direct 
phosphorylation and inactivation of GR. The identity of the phophatase activated 
by formoterol which results in the prevention of p38γ phosphorylation of GR is of 
great pharmacological interest. 
Our conventional GR screening system and findings offers the potential to 
develop a tailor-made treatment for severe asthmatics. Although it is still at an in 
vitro laboratory based level, the system is able to reflect the properties of current 
therapies, such as LABA and theophylline. We would like to confirm this finding 
in clinical studies as this would be beneficial for both patients and the health care 
system. Our system is feasible and can result in the creation of a general kit for 
clinical use. In the future, it will be interesting to screen all UK severe asthma 
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patients to identify abnormalities and better add-on treatments. Thus, clinical 
together with epidemiologic studies should be performed for better treatment of 
severe asthma. 
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